A Systematic Comparison of the Properties of Clinically Used Angiotensin II Type 1 Receptor Antagonists

Angiotensin II type 1 receptor antagonists (ARBs) have become an important drug class in the treatment of hypertension and heart failure and the protection from diabetic nephropathy. Eight ARBs are clinically available [azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisart...

Full description

Saved in:
Bibliographic Details
Published inPharmacological reviews Vol. 65; no. 2; pp. 809 - 848
Main Authors Michel, Martin C., Foster, Carolyn, Brunner, Hans R., Liu, Lisheng
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.04.2013
Subjects
Angiotensin II Type 1 Receptor Blockers - chemistry
Angiotensin II Type 1 Receptor Blockers - pharmacokinetics
Angiotensin II Type 1 Receptor Blockers - therapeutic use
Animals
Binding Sites
Diabetic Nephropathies - metabolism
Diabetic Nephropathies - prevention & control
Drug Interactions
Heart Failure - drug therapy
Heart Failure - metabolism
Humans
Hypertension - drug therapy
Hypertension - metabolism
Molecular Structure
Receptor, Angiotensin, Type 1 - metabolism
Tissue Distribution
Cmax
ACE
P-gp
RAS
tmax
AT1R
OATP
AT2R
Vd
AUC
ARB
PPAR
t1/2
TM
ANG
P450
PET
AGE
Online AccessGet full text
ISSN0031-6997
1521-0081
1521-0081
DOI10.1124/pr.112.007278

Cover

Abstract Angiotensin II type 1 receptor antagonists (ARBs) have become an important drug class in the treatment of hypertension and heart failure and the protection from diabetic nephropathy. Eight ARBs are clinically available [azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan]. Azilsartan (in some countries), candesartan, and olmesartan are orally administered as prodrugs, whereas the blocking action of some is mediated through active metabolites. On the basis of their chemical structures, ARBs use different binding pockets in the receptor, which are associated with differences in dissociation times and, in most cases, apparently insurmountable antagonism. The physicochemical differences between ARBs also manifest in different tissue penetration, including passage through the blood-brain barrier. Differences in binding mode and tissue penetration are also associated with differences in pharmacokinetic profile, particularly duration of action. Although generally highly specific for angiotensin II type 1 receptors, some ARBs, particularly telmisartan, are partial agonists at peroxisome proliferator-activated receptor-γ. All of these properties are comprehensively reviewed in this article. Although there is general consensus that a continuous receptor blockade over a 24-hour period is desirable, the clinical relevance of other pharmacological differences between individual ARBs remains to be assessed.
AbstractList Angiotensin II type 1 receptor antagonists (ARBs) have become an important drug class in the treatment of hypertension and heart failure and the protection from diabetic nephropathy. Eight ARBs are clinically available [azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan]. Azilsartan (in some countries), candesartan, and olmesartan are orally administered as prodrugs, whereas the blocking action of some is mediated through active metabolites. On the basis of their chemical structures, ARBs use different binding pockets in the receptor, which are associated with differences in dissociation times and, in most cases, apparently insurmountable antagonism. The physicochemical differences between ARBs also manifest in different tissue penetration, including passage through the blood-brain barrier. Differences in binding mode and tissue penetration are also associated with differences in pharmacokinetic profile, particularly duration of action. Although generally highly specific for angiotensin II type 1 receptors, some ARBs, particularly telmisartan, are partial agonists at peroxisome proliferator-activated receptor-γ. All of these properties are comprehensively reviewed in this article. Although there is general consensus that a continuous receptor blockade over a 24-hour period is desirable, the clinical relevance of other pharmacological differences between individual ARBs remains to be assessed.Angiotensin II type 1 receptor antagonists (ARBs) have become an important drug class in the treatment of hypertension and heart failure and the protection from diabetic nephropathy. Eight ARBs are clinically available [azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan]. Azilsartan (in some countries), candesartan, and olmesartan are orally administered as prodrugs, whereas the blocking action of some is mediated through active metabolites. On the basis of their chemical structures, ARBs use different binding pockets in the receptor, which are associated with differences in dissociation times and, in most cases, apparently insurmountable antagonism. The physicochemical differences between ARBs also manifest in different tissue penetration, including passage through the blood-brain barrier. Differences in binding mode and tissue penetration are also associated with differences in pharmacokinetic profile, particularly duration of action. Although generally highly specific for angiotensin II type 1 receptors, some ARBs, particularly telmisartan, are partial agonists at peroxisome proliferator-activated receptor-γ. All of these properties are comprehensively reviewed in this article. Although there is general consensus that a continuous receptor blockade over a 24-hour period is desirable, the clinical relevance of other pharmacological differences between individual ARBs remains to be assessed.
Angiotensin II type 1 receptor antagonists (ARBs) have become an important drug class in the treatment of hypertension and heart failure and the protection from diabetic nephropathy. Eight ARBs are clinically available [azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan]. Azilsartan (in some countries), candesartan, and olmesartan are orally administered as prodrugs, whereas the blocking action of some is mediated through active metabolites. On the basis of their chemical structures, ARBs use different binding pockets in the receptor, which are associated with differences in dissociation times and, in most cases, apparently insurmountable antagonism. The physicochemical differences between ARBs also manifest in different tissue penetration, including passage through the blood-brain barrier. Differences in binding mode and tissue penetration are also associated with differences in pharmacokinetic profile, particularly duration of action. Although generally highly specific for angiotensin II type 1 receptors, some ARBs, particularly telmisartan, are partial agonists at peroxisome proliferator-activated receptor-γ. All of these properties are comprehensively reviewed in this article. Although there is general consensus that a continuous receptor blockade over a 24-hour period is desirable, the clinical relevance of other pharmacological differences between individual ARBs remains to be assessed.
Author Brunner, Hans R.
Foster, Carolyn
Michel, Martin C.
Liu, Lisheng
Author_xml – sequence: 1
  givenname: Martin C.
  surname: Michel
  fullname: Michel, Martin C.
  email: martin.michel@boehringer-ingelheim.com
– sequence: 2
  givenname: Carolyn
  surname: Foster
  fullname: Foster, Carolyn
– sequence: 3
  givenname: Hans R.
  surname: Brunner
  fullname: Brunner, Hans R.
– sequence: 4
  givenname: Lisheng
  surname: Liu
  fullname: Liu, Lisheng
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23487168$$D View this record in MEDLINE/PubMed
BookMark eNp1kD1PwzAQhi1URD9gZEUeWVLsxI2Tsar4qFQJBGWOXPtSjBI72C5S_j2uWhiQOr26u-e94RmjgbEGELqmZEppyu46t88pITzlxRka0VlKE0IKOkAjQjKa5GXJh2js_SchlM2K2QUaphkrOM2LEdrO8VvvA7QiaIkXtu2E094abGscPgC_ONuBCxr8frNotNFSNE2P3z0oPDdbbQMYrw1eLvG67wBT_AoSumBdPAextUb74C_ReS0aD1fHnKD1w_168ZSsnh-Xi_kqkYzwkDBgOZdyIyAl-aZUUOSZqonIFUsVY6wEmVEuVc4IyDqNa1HmAsqUzeSGQzZBt4e3nbNfO_CharWX0DTCgN35isY2IyXLaERvjuhu04KqOqdb4frq100EkgMgnfXeQf2HUFLt3cd5n9XBfeSzf7zUIWq1Jjihm5MtfmhBtPKtwVVeajASlHYgQ6WsPtH8AXgdmkg
CitedBy_id crossref_primary_10_3390_biomedicines9060651
crossref_primary_10_1161_HYPERTENSIONAHA_113_02860
crossref_primary_10_1038_s41569_024_00996_1
crossref_primary_10_1038_ncomms3516
crossref_primary_10_1124_mol_117_110890
crossref_primary_10_3390_cells9091923
crossref_primary_10_1093_brain_awv172
crossref_primary_10_1111_jcpt_13540
crossref_primary_10_1016_j_bbrc_2017_07_134
crossref_primary_10_1080_00498254_2020_1745318
crossref_primary_10_1016_j_molstruc_2017_02_063
crossref_primary_10_3109_10641963_2013_863325
crossref_primary_10_1111_bph_12949
crossref_primary_10_1016_j_diabres_2014_11_007
crossref_primary_10_1517_13543776_2013_830104
crossref_primary_10_1007_s10930_023_10127_3
crossref_primary_10_1016_j_ejphar_2022_174911
crossref_primary_10_1016_j_bbamem_2014_06_003
crossref_primary_10_1371_journal_pone_0088542
crossref_primary_10_1111_jcpt_12224
crossref_primary_10_23736_S2724_5683_23_06463_3
crossref_primary_10_1007_s11357_020_00231_y
crossref_primary_10_1016_j_nbd_2014_04_018
crossref_primary_10_1080_10826076_2016_1202265
crossref_primary_10_1111_joim_12838
crossref_primary_10_1016_j_yjmcc_2016_05_012
crossref_primary_10_1016_j_intimp_2023_110761
crossref_primary_10_3390_ijms222312716
crossref_primary_10_1111_apha_12281
crossref_primary_10_1016_j_jns_2013_10_040
crossref_primary_10_1021_acs_jcim_7b00424
crossref_primary_10_1007_s00059_016_4415_7
crossref_primary_10_15829_1728_8800_2018_6_69_76
crossref_primary_10_1007_s12035_015_9201_7
crossref_primary_10_1016_j_heliyon_2023_e16951
crossref_primary_10_1155_2017_1591762
crossref_primary_10_1371_journal_pone_0222005
crossref_primary_10_3346_jkms_2020_35_e289
crossref_primary_10_1016_j_brainres_2014_11_035
crossref_primary_10_2344_anpr_68_02_08
crossref_primary_10_1038_srep08116
crossref_primary_10_1080_14737175_2020_1708195
crossref_primary_10_1016_j_xphs_2017_04_046
crossref_primary_10_12701_yujm_2019_00059
crossref_primary_10_1007_s00535_015_1104_x
crossref_primary_10_1002_anie_201805961
crossref_primary_10_1111_jch_12895
crossref_primary_10_1016_j_cjca_2023_06_421
crossref_primary_10_1080_00397911_2021_1939056
crossref_primary_10_1080_14656566_2020_1770728
crossref_primary_10_26442_SG28988
crossref_primary_10_1080_17425255_2019_1558204
crossref_primary_10_3389_fphar_2019_00705
crossref_primary_10_1016_j_biopsych_2021_05_012
crossref_primary_10_1002_qua_26390
crossref_primary_10_4330_wjc_v9_i3_200
crossref_primary_10_3389_fphar_2021_603736
crossref_primary_10_1097_MD_0000000000029398
crossref_primary_10_1080_10641963_2018_1445750
crossref_primary_10_1111_hepr_13281
crossref_primary_10_3389_fnins_2019_01043
crossref_primary_10_1016_j_atherosclerosis_2014_06_016
crossref_primary_10_1002_ddr_21679
crossref_primary_10_1002_cbdv_202401634
crossref_primary_10_3390_molecules27041291
crossref_primary_10_1016_j_tetlet_2017_03_056
crossref_primary_10_1038_hr_2015_105
crossref_primary_10_1167_iovs_61_5_51
crossref_primary_10_1016_j_bbrc_2020_02_007
crossref_primary_10_1016_j_pharmthera_2016_03_019
crossref_primary_10_1111_1440_1681_12099
crossref_primary_10_1111_jch_12873
crossref_primary_10_1016_j_colsurfb_2024_113799
crossref_primary_10_1016_j_repc_2023_08_005
crossref_primary_10_1016_j_tox_2024_153970
crossref_primary_10_1039_D0CY02059A
crossref_primary_10_1186_s12871_022_01899_9
crossref_primary_10_1517_13543776_2015_1061997
crossref_primary_10_1021_acscatal_1c04923
crossref_primary_10_1007_s12664_021_01220_5
crossref_primary_10_1111_hepr_12860
crossref_primary_10_1002_hep4_1104
crossref_primary_10_1111_jcpt_13202
crossref_primary_10_3390_ph14020166
crossref_primary_10_2147_IJGM_S318129
crossref_primary_10_1124_pharmrev_123_000990
crossref_primary_10_1016_j_ejphar_2015_05_011
crossref_primary_10_15829_1728_8800_2022_3195
crossref_primary_10_1007_s13318_016_0371_0
crossref_primary_10_1080_00015385_2021_1963101
crossref_primary_10_1080_21655979_2021_1981799
crossref_primary_10_1007_s11845_017_1580_5
crossref_primary_10_1016_j_bbrc_2014_10_077
crossref_primary_10_3389_fphar_2022_937759
crossref_primary_10_1016_j_phrs_2017_05_009
crossref_primary_10_1152_physiol_00036_2020
crossref_primary_10_1016_j_jvs_2016_12_110
crossref_primary_10_1016_j_pharmthera_2022_108175
crossref_primary_10_1016_j_jconrel_2018_04_010
crossref_primary_10_1371_journal_pone_0201719
crossref_primary_10_3389_fneur_2024_1410389
crossref_primary_10_1111_epi_13965
crossref_primary_10_3346_jkms_2019_34_e266
crossref_primary_10_1177_2040622315596119
crossref_primary_10_1016_j_jclinane_2024_111401
crossref_primary_10_1039_C9RA02180A
crossref_primary_10_3390_ijms24065869
crossref_primary_10_3389_fnagi_2023_1137197
crossref_primary_10_1126_scitranslmed_aag1303
crossref_primary_10_1590_1414_431x20176665
crossref_primary_10_1002_prp2_1083
crossref_primary_10_1007_s00011_015_0895_9
crossref_primary_10_3389_fphar_2021_647747
crossref_primary_10_1002_ange_201805961
crossref_primary_10_1124_pr_114_010454
crossref_primary_10_1007_s11906_020_01073_x
crossref_primary_10_1016_j_exer_2022_108940
crossref_primary_10_3389_fnins_2021_628403
crossref_primary_10_1002_psp4_13154
crossref_primary_10_3109_15569527_2014_979427
crossref_primary_10_1038_s42003_020_01483_2
crossref_primary_10_1007_s12035_024_04237_x
crossref_primary_10_1016_j_canep_2022_102245
crossref_primary_10_1016_j_jphs_2023_07_005
crossref_primary_10_1097_HJH_0000000000003240
crossref_primary_10_1080_17425255_2022_2086121
crossref_primary_10_2957_kanzo_56_324
crossref_primary_10_1016_j_dsx_2016_08_009
crossref_primary_10_1016_j_eclinm_2021_100962
crossref_primary_10_1007_s11325_014_1081_y
crossref_primary_10_1146_annurev_pharmtox_010814_124446
crossref_primary_10_3389_fcvm_2024_1372505
crossref_primary_10_7717_peerj_5061
crossref_primary_10_1016_j_amjmed_2014_04_014
crossref_primary_10_1007_s10571_015_0285_4
crossref_primary_10_1016_j_ijcard_2019_04_074
crossref_primary_10_3390_jcm12206627
crossref_primary_10_1254_fpj_22028
crossref_primary_10_1007_s13346_018_00610_1
crossref_primary_10_3389_fphar_2021_739637
crossref_primary_10_1007_s13311_023_01435_8
crossref_primary_10_2174_1385272823666191014154129
crossref_primary_10_5761_atcs_oa_16_00054
crossref_primary_10_1038_nrendo_2015_6
crossref_primary_10_1124_dmd_115_065748
crossref_primary_10_1107_S2056989014028023
crossref_primary_10_1016_j_apsb_2018_09_003
crossref_primary_10_26442_00403660_2023_09_202423
crossref_primary_10_1016_j_ijcard_2016_09_015
crossref_primary_10_1007_s00228_016_2072_7
crossref_primary_10_1016_j_expneurol_2018_08_013
crossref_primary_10_1016_j_lfs_2020_118924
crossref_primary_10_3389_fphar_2017_00318
crossref_primary_10_1507_endocrj_EJ16_0084
crossref_primary_10_1002_jcb_30014
crossref_primary_10_1021_jm501100b
crossref_primary_10_1080_10717544_2023_2179127
crossref_primary_10_1073_pnas_1818357116
crossref_primary_10_1016_j_pharmthera_2020_107750
crossref_primary_10_1021_acs_joc_3c02076
crossref_primary_10_1097_HJH_0000000000000974
crossref_primary_10_1016_j_ejphar_2023_175915
crossref_primary_10_1152_physiol_00057_2018
crossref_primary_10_1016_j_lfs_2013_12_216
crossref_primary_10_1111_bph_13445
crossref_primary_10_1186_s12974_025_03378_7
crossref_primary_10_1016_j_jpba_2020_113887
crossref_primary_10_1016_S1875_5364_19_30024_X
crossref_primary_10_1038_jhh_2014_43
crossref_primary_10_3390_biom13050787
crossref_primary_10_1517_13543784_2013_812631
crossref_primary_10_1186_s13020_025_01065_6
crossref_primary_10_7554_eLife_69795
crossref_primary_10_1016_j_bmc_2018_06_036
crossref_primary_10_3390_neuroglia5020014
crossref_primary_10_1371_journal_pcbi_1007719
crossref_primary_10_1016_j_freeradbiomed_2014_03_020
crossref_primary_10_2967_jnumed_115_170951
crossref_primary_10_1093_ajh_hpu076
crossref_primary_10_1093_ajh_hpu197
crossref_primary_10_1111_nyas_14233
crossref_primary_10_15829_1728_8800_2019_1_73_81
crossref_primary_10_14814_phy2_12274
crossref_primary_10_15829_1728_8800_2013_3_55_57
crossref_primary_10_1016_j_vph_2014_02_003
crossref_primary_10_1016_j_vph_2015_10_001
crossref_primary_10_1016_j_tcm_2015_06_004
crossref_primary_10_1161_ATVBAHA_124_320259
crossref_primary_10_1007_s11095_024_03687_1
crossref_primary_10_1248_bpb_b16_00987
crossref_primary_10_1016_j_intimp_2024_112707
crossref_primary_10_1186_s13195_015_0167_5
crossref_primary_10_1001_jamanetworkopen_2020_20330
crossref_primary_10_1007_s00228_020_02963_4
crossref_primary_10_1021_acs_jcim_8b00364
crossref_primary_10_1126_scisignal_2005965
crossref_primary_10_1208_s12249_017_0879_x
crossref_primary_10_1002_nau_24141
crossref_primary_10_1111_bph_13461
crossref_primary_10_51847_oBCZPVxvJP
crossref_primary_10_1111_bph_14439
crossref_primary_10_1007_s40119_017_0087_5
crossref_primary_10_1152_ajpcell_00389_2014
crossref_primary_10_1111_jvim_13639
crossref_primary_10_1016_j_canlet_2020_07_015
crossref_primary_10_1016_j_cellsig_2021_109967
crossref_primary_10_1177_1753944719868134
crossref_primary_10_3892_etm_2017_5451
crossref_primary_10_1111_apt_13413
crossref_primary_10_1586_14737175_2014_972945
crossref_primary_10_1161_HYPERTENSIONAHA_113_02550
crossref_primary_10_1536_ihj_16_511
crossref_primary_10_3390_polym13071164
crossref_primary_10_1007_s13311_014_0286_x
crossref_primary_10_1016_j_pbb_2016_06_010
crossref_primary_10_1038_srep22213
crossref_primary_10_2174_0115701638279362240223070810
Cites_doi 10.1007/BF00164582
10.1161/01.CIR.103.6.904
10.1002/(SICI)1099-081X(199809)19:6<351::AID-BDD115>3.0.CO;2-V
10.1023/A:1011930411574
10.1016/j.biopha.2010.09.014
10.1515/CCLM.2009.019
10.5414/CPP40035
10.1016/S0022-3565(25)21024-2
10.1016/S0022-3565(25)38613-1
10.1038/ajh.2008.27
10.1038/sj.bjp.0707323
10.1254/jjp.79.131
10.1016/j.nucmedbio.2012.01.008
10.1016/S0026-895X(25)09072-8
10.2337/diabetes.54.12.3442
10.1097/00004872-199507001-00007
10.1124/jpet.108.138073
10.1677/joe.0.1540133
10.1038/hr.2012.147
10.1161/01.HYP.25.1.14
10.1007/BF00169183
10.1097/00004872-200106001-00002
10.1161/01.HYP.24.4.467
10.1124/dmd.110.036129
10.1016/j.cardiores.2006.07.014
10.1097/00005344-199711000-00011
10.1046/j.1365-2125.1997.00608.x
10.1097/00007691-200108000-00008
10.1016/0922-4106(93)90077-M
10.1007/BF00266358
10.1007/s10038-008-0324-9
10.1016/S0014-2999(98)00983-2
10.1016/S0022-3565(25)09579-5
10.1291/hypres.24.65
10.1007/s00210-002-0545-y
10.1177/009127000004001204
10.1016/S0006-8993(00)02377-5
10.1038/clpt.1992.56
10.1097/01.hjh.0000244952.54738.f6
10.1177/147323000703500407
10.1038/hr.2009.95
10.1139/y92-093
10.1016/j.clpt.2006.01.011
10.1177/0091270006297225
10.1016/j.ejphar.2012.01.026
10.1111/j.1745-7254.2008.00839.x
10.1177/0091270008329547
10.1016/0014-2999(92)90593-S
10.1016/0014-2999(94)90753-6
10.1097/00004872-200103001-00007
10.1172/JCI1899
10.1007/s10557-011-6361-1
10.1097/01.fjc.0000180902.78230.fd
10.1016/S0022-3565(25)22844-0
10.1097/00004872-200311000-00028
10.1177/009127000004001205
10.1016/S0014-2999(97)01542-2
10.1152/ajpendo.00024.2007
10.1016/S0090-9556(25)06520-1
10.1016/0303-7207(92)90101-B
10.1111/j.1365-2125.1995.tb05802.x
10.1038/sj.bjp.0700897
10.1016/j.febslet.2004.09.027
10.1016/S0022-3565(25)10800-8
10.1124/dmd.111.039842
10.1254/jphs.09343SC
10.1097/00019501-199706000-00003
10.1517/17425255.2010.494597
10.1177/009127000004001207
10.1038/hr.2012.63
10.1211/jpp.58.11.0011
10.1016/j.bbrc.2010.11.139
10.2165/00003495-200868090-00005
10.1291/hypres.31.1549
10.1016/j.amjhyper.2006.12.010
10.1016/0922-4106(95)90103-5
10.1097/FPC.0b013e32833a6d4a
10.1124/jpet.110.176636
10.1016/S0026-895X(24)09251-4
10.1016/j.atherosclerosis.2007.09.013
10.1111/j.1476-5381.1993.tb13877.x
10.1016/0304-3940(91)90420-X
10.1161/HYPERTENSIONAHA.109.132886
10.1038/hr.2010.135
10.1111/j.1463-1326.2011.01471.x
10.1021/jm031100t
10.1016/j.mce.2008.06.006
10.1016/j.bbrc.2008.08.032
10.1016/S0022-3565(25)38210-8
10.1002/bdd.664
10.1007/s11906-008-0019-9
10.1021/jm9904147
10.1016/j.bcp.2008.07.006
10.1016/S0090-9556(24)15292-0
10.1016/S0022-3565(24)39054-8
10.1161/01.HYP.30.5.1260
10.18433/J3SK5V
10.1016/j.clpt.2003.08.001
10.1113/jphysiol.2007.138578
10.1177/009127000004001206
10.1016/S0022-3565(25)11466-3
10.2165/00003495-200262090-00005
10.1016/S0022-3565(24)35282-6
10.1161/HYPERTENSIONAHA.111.173542
10.1097/00005344-199711000-00008
10.1177/009127000004001209
10.1016/j.cca.2008.09.020
10.1161/HYPERTENSIONAHA.107.099028
10.1016/S0014-2999(99)00662-7
10.1016/j.atherosclerosis.2008.12.036
10.1016/j.bbrc.2011.04.142
10.1152/ajpcell.1992.263.4.C750
10.1016/S0022-3565(25)23835-6
10.5414/CP201467
10.1002/j.1552-4604.1998.tb04809.x
10.1097/00005344-199702000-00019
10.1038/sj.bjp.0702398
10.1097/00004872-200206000-00027
10.1023/A:1016086930019
10.1016/j.bbrc.2009.11.008
10.1097/00004872-200209000-00028
10.1016/S0026-895X(25)08819-4
10.1097/HJH.0b013e3282f56ba5
10.1021/jm200409s
10.2165/00003088-200038060-00005
10.1254/jjp.75.259
10.1159/000139357
10.1021/jm00077a007
10.1177/147323000803600204
10.1046/j.1365-2125.1998.00636.x
10.1111/j.1476-5381.1993.tb13800.x
10.1016/S0022-3565(25)39603-5
10.1111/j.1474-8673.2004.00301.x
10.1111/j.1582-4934.2009.00829.x
10.1016/S0024-3205(98)00278-1
10.1007/s00228-011-1098-0
10.1254/jphs.09202FP
10.1016/S0006-2952(00)00546-3
10.1038/sj.jhh.1001442
10.1097/HJH.0b013e3282f52c36
10.1080/00498250903134435
10.1002/j.1552-4604.1995.tb04097.x
10.1007/BF03190880
10.1016/0014-2999(95)00401-6
10.1210/me.2007-0312
10.1002/bdd.699
10.1021/bi0159581
10.1097/01.hjh.0000242415.73406.17
10.1016/S0022-3565(25)38647-7
10.1097/00004872-199402000-00008
10.1161/01.HYP.0000123072.34629.57
10.1097/HJH.0b013e32833a551a
10.1161/01.HYP.34.1.138
10.1111/j.1527-3466.2000.tb00039.x
10.1007/s002280050317
10.1002/j.1552-4604.1998.tb04422.x
10.1139/y95-058
10.1161/01.ATV.0000240050.15321.fe
10.1097/HJH.0b013e328336b86b
10.1177/0091270007307880
10.1038/jhg.2012.63
10.1007/BF02570503
10.1210/endo.133.4.8404609
10.1097/01.hjh.0000249704.34607.4c
10.1592/phco.19.8.612.31518
10.1016/0167-0115(94)90029-9
10.2133/dmpk.19.15
10.1161/01.HYP.0000168046.19884.6a
10.1016/S0009-9236(97)90029-1
10.1046/j.1365-2125.1998.00778.x
10.1006/phrs.2000.0767
10.1254/jphs.09361FP
10.1021/bi961593m
10.1097/00004872-200112000-00018
10.1007/s002280050318
10.1124/dmd.105.008888
10.1093/ajh/5.9.648
10.1016/j.clpt.2004.04.001
10.5551/jat.14.133
10.1016/0167-0115(95)00085-P
10.3109/03639045.2012.693502
10.1016/S0895-7061(97)00391-9
10.1002/j.1552-4604.1995.tb04018.x
10.2174/138161209788923859
10.1007/BF00192369
10.1177/009127000004001208
10.1111/j.1476-5381.1994.tb14036.x
10.1124/mol.105.011601
10.1097/00004872-199210120-00005
10.1053/cp.1999.v66.a101162
10.1097/HJH.0b013e328165d159
10.1021/jm9604383
10.1093/cvr/cvn064
10.1016/S0008-6363(99)00249-7
10.1074/jbc.270.21.12846
10.1161/01.HYP.19.3.221
10.1124/dmd.106.012351
10.1016/S0026-895X(25)08561-X
10.1097/FPC.0b013e3283482502
10.1016/S0014-2999(98)00965-0
10.1124/dmd.105.009175
10.1291/hypres.26.937
10.2165/00044011-200626010-00004
10.1016/S0021-9258(19)89420-6
10.1124/dmd.107.018903
10.1159/000028308
10.1016/0006-2952(93)90420-2
10.1016/S0149-2918(00)83062-3
10.1161/HYPERTENSIONAHA.112.192401
10.1067/mcp.2002.127945
10.1345/aph.17188
10.1021/jm960547h
10.1007/s002100100396
10.1016/0922-4106(93)90170-E
10.1161/HYPERTENSIONAHA.108.126656
10.1016/0014-2999(94)90183-X
10.1007/s00125-010-1744-6
10.1111/j.1476-5381.1994.tb16191.x
10.1002/(SICI)1099-081X(199805)19:4<237::AID-BDD100>3.0.CO;2-7
10.1291/hypres.19.75
10.1038/sj.jhh.1001941
10.1016/j.pneurobio.2011.07.001
10.1046/j.1472-8206.2001.00018.x
10.1007/BF00316470
10.1097/00005344-200006000-00012
10.2165/00003088-200140080-00004
10.1053/j.ajkd.2005.08.034
10.1177/147323000002800401
10.1016/S0090-9556(25)09049-X
10.1002/bjs.1800810609
10.1177/00912709922007886
10.1111/j.1751-7176.2008.00022.x
10.1161/01.CIR.0000127955.36250.65
10.1177/1470320310370852
10.1016/j.metabol.2009.11.013
10.1124/dmd.111.041475
10.1021/jm049024x
10.1016/S0009-9236(97)90180-6
10.1161/01.HYP.15.5.459
10.1124/jpet.106.112755
10.1111/j.1476-5381.1992.tb09039.x
10.1097/00004872-199402000-00003
10.1007/s11095-007-9401-6
10.1097/HJH.0b013e32834c46fd
10.1016/S0009-9236(96)80004-X
10.1124/jpet.110.173005
10.1038/aps.2011.100
10.1016/S0031-6997(25)06844-9
10.1016/S0731-7085(01)00603-3
10.1021/jm00074a018
10.1016/j.pharmthera.2005.10.009
10.1007/s002280050259
10.1016/0014-2999(94)00484-6
10.1007/s11596-008-0512-z
10.1161/HYPERTENSIONAHA.109.138750
10.1161/01.HYP.15.6.823
10.1002/j.1552-4604.1998.tb04434.x
10.1016/S0009-9236(97)90120-X
10.1016/0006-291X(90)91993-3
10.1016/0006-291X(90)91575-D
10.1021/jm00092a017
10.1177/0091270002239710
10.1016/0165-6147(94)90156-2
10.1038/sj.bjp.0702722
10.1016/S0968-0896(01)00059-1
10.1159/000313363
10.1254/jphs.10064SC
10.1023/A:1007600924033
10.1046/j.1365-2125.1998.00837.x
10.1177/009127000004001203
10.1291/hypres.18.69
10.1016/S0009-9236(98)90163-1
10.1161/ATVBAHA.110.222067
10.1111/j.1476-5381.1994.tb16899.x
10.1007/s00228-003-0664-5
10.1016/0922-4106(95)90121-3
10.1007/s002280050731
10.1097/00004872-200103000-00015
10.1111/j.1365-2710.2011.01279.x
10.1021/jm7011563
10.1016/0006-291X(92)91335-N
10.1016/S0026-895X(25)09255-7
10.1016/S0006-2952(96)00691-0
10.1111/j.1471-4159.1992.tb10065.x
10.3109/10799899309073697
10.1161/HYPERTENSIONAHA.109.143958
10.1074/jbc.M109.072629
10.1161/STROKEAHA.110.583948
10.1248/bpb.32.416
10.3109/0886022X.2010.501936
10.1074/jbc.C800156200
10.1021/jm00114a021
10.1067/mcp.2002.121425
10.1177/00912700122010645
10.1016/0922-4106(93)90071-G
10.1007/s10620-007-9741-4
10.1139/y98-002
10.1016/S0090-9556(24)15006-4
10.1016/S0169-409X(02)00064-9
10.1097/FJC.0b013e3182576098
10.1007/s00125-006-0437-7
10.1161/01.CIR.101.10.1199
10.3233/JAD-2010-091552
10.1016/0014-2999(93)90892-L
10.1021/jm00108a043
10.1007/s002280050303
10.1111/j.1365-2362.2008.02025.x
10.1124/dmd.105.008938
10.1080/10641960600946171
10.1007/s11926-012-0240-z
10.1016/S0022-3565(25)19981-3
10.1016/j.vph.2006.05.002
10.1111/j.1527-3466.2004.tb00146.x
10.1111/j.1476-5381.2010.00875.x
10.1046/j.1365-2125.2002.01646.x
10.3109/10641960903254430
10.1016/j.atherosclerosis.2007.10.037
10.1074/jbc.M602144200
10.1016/S0009-9236(97)90080-1
10.1016/S0022-3565(25)38306-0
10.1016/j.nucmedbio.2012.06.012
10.2133/dmpk.23.115
10.1007/s002280050405
10.1124/mol.110.067066
10.1016/j.lfs.2009.05.001
10.1097/00005344-200207000-00007
10.1210/endo.130.6.1597161
10.1097/HJH.0b013e32834cf1c0
10.1111/j.1365-2125.1993.tb05696.x
10.1097/00004872-200106001-00005
10.1007/s00210-011-0706-y
10.1056/NEJMra0800885
10.1124/dmd.107.019026
10.1038/sj.jhh.1000749
10.1016/j.bbrc.2011.06.012
10.1016/j.lfs.2009.11.006
10.2337/db07-0839
10.1111/j.1472-8206.2000.tb00443.x
10.1055/s-0029-1237359
10.1177/009127000004001202
10.1021/jm950450f
10.1038/ajh.2010.241
10.1038/sj.bjp.0703150
10.1124/pr.55.4.4
10.1210/en.2008-0502
10.1161/01.HYP.37.3.981
10.2133/dmpk.24.376
10.1016/S0022-3565(25)10995-6
10.1007/s00894-009-0612-0
10.1023/A:1011902625609
10.1161/01.HYP.33.3.850
10.1161/HYPERTENSIONAHA.107.104570
10.1016/j.neulet.2009.08.043
10.1177/00912700122010393
10.1007/BF00169271
10.1124/mol.65.1.2
10.1067/mcp.2000.111182
10.1161/HYPERTENSIONAHA.109.136879
10.1016/S0090-9556(25)06533-X
10.1111/j.1476-5381.1992.tb14322.x
10.2165/00003088-200544120-00011
10.1016/0014-2999(95)00237-F
10.1161/01.HYP.33.6.1406
10.1007/s00228-009-0624-9
10.1124/dmd.110.037457
10.1016/S0014-2999(96)00837-0
10.1161/HYPERTENSIONAHA.111.176263
10.1159/000139534
10.1124/pr.108.000612
10.1097/HJH.0b013e32834dde5f
10.1016/j.ejphar.2011.07.014
10.1097/00005344-200107000-00015
10.1016/S0895-7061(99)00133-8
10.1021/jm990554g
10.1002/j.1552-4604.1998.tb04473.x
10.1016/0014-2999(94)90394-8
10.1016/0960-0760(92)90161-B
10.1007/s12325-011-0098-x
10.1097/00004872-200106001-00004
10.1111/j.1742-7843.2008.00283.x
10.1038/jcbfm.2008.158
10.1007/s00228-005-0976-8
10.2133/dmpk.22.267
10.1080/004982597240767
10.1002/j.1552-4604.1997.tb04783.x
10.1007/s00228-006-0121-3
10.1097/00005344-199509000-00021
10.1111/j.1365-2710.2009.01053.x
10.1016/S0022-3565(25)11212-3
10.1016/0090-6980(92)90070-A
10.1002/j.1875-9114.1998.tb03825.x
10.1080/00498250500158175
10.1016/S0022-3565(25)22812-9
10.1016/S0090-9556(25)08163-2
10.1124/jpet.102.036772
10.1016/S0014-2999(98)00329-X
10.3317/jraas.2000.063
10.1111/j.1476-5381.1991.tb12503.x
10.1177/0091270008317847
10.1016/S0090-9556(25)08584-8
10.1097/HJH.0b013e3282f9b58a
10.1016/S0022-3565(25)24448-2
10.1177/00912700022009099
10.3317/jraas.2002.046
10.1016/S0014-2999(98)00134-4
10.1124/pr.109.002014
10.1185/030079906X167471
10.1038/sj.tpj.6500063
10.1016/j.cbi.2010.03.030
10.1002/j.1552-4604.1998.tb04449.x
10.1042/cs0990331
10.1007/s002280050629
10.1016/S0022-3565(25)19984-9
10.1016/0009-9236(95)90020-9
10.1016/S0022-3565(25)12755-9
10.1016/S0022-5347(17)35685-9
10.1016/S0022-3565(25)12239-8
10.1007/s00210-003-0813-5
10.1002/j.1552-4604.1998.tb04401.x
10.1097/00005344-200111000-00004
10.1016/S0031-6997(24)01458-3
10.1016/0361-9230(93)90036-B
10.1021/jm00064a011
10.1097/00004872-200412000-00003
10.1021/jm00061a014
10.1124/dmd.107.017459
10.1161/01.CIR.83.4.1333
10.1016/S0022-3565(24)29352-6
10.1021/jm0204237
10.1067/mcp.2002.121216
10.1007/s002280050406
10.1211/0022357001774994
10.1016/j.neuroscience.2005.03.054
10.2174/092986608785203746
10.1016/S0090-9556(24)13658-6
10.1016/S0022-3565(25)24563-3
10.1038/hr.2012.17
10.1046/j.1365-2125.1998.00722.x
10.1007/s10157-008-0067-0
10.1124/jpet.107.130294
10.1021/mp200160t
10.1111/j.1751-7176.2010.00335.x
10.1016/S0149-2918(04)90141-5
10.1097/01.hjh.0000242405.68461.84
10.1592/phco.23.6.720.32187
10.1016/0922-4106(95)90084-5
10.1016/j.coph.2006.11.008
ContentType Journal Article
Copyright 2013 American Society for Pharmacology and Experimental Therapeutics
Copyright_xml – notice: 2013 American Society for Pharmacology and Experimental Therapeutics
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1124/pr.112.007278
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1521-0081
EndPage 848
ExternalDocumentID 23487168
10_1124_pr_112_007278
S0031699724010548
Genre Journal Article
Comparative Study
Review
GroupedDBID ---
-~X
.55
.GJ
0R~
123
18M
1KJ
2WC
3O-
4.4
53G
5RE
5VS
AAJMC
AALRI
AAXUO
AAYOK
ABCQX
ABJNI
ABOCM
ABSQV
ACGFO
ACGFS
ADBBV
ADCOW
AENEX
AERNN
AFHIN
AFOSN
AGFXO
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BTFSW
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
F9R
FDB
GX1
H13
HZ~
INIJC
KQ8
L7B
LSO
MVM
N4W
N9A
O9-
OK1
P2P
RHF
RHI
RPT
SJN
TR2
W8F
WOQ
X7M
YBU
YHG
YNH
ZGI
ZKB
ZXP
AAYXX
AETEA
CITATION
M41
ROL
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c407t-4e467ccbae206b9de863df0a6d42d4449ec317cd640ecf26d4a96ae9245cb7e3
ISSN 0031-6997
1521-0081
IngestDate Fri Jul 11 06:15:04 EDT 2025
Mon Jul 21 06:00:23 EDT 2025
Tue Jul 01 05:41:46 EDT 2025
Thu Apr 24 22:58:29 EDT 2025
Sat Jan 25 15:59:00 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Cmax
ACE
P-gp
RAS
tmax
AT1R
OATP
AT2R
Vd
AUC
ARB
PPAR
t1/2
TM
ANG
P450
PET
AGE
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c407t-4e467ccbae206b9de863df0a6d42d4449ec317cd640ecf26d4a96ae9245cb7e3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-Review-3
content type line 23
PMID 23487168
PQID 1317409431
PQPubID 23479
PageCount 40
ParticipantIDs proquest_miscellaneous_1317409431
pubmed_primary_23487168
crossref_primary_10_1124_pr_112_007278
crossref_citationtrail_10_1124_pr_112_007278
elsevier_sciencedirect_doi_10_1124_pr_112_007278
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2013-04-01
PublicationDateYYYYMMDD 2013-04-01
PublicationDate_xml – month: 04
  year: 2013
  text: 2013-04-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Pharmacological reviews
PublicationTitleAlternate Pharmacol Rev
PublicationYear 2013
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Cappelli, Nannicini, Gallelli, Giuliani, Valenti, Mohr, Anzini, Mennuni, Ferrari, Caselli (bib490) 2008; 51
Wienen, Entzeroth (bib438) 1994; 12
Gandhi, Meyer, Brooks (bib123) 1999; 59
Miura, Satoh, Kagaya, Saito, Inoue, Ohkubo, Habuchi, Suzuki (bib268) 2009; 34
Crawford, Frey, Cote (bib74) 1992; 41
Séchaud, Graf, Bigler, Gruendl, Letzkus, Merz (bib349) 2002; 40
Bühlmayer, Criscione, Fuhrer, Furet, de Gasparo, Stutz, Whitebread (bib44) 1991; 34
Kamiyama, Nakai, Mikkaichi, Okudaira, Okazaki (bib184) 2010; 86
Li, Zhu, Yang, Shi (bib228) 2010; 16
Takashima, Hashizume, Katayama, Murai, Wada, Maeda, Sugiyama, Watanabe (bib390) 2011; 8
Yasar, Babaoglu, Bozkurt (bib463) 2008; 103
Poggioli, Lazar, Houillier, Gardin, Achard, Paillard (bib320) 1992; 263
Cianchetti, Del Fiorentino, Colognato, Di Stefano, Franzoni, Pedrinelli (bib69) 2008; 198
Han, Guo, Chen, Chen, Tan, Zhou (bib141) 2009; 65
de Gasparo, Catt, Inagami, Wright, Unger (bib81) 2000; 52
Krieter, Colletti, Miller, Stearns (bib209) 1995; 273
Li, Bains, Ferguson (bib232) 1993; 30
Miura, Karnik, Saku (bib270) 2011; 12
Bhuiyan, Ishiguro, Hossain, Nakamura, Ozaki, Miura, Nagatomo (bib33) 2009; 85
Kazierad, Martin, Blum, Tenero, Ilson, Boike, Etheredge, Jorkasky (bib190) 1997; 62
Mizuno, Sada, Ikeda, Fukuda, Miyamoto, Yanagisawa, Koike (bib275) 1995; 285
Polevaya, Mavromoustakos, Zoumboulakis, Golic Grdadolnik, Roumelioti, Giatas, Mutule, Keivish, Vlahakos, Iliodromitis (bib321) 2001; 9
Shimizu, Takashima, Yamane, Sasaki, Kageyama, Hashizume, Maeda, Sugiyama, Watanabe, Senda (bib355) 2012; 39
.
Watanabe, Kusuhara, Watanabe, Debori, Maeda, Kondo, Nakayama, Horita, Ogilvie, Parkinson (bib433) 2011; 39
Hosomi, Nishiyama, Ban, Naya, Takahashi, Kohno, Koziol (bib156) 2005; 134
Maillard, Würzner, Nussberger, Centeno, Burnier, Brunner (bib249) 2002; 71
Nakaya, Ayaori, Hisada, Sawada, Tanaka, Iwamoto, Ogura, Yakushiji, Kusuhara, Nakamura (bib293) 2007; 14
Schwocho, Masonson (bib347) 2001; 41
Chiu, McCall, Roscoe (bib63) 1992; 188
He, Yang, Ma, Luo, Ma, Feng, Cao, Yan, Liu, Tepel (bib149) 2010; 55
Klaassen, Aleksunes (bib198) 2010; 62
Duron, Hanon (bib92) 2010; 20
Kenakin (bib193) 2004; 65
Chando, Everett, Kahle, Starrett, Vachharajani, Shyu, Kripalani, Barbhaiya (bib57) 1998; 26
Fogari, Zoppi, Ferrari, Mugellini, Preti, Lazzari, Derosa (bib112) 2009; 41
Tsuchida, Matsusaka, Chen, Okubo, Niimura, Nishimura, Fogo, Utsunomiya, Inagami, Ichikawa (bib406) 1998; 101
Abdelrahman, Pang (bib1) 1992; 70
Huber, Bolbrinker, Kreutz (bib158) 2006; 28
Siragy, Carey (bib361) 2010; 31
Herbert, Delisée, Dol, Schaeffer, Cazaubon, Nisato, Chatelain (bib151) 1994; 251
Tsukuda, Mogi, Iwanami, Min, Sakata, Jing, Iwai, Horiuchi (bib409) 2009; 54
Yazdanian, Glynn, Wright, Hawi (bib467) 1998; 15
Wada, Inada, Sanada, Ojima, Shibouta, Noda, Nishikawa (bib427) 1994; 253
Tanaka, Nagasawa, Matsui, Hamano, Iwatani, Kawada, Horio, Ito, Isaka, Imai (bib394) 2009; 13
Lambert, Champion, Kadowitz (bib218) 1998; 76
Kappert, Tsuprykov, Kaufmann, Fritzsche, Ott, Goebel, Bähr, Hässle, Gust, Fleck (bib186) 2009; 54
Casimiro-Garcia, Filzen, Flynn, Bigge, Chen, Davis, Dudley, Edmunds, Esmaeil, Geyer (bib50) 2011; 54
Lacour, Canals, Galindo, Cazaubon, Segondy, Nisato (bib216) 1994; 264
Ransom, Sharif, Dunne, Momiyama, Melching (bib323) 1992; 58
Li, Wang, Gao, Zou (bib229) 2009; 37
Yanagisawa, Amemiya, Kanazaki, Shimoji, Fujimoto, Kitahara, Sada, Mizuno, Ikeda, Miyamoto (bib460) 1996; 39
Tsukamoto O and Kitakaze M (2013) It is time to reconsider the cardiovascular protection afforded by RAAS blockade-overview of RAAS systems.
Arsenault, Lehoux, Lanthier, Cabana, Guillemette, Lavigne, Leduc, Escher (bib12) 2010; 20
Fukuhara, Neves, Li, Diz, Ferrario, Brosnihan (bib121) 2001; 19
Boulay, Servant, Luong, Escher, Guillemette (bib39) 1992; 41
Trippodo, Panchal, Fox (bib405) 1995; 272
Hong, Zhang, Mao, Jiang, Zhang, Yu, Tang, Xing, Xu (bib154) 2005; 61
Nishikawa, Inada, Shibouta, Wada, Ojima, Kubo, Naka (bib297) 1994; 5
Fabiani, Dinh, Nassis, Casley, Johnston (bib100) 2000; 99
Zhang, Pfaffendorf, Zhang, Van Zwieten (bib478) 1994; 252
Kovacs, Tenero, Martin, Ilson, Jorkasky (bib207) 1999; 19
Leung, Rapp, Walsh, Zeitung, Eglen (bib226) 1993; 267
Erbe, Gartrell, Zhang, Suri, Kirincich, Will, Perreault, Wang, Tobin (bib97) 2006; 45
Yin, Maekawa, Kamide, Saito, Hanada, Miyashita, Kokubo, Akaiwa, Otsubo, Nagatsuka (bib468) 2008; 31
Huwiler, van Rossum, Wartmann, Pfeilschifter (bib161) 1998; 343
Liu, Shankley, Welsh, Black (bib240) 1992; 106
Tanigawara, Yoshihara, Kuramoto, Arakawa (bib395) 2009; 24
Tu, Liao, Zou, Du, Run, Wang, Li (bib410) 2008; 29
Noda, Fushiki, Murakami, Sasaki, Miyoshi, Kakuta, Nishimura (bib300) 2012; 39
Miura, Matsuo, Kiya, Karnik, Saku (bib272) 2010; 391
Tian, Miyazaki, Ichiki, Imayama, Inanaga, Ohtsubo, Yano, Takeda, Sunagawa (bib401) 2009; 53
Sica, Marino, Hammett, Ferreira, Gehr, Ford (bib359) 1997; 62
Hsueh, Davidai, Henry, Mudaliar (bib157) 2010; 12
Stangier, Su (bib369) 2000; 40
Sung, Arleth, Storer, Ohlstein (bib383) 1994; 271
Stearns, Doss, Miller, Chiu (bib377) 1991; 19
Lipkowitz (bib236) 2012; 14
Stangier, Su, Fraunhofer, Tetzloff (bib371) 2000; 40
Ojima, Inada, Shibouta, Wada, Sanada, Kubo, Nishikawa (bib311) 1997; 319
Verheijen, Fierens, Debacker, Vauquelin, Vanderheyden (bib422) 2000; 14
Bernhart, Perreaut, Ferrari, Muneaux, Assens, Clément, Haudricourt, Muneaux, Taillades, Vignal (bib29) 1993; 36
Kumar, Luan, Pathak, Salhan, Magoon, Singhal (bib211) 2010; 32
Zoumpoulakis, Grdadolnik, Matsoukas, Mavromoustakos (bib483) 2002; 28
Wang, Brooks (bib430) 1992; 261
Müller, Cohen, de Gasparo, Sioufi, Racine-Poon, Howald (bib281) 1994; 47
Maillard, Mazzolai, Daven, Centeno, Nussberger, Brunner, Burnier (bib247) 1999; 12
Tanabe, Ueno, Tsujimoto (bib393) 1993; 150
Yamashita, Ohtani, Koyabu, Ushigome, Satoh, Murakami, Uchiumi, Nakamura, Kuwano, Tsujimoto (bib458) 2006; 58
Fromm (bib114) 2002; 54
Ko, Glodny, Stier, Totzke, Nickenig, Düsing, Sachinidis, Vetter (bib200) 1997; 53
Rong, Li, Ebihara, Zhao, Naowaboot, Kusakabe, Kuwahara, Murray, Nakao (bib332) 2010; 53
Sato, Iwanaga, Mamada, Ogihara, Yabuuchi, Maeda, Tamai (bib337) 2008; 25
Pepperell, Nemeth, Yamada, Naftolin (bib318) 1993; 133
Nishimura, Ito, Hoe, Saavedra (bib298) 2000; 871
Schupp, Janke, Clasen, Unger, Kintscher (bib346) 2004; 109
Choi, Kim, Chung, Lee, Jang, Bae, Lee (bib64) 2012; 68
Liu, Hedberg, Goldenberg, Harris, Webb (bib237) 1992; 44
Hübner, Högemann, Sunzel, Riddell (bib159) 1997; 11
Stangier, Schmid, Türck, Switek, Verhagen, Peeters, van Marle, Tamminga, Sollie, Jonkman (bib367) 2000; 40
Gleiter, Jägle, Gresser, Mörike (bib127) 2004; 22
Almansa, Gómez, Cavalcanti, de Arriba, García-Rafanell, Forn (bib6) 1997; 40
Wong, Price, Chiu, Duncia, Carini, Wexler, Johnson, Timmermans (bib445) 1990; 252
Jonkman, van Lier, van Heiningen, Lins, Sennewald, Högemann (bib181) 1997; 11
Clemenz, Frost, Schupp, Caron, Foryst-Ludwig, Böhm, Hartge, Gust, Staels, Unger (bib71) 2008; 57
Wellstein, Belz, Palm (bib436) 1988; 246
Kondo, Yoshida, Yoshimura, Motohashi, Tanayama (bib205) 1996; 46
Violin, DeWire, Yamashita, Rominger, Nguyen, Schiller, Whalen, Gowen, Lark (bib423) 2010; 335
Aguilera (bib3) 1992; 90
Jiang, Liu, Hu (bib179) 2009; 64
Ojima, Igata, Tanaka, Sakamoto, Kuroita, Kohara, Kubo, Fuse, Imura, Kusumoto (bib310) 2011; 336
Faure, Oudart, Javellaud, Fournier, Warnock, Achard (bib101) 2006; 24
Ishizuka, Fujimori, Nishida, Sakurai, Yoshigae, Nakahara, Kurihara, Ikeda, Izumi (bib169) 2012; 40
Kaukonen, Olkkola, Neuvonen (bib189) 1998; 53
Amano, Yamaguchi, Ohno, Niimi, Orita, Sakashita, Takeuchi (bib8) 2012; 35
Washida, Ihara, Nishio, Fujita, Maki, Yamada, Takahashi, Wu, Kihara, Ito (bib432) 2010; 41
Rohatagi, Carrothers, Kshirsagar, Khariton, Lee, Salazar (bib331) 2008; 48
Fierens, Vanderheyden, De Backer, Vauquelin (bib107) 1999; 367
Nussberger, Koike (bib303) 2004; 26
Colussi, Parisot, Rossolino, Brunner, Lefèvre (bib72) 1997; 37
Sugimoto, Kazdová, Qi, Hyakukoku, Kren, Simáková, Zídek, Kurtz, Pravenec (bib382) 2008; 26
de Gasparo, Whitebread (bib82) 1995; 59
Iwai, Chen, Imura, Horiuchi (bib173) 2007; 20
Nakamura, Nagano, Kobayashi, Higaki, Mikami, Kawaguchi, Onishi, Ogihara (bib286) 1994; 267
Balt, Mathy, Pfaffendorf, van Zwieten (bib21) 2001; 19
Tatami, Yamamura, Sarashina, Yong, Igarashi, Tanigawara (bib396) 2004; 19
Miura, Okabe, Matsuo, Karnik, Saku (bib273) 2013; 36
Vanderheyden, Fierens, De Backer, Fraeyman, Vauquelin (bib418) 1999; 126
Steinmetz, Brouwers, Nickenig, Wassmann (bib379) 2010; 14
Ishizuka, Fujimori, Kato, Noji-Sakikawa, Saito, Yoshigae, Kubota, Kurihara, Izumi, Ikeda (bib168) 2010; 285
Zhang, Mayeux (bib477) 2012; 63
Anzai, Ichida, Jutabha, Kimura, Babu, Jin, Srivastava, Kitamura, Hisatome, Endou (bib10) 2008; 283
Endo, Fukahori, Tokuhiro, Shinagawa, Walker, Yoshihara, Ishizuka, Ieiri, Sugiyama (bib96) 2012; 57
Champion, Kadowitz (bib56) 1997; 30
Challa VR, Ravindra Babu P, Challa SR, Johnson B, and Maheswari C (2013) Pharmacokinetic interaction study between quercetin and valsartan in rats and in vitro models.
Zhang, Zhang, Chen, Li, Yin, Zhong (bib480) 2006; 56
Alonen, Finel, Kostiainen (bib7) 2008; 76
Soldner, Christians, Susanto, Wacher, Silverman, Benet (bib363) 1999; 16
Delacrétaz, Nussberger, Biollaz, Waeber, Brunner (bib87) 1995; 25
Ribadeneira, Aungst, Eyermann, Huang (bib324) 1996; 13
DOI
Cassis, Police, Yiannikouris, Thatcher (bib51) 2008; 10
Ouali, Poulette, Penhoat, Saez (bib313) 1992; 43
Wienen, Hauel, Van Meel, Narr, Ries, Entzeroth (bib440) 1993; 110
Walcher, Hess, Heinz, Petscher, Vasic, Kintscher, Clemenz, Hartge, Raps, Hombach (bib428) 2008; 51
Caballero, Delpón, Valenzuela, Longobardo, González, Tamargo (bib47) 2001; 59
Kong, Tomasko, Waldman, Osborne, Deutsch, Goldberg, Bjornsson (bib206) 1995; 35
Virone-Oddos, Desangle, Provost, Cazes, Caussade, Cloarec (bib424) 1997; 120
Polidori, Ciccocioppo, Nisato, Cazaubon, Massi (bib322) 1998; 352
Wong, Christ, Wong, Lam (bib444) 1996; 52
Chansel, Vandermeersch, Pham, Ardaillou (bib59) 1993; 247
de Zeeuw, Remuzzi, Kirch (bib85) 1997; 11
Kobayashi, Ohno, Yoshida, Fukushima, Mamada, Nomura, Hirata, Machida, Shinoda, Suz
Montón (10.1124/pr.112.007278_bib277) 2000; 35
Bourrié (10.1124/pr.112.007278_bib40) 1999; 27
Brooks (10.1124/pr.112.007278_bib42) 1992; 345
Shibouta (10.1124/pr.112.007278_bib353) 1993; 266
Bühlmayer (10.1124/pr.112.007278_bib44) 1991; 34
Kaukonen (10.1124/pr.112.007278_bib189) 1998; 53
Nakashima (10.1124/pr.112.007278_bib290) 2005; 35
Patel (10.1124/pr.112.007278_bib315) 2010; 78
Weiss (10.1124/pr.112.007278_bib435) 2010; 31
Yoshihara (10.1124/pr.112.007278_bib471) 2005; 44
Sanni (10.1124/pr.112.007278_bib336) 2010; 161
Rosskopf (10.1124/pr.112.007278_bib333) 2008; 60
Fierens (10.1124/pr.112.007278_bib107) 1999; 367
Belz (10.1124/pr.112.007278_bib24) 1999; 66
Trippodo (10.1124/pr.112.007278_bib405) 1995; 272
Verheijen (10.1124/pr.112.007278_bib422) 2000; 14
Miura (10.1124/pr.112.007278_bib269) 2006; 281
Walcher (10.1124/pr.112.007278_bib428) 2008; 51
Li (10.1124/pr.112.007278_bib231) 2001; 15
Balt (10.1124/pr.112.007278_bib22) 2001; 19
Hawcock (10.1124/pr.112.007278_bib147) 1992; 105
Wada (10.1124/pr.112.007278_bib426) 1996; 19
Ouali (10.1124/pr.112.007278_bib313) 1992; 43
Bae (10.1124/pr.112.007278_bib16) 2012; 50
Hong (10.1124/pr.112.007278_bib154) 2005; 61
Yasar (10.1124/pr.112.007278_bib463) 2008; 103
Blumer (10.1124/pr.112.007278_bib37) 2009; 49
Sakarcan (10.1124/pr.112.007278_bib334) 2001; 41
Aguilera (10.1124/pr.112.007278_bib3) 1992; 90
Herbert (10.1124/pr.112.007278_bib151) 1994; 251
Ito (10.1124/pr.112.007278_bib171) 1995; 18
Hayashi (10.1124/pr.112.007278_bib148) 1997; 47
De Smet (10.1124/pr.112.007278_bib84) 1995; 40
Funao (10.1124/pr.112.007278_bib122) 2009; 2
Goyal (10.1124/pr.112.007278_bib135) 2010; 185
Yamada (10.1124/pr.112.007278_bib453) 2007; 35
Balt (10.1124/pr.112.007278_bib20) 2002; 40
Feig (10.1124/pr.112.007278_bib102) 2008; 359
Imayama (10.1124/pr.112.007278_bib163) 2006; 72
Kusumoto (10.1124/pr.112.007278_bib214) 2011; 669
Washida (10.1124/pr.112.007278_bib432) 2010; 41
Kusunoki (10.1124/pr.112.007278_bib215) 2012; 59
Ernsberger (10.1124/pr.112.007278_bib99) 1992; 263
Poggioli (10.1124/pr.112.007278_bib320) 1992; 263
Duron (10.1124/pr.112.007278_bib92) 2010; 20
Lin (10.1124/pr.112.007278_bib234) 1992; 35
Ernsberger (10.1124/pr.112.007278_bib98) 2007; 7
Liu (10.1124/pr.112.007278_bib239) 1993; 240
Flesch (10.1124/pr.112.007278_bib111) 1995; 289
Benson (10.1124/pr.112.007278_bib26) 2008; 26
Booz (10.1124/pr.112.007278_bib38) 1992; 130
Yanagisawa (10.1124/pr.112.007278_bib460) 1996; 39
Caballero (10.1124/pr.112.007278_bib48) 2000; 101
Kajiya (10.1124/pr.112.007278_bib182) 2011; 29
Cassis (10.1124/pr.112.007278_bib51) 2008; 10
Edwards (10.1124/pr.112.007278_bib94) 1992; 260
Yamamoto (10.1124/pr.112.007278_bib456) 2009; 54
Balt (10.1124/pr.112.007278_bib19) 2001; 38
Vauquelin (10.1124/pr.112.007278_bib421) 2001; 61
Sandwall (10.1124/pr.112.007278_bib335) 1999; 55
Kim (10.1124/pr.112.007278_bib195) 2012; 60
Li (10.1124/pr.112.007278_bib232) 1993; 30
Zanchi (10.1124/pr.112.007278_bib476) 2007; 293
Nussberger (10.1124/pr.112.007278_bib303) 2004; 26
Wienen (10.1124/pr.112.007278_bib440) 1993; 110
Chansel (10.1124/pr.112.007278_bib59) 1993; 247
Maillard (10.1124/pr.112.007278_bib249) 2002; 71
Zhang (10.1124/pr.112.007278_bib477) 2012; 63
Nishimura (10.1124/pr.112.007278_bib298) 2000; 871
Delacrétaz (10.1124/pr.112.007278_bib87) 1995; 25
Ferrington (10.1124/pr.112.007278_bib106) 2011; 3
Nakaya (10.1124/pr.112.007278_bib293) 2007; 14
Miura (10.1124/pr.112.007278_bib271) 2008; 22
Gohlke (10.1124/pr.112.007278_bib129) 2001; 298
Zhang (10.1124/pr.112.007278_bib478) 1994; 252
Kong (10.1124/pr.112.007278_bib206) 1995; 35
Steinmetz (10.1124/pr.112.007278_bib379) 2010; 14
Ji (10.1124/pr.112.007278_bib178) 1994; 269
Tanigawara (10.1124/pr.112.007278_bib395) 2009; 24
Inada (10.1124/pr.112.007278_bib165) 1994; 268
Manolis (10.1124/pr.112.007278_bib251) 2000; 22
Tamura (10.1124/pr.112.007278_bib392) 1997; 12
Séchaud (10.1124/pr.112.007278_bib349) 2002; 40
Wong (10.1124/pr.112.007278_bib448) 1990; 255
Suzuki (10.1124/pr.112.007278_bib386) 2001; 24
Inada (10.1124/pr.112.007278_bib164) 1999; 13
Scalera (10.1124/pr.112.007278_bib338) 2008; 51
Lambert (10.1124/pr.112.007278_bib218) 1998; 76
Chiu (10.1124/pr.112.007278_bib61) 1990; 1
Fischer (10.1124/pr.112.007278_bib108) 2002; 72
Kurtz (10.1124/pr.112.007278_bib213) 2004; 22
Berellini (10.1124/pr.112.007278_bib28) 2005; 48
Kenakin (10.1124/pr.112.007278_bib193) 2004; 65
Nakagomi-Hagihara (10.1124/pr.112.007278_bib285) 2006; 34
Robertson (10.1124/pr.112.007278_bib329) 1994; 50
Christophe (10.1124/pr.112.007278_bib68) 1995; 281
Comiter (10.1124/pr.112.007278_bib73) 2012; 385
Guo (10.1124/pr.112.007278_bib140) 2009; 47
Wong (10.1124/pr.112.007278_bib444) 1996; 52
Yang (10.1124/pr.112.007278_bib461) 2012; 37
Yoshida (10.1124/pr.112.007278_bib470) 2006; 49
Lee (10.1124/pr.112.007278_bib223) 2003; 23
Martin (10.1124/pr.112.007278_bib255) 1998; 38
Zhou (10.1124/pr.112.007278_bib482) 2009; 30
Le (10.1124/pr.112.007278_bib220) 2007; 151
Asano (10.1124/pr.112.007278_bib14) 2006; 34
Delisée (10.1124/pr.112.007278_bib88) 1993; 247
Jenkinson (10.1124/pr.112.007278_bib177) 1995; 47
Madwed (10.1124/pr.112.007278_bib245) 1994; 12
Feng (10.1124/pr.112.007278_bib103) 1995; 270
Iwanami (10.1124/pr.112.007278_bib175) 2010; 28
Bähr (10.1124/pr.112.007278_bib17) 2011; 58
Link (10.1124/pr.112.007278_bib235) 2006; 24
Nishikawa (10.1124/pr.112.007278_bib297) 1994; 5
Nakashima (10.1124/pr.112.007278_bib292) 1996; 2
Martineau (10.1124/pr.112.007278_bib257) 1995; 73
Pang (10.1124/pr.112.007278_bib314) 2012; 30
Michel (10.1124/pr.112.007278_bib264) 1995; 352
Malerczyk (10.1124/pr.112.007278_bib250) 1998; 45
Gandhi (10.1124/pr.112.007278_bib123) 1999; 59
Stangier (10.1124/pr.112.007278_bib368) 2000; 40
Jiang (10.1124/pr.112.007278_bib179) 2009; 64
Brunner (10.1124/pr.112.007278_bib43) 1997; 10
Kasichayanula (10.1124/pr.112.007278_bib188) 2012; 29
Casimiro-Garcia (10.1124/pr.112.007278_bib50) 2011; 54
Cazaubon (10.1124/pr.112.007278_bib52) 1993; 265
Vanderheyden (10.1124/pr.112.007278_bib418) 1999; 126
Schmidt (10.1124/pr.112.007278_bib343) 1998; 53
Tamura (10.1124/pr.112.007278_bib391) 1997; 30
Müller (10.1124/pr.112.007278_bib281) 1994; 47
Schupp (10.1124/pr.112.007278_bib346) 2004; 109
Nishino (10.1124/pr.112.007278_bib299) 2000; 28
Kohara (10.1124/pr.112.007278_bib203) 1996; 39
Suwannakul (10.1124/pr.112.007278_bib385) 2008; 53
Ohlstein (10.1124/pr.112.007278_bib307) 1992; 262
Zaidenstein (10.1124/pr.112.007278_bib475) 2001; 23
Bhuiyan (10.1124/pr.112.007278_bib33) 2009; 85
Soldner (10.1124/pr.112.007278_bib362) 2000; 129
Yao (10.1124/pr.112.007278_bib462) 2008; 28
Champion (10.1124/pr.112.007278_bib55) 1998; 274
Cianchetti (10.1124/pr.112.007278_bib69) 2008; 198
Stangier (10.1124/pr.112.007278_bib369) 2000; 40
Abdelrahman (10.1124/pr.112.007278_bib1) 1992; 70
Martin (10.1124/pr.112.007278_bib256) 1997; 43
Kamiyama (10.1124/pr.112.007278_bib184) 2010; 86
Garcha (10.1124/pr.112.007278_bib136) 1999; 127
Miura (10.1124/pr.112.007278_bib272) 2010; 391
Rong (10.1124/pr.112.007278_bib332) 2010; 53
Liu (10.1124/pr.112.007278_bib238) 2008; 325
Fukuda (10.1124/pr.112.007278_bib120) 2008; 36
Tenero (10.1124/pr.112.007278_bib399) 1998; 46
Stangier (10.1124/pr.112.007278_bib373) 2000; 28
de Mey (10.1124/pr.112.007278_bib83) 1993; 44
Roccon (10.1124/pr.112.007278_bib330) 1994; 111
Kenakin (10.1124/pr.112.007278_bib194) 1987
Wong (10.1124/pr.112.007278_bib447) 1990; 15
Ishizuka (10.1124/pr.112.007278_bib168) 2010; 285
van Lier (10.1124/pr.112.007278_bib416) 1997; 11
Tsuchida (10.1124/pr.112.007278_bib406) 1998; 101
García-Sáinz (10.1124/pr.112.007278_bib124) 1997; 154
Bui (10.1124/pr.112.007278_bib45) 1992; 219
Tanaka (10.1124/pr.112.007278_bib394) 2009; 13
Ojima (10.1124/pr.112.007278_bib311) 1997; 319
Wennerholm (10.1124/pr.112.007278_bib437) 2006; 62
Sica (10.1124/pr.112.007278_bib356) 2002; 3
Lo (10.1124/pr.112.007278_bib241) 1995; 58
Tenero (10.1124/pr.112.007278_bib397) 1998; 18
Sica (10.1124/pr.112.007278_bib359) 1997; 62
Huber (10.1124/pr.112.007278_bib158) 2006; 28
Varty (10.1124/pr.112.007278_bib420) 1994; 81
Ribadeneira (10.1124/pr.112.007278_bib324) 1996; 13
10.1124/pr.112.007278_bib53
Sugimoto (10.1124/pr.112.007278_bib382) 2008; 26
Yamashita (10.1124/pr.112.007278_bib458) 2006; 58
Feolde (10.1124/pr.112.007278_bib105) 1993; 245
Wong (10.1124/pr.112.007278_bib446) 1990; 15
Soldner (10.1124/pr.112.007278_bib363) 1999; 16
Hosomi (10.1124/pr.112.007278_bib156) 2005; 134
Ikejima (10.1124/pr.112.007278_bib162) 2008; 26
Alonen (10.1124/pr.112.007278_bib7) 2008; 76
Morgan (10.1124/pr.112.007278_bib278) 1997; 61
Chang (10.1124/pr.112.007278_bib58) 2006; 34
Miura (10.1124/pr.112.007278_bib267) 2009; 399
Polidori (10.1124/pr.112.007278_bib322) 1998; 352
Klaassen (10.1124/pr.112.007278_bib198) 2010; 62
Polevaya (10.1124/pr.112.007278_bib321) 2001; 9
Li (10.1124/pr.112.007278_bib228) 2010; 16
Belz (10.1124/pr.112.007278_bib23) 2000; 1
Arsenault (10.1124/pr.112.007278_bib12) 2010; 20
Miura (10.1124/pr.112.007278_bib274) 2003; 26
Miura (10.1124/pr.112.007278_bib268) 2009; 34
Gossmann (10.1124/pr.112.007278_bib134) 2000; 68
Wellstein (10.1124/pr.112.007278_bib436) 1988; 246
Toba (10.1124/pr.112.007278_bib402) 2012; 685
Yamada (10.1124/pr.112.007278_bib452) 2011; 21
Kline (10.1124/pr.112.007278_bib199) 1994; 24
Obermüller (10.1124/pr.112.007278_bib304) 1991; 132
Cappelli (10.1124/pr.112.007278_bib49) 2004; 47
Speth (10.1124/pr.112.007278_bib366) 1990; 169
Kiya (10.1124/pr.112.007278_bib197) 2010; 32
Wright (10.1124/pr.112.007278_bib450) 2011; 95
Groth (10.1124/pr.112.007278_bib137) 2003; 21
Younis (10.1124/pr.112.007278_bib473) 2010; 59
Kazierad (10.1124/pr.112.007278_bib191) 1998; 38
Young (10.1124/pr.112.007278_bib472) 2000; 40
Vachharajani (10.1124/pr.112.007278_bib412) 1998; 38
Gardiner (10.1124/pr.112.007278_bib125) 2011; 39
Wang (10.1124/pr.112.007278_bib430) 1992; 261
Yoshida (10.1124/pr.112.007278_bib469) 2008; 36
Burnier (10.1124/pr.112.007278_bib46) 2001; 103
Tenero (10.1124/pr.112.007278_bib398) 1998; 19
Schwocho (10.1124/pr.112.007278_bib347) 2001; 41
Crawford (10.1124/pr.112.007278_bib74) 1992; 41
Li (10.1124/pr.112.007278_bib233) 2009; 39
Violin (10.1124/pr.112.007278_bib423) 2010; 335
Kondo (10.11
References_xml – volume: 15
  start-page: 364
  year: 1994
  end-page: 369
  ident: bib328
  article-title: Agonist-antagonist interactions at angiotensin receptors: application of a two-state receptor model
  publication-title: Trends Pharmacol Sci
– volume: 62
  start-page: 417
  year: 1997
  end-page: 425
  ident: bib190
  article-title: Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers
  publication-title: Clin Pharmacol Ther
– volume: 263
  start-page: F411
  year: 1992
  end-page: F416
  ident: bib99
  article-title: Angiotensin II receptor subtypes in cultured rat renal mesangial cells
  publication-title: Am J Physiol
– volume: 292
  start-page: 238
  year: 2000
  end-page: 246
  ident: bib230
  article-title: Novel angiotensin II AT(
  publication-title: J Pharmacol Exp Ther
– volume: 90
  start-page: 53
  year: 1992
  end-page: 60
  ident: bib3
  article-title: Role of angiotensin II receptor subtypes on the regulation of aldosterone secretion in the adrenal glomerulosa zone in the rat
  publication-title: Mol Cell Endocrinol
– volume: 72
  start-page: 184
  year: 2006
  end-page: 190
  ident: bib163
  article-title: Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor γ
  publication-title: Cardiovasc Res
– volume: 28
  start-page: 125
  year: 2002
  end-page: 135
  ident: bib483
  article-title: Structure elucidation and conformational properties of eprosartan, a non peptide angiotensin II AT
  publication-title: J Pharm Biomed Anal
– volume: 260
  start-page: 175
  year: 1992
  end-page: 181
  ident: bib93
  article-title: Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566
  publication-title: J Pharmacol Exp Ther
– volume: 38
  start-page: 246
  year: 1998
  end-page: 255
  ident: bib252
  article-title: Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects
  publication-title: J Clin Pharmacol
– volume: 302
  start-page: 237
  year: 2009
  end-page: 243
  ident: bib415
  article-title: Sartan-AT
  publication-title: Mol Cell Endocrinol
– volume: 19
  start-page: 465
  year: 2001
  end-page: 473
  ident: bib21
  article-title: Inhibition of angiotensin II-induced facilitation of sympathetic neurotransmission in the pithed rat: a comparison between losartan, irbesartan, telmisartan, and captopril
  publication-title: J Hypertens
– volume: 13
  start-page: 111
  year: 2003
  end-page: 119
  ident: bib381
  article-title: Binding properties of telmisartan (micardis) for human angiotensin II receptors
  publication-title: Clin Pharmacol Ther (Tokyo)
– volume: 252
  start-page: 337
  year: 1994
  end-page: 340
  ident: bib478
  article-title: A non-competitive type of angiotensin-receptor antagonism by losartan in renal artery preparations
  publication-title: Eur J Pharmacol
– volume: 150
  start-page: 862
  year: 2009
  end-page: 870
  ident: bib388
  article-title: A selective peroxisome proliferator-activated receptor-γ modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones
  publication-title: Endocrinology
– volume: 111
  start-page: 145
  year: 2006
  end-page: 173
  ident: bib139
  article-title: Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance
  publication-title: Pharmacol Ther
– volume: 15
  start-page: 459
  year: 1990
  end-page: 468
  ident: bib447
  article-title: Hypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Nonpeptide angiotensin II receptor antagonists: X
  publication-title: Hypertension
– volume: 252
  start-page: 719
  year: 1990
  end-page: 725
  ident: bib445
  article-title: Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent
  publication-title: J Pharmacol Exp Ther
– volume: 47
  start-page: 620
  year: 1997
  end-page: 625
  ident: bib148
  article-title: Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 3rd Communication: hemodynamic effects of valsartan in rats and dogs
  publication-title: Arzneimittelforschung
– volume: 56
  start-page: 135
  year: 2000
  end-page: 140
  ident: bib387
  article-title: In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists
  publication-title: Eur J Clin Pharmacol
– reference: DOI
– volume: 219
  start-page: 147
  year: 1992
  end-page: 151
  ident: bib45
  article-title: Losartan potassium, a nonpeptide antagonist of angiotensin II, chronically administered p.o. does not readily cross the blood-brain barrier
  publication-title: Eur J Pharmacol
– volume: 40
  start-page: 1331
  year: 2000
  end-page: 1337
  ident: bib372
  article-title: Steady-state pharmacodynamics and pharmacokinetics of warfarin in the presence and absence of telmisartan in healthy male volunteers
  publication-title: J Clin Pharmacol
– volume: 30
  start-page: 259
  year: 2009
  end-page: 264
  ident: bib482
  article-title: Transport characteristics of candesartan in human intestinal Caco-2 cell line
  publication-title: Biopharm Drug Dispos
– volume: 1
  start-page: 288
  year: 2001
  end-page: 292
  ident: bib142
  article-title: CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro
  publication-title: Pharmacogenomics J
– volume: 18
  start-page: 69
  year: 1995
  end-page: 75
  ident: bib171
  article-title: Effects of the non-peptide angiotensin II receptor antagonist TCV-116 on systemic and renal hemodynamics in dogs with renal hypertension
  publication-title: Hypertens Res
– volume: 267
  start-page: 1521
  year: 1993
  end-page: 1528
  ident: bib226
  article-title: Characterization of angiotensin II receptors in smooth muscle preparations of the guinea pig in vitro
  publication-title: J Pharmacol Exp Ther
– volume: 68
  start-page: 149
  year: 2012
  end-page: 154
  ident: bib64
  article-title: CYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects
  publication-title: Eur J Clin Pharmacol
– volume: 20
  start-page: 281
  year: 1992
  end-page: 287
  ident: bib378
  article-title: The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices
  publication-title: Drug Metab Dispos
– volume: 53
  start-page: 1727
  year: 2010
  end-page: 1731
  ident: bib332
  article-title: Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice
  publication-title: Diabetologia
– volume: 29
  start-page: 284
  year: 1997
  end-page: 290
  ident: bib145
  article-title: The pharmacologic profile of 606A, a novel angiotensin II receptor antagonist
  publication-title: J Cardiovasc Pharmacol
– volume: 19
  start-page: 75
  year: 1996
  end-page: 81
  ident: bib426
  article-title: Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats
  publication-title: Hypertens Res
– volume: 20
  start-page: 903
  year: 2010
  end-page: 914
  ident: bib92
  article-title: Antihypertensive treatments, cognitive decline, and dementia
  publication-title: J Alzheimers Dis
– volume: 59
  start-page: 89
  year: 1999
  end-page: 94
  ident: bib123
  article-title: Effects of eprosartan on glomerular injury in rats with reduced renal mass
  publication-title: Pharmacology
– volume: 16
  start-page: S64
  year: 2002
  end-page: S70
  ident: bib76
  article-title: The renin-angiotensin system in the brain: possible therapeutic implications for AT(
  publication-title: J Hum Hypertens
– volume: 283
  start-page: 26834
  year: 2008
  end-page: 26838
  ident: bib10
  article-title: Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans
  publication-title: J Biol Chem
– volume: 199
  start-page: 295
  year: 2008
  end-page: 303
  ident: bib36
  article-title: Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice
  publication-title: Atherosclerosis
– volume: 43
  start-page: 993
  year: 2004
  end-page: 1002
  ident: bib27
  article-title: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity
  publication-title: Hypertension
– volume: 24
  start-page: 1809
  year: 2006
  end-page: 1816
  ident: bib176
  article-title: Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-γ activation
  publication-title: J Hypertens
– volume: 55
  start-page: 279
  year: 1999
  end-page: 283
  ident: bib335
  article-title: Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19)
  publication-title: Eur J Clin Pharmacol
– volume: 289
  start-page: 267
  year: 1995
  end-page: 273
  ident: bib143
  article-title: Kinetic studies on the interaction of nonlabeled antagonists with the angiotensin II receptor
  publication-title: Eur J Pharmacol
– volume: 26
  start-page: 964
  year: 2008
  end-page: 972
  ident: bib162
  article-title: Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-γ-modulating activity, on nitric oxide bioavailability and atherosclerotic change
  publication-title: J Hypertens
– volume: 29
  start-page: 640
  year: 2009
  end-page: 647
  ident: bib109
  article-title: Angiotensin II modulates BBB permeability via activation of the AT(
  publication-title: J Cereb Blood Flow Metab
– volume: 19
  start-page: S33
  year: 2001
  end-page: S40
  ident: bib425
  article-title: Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil
  publication-title: J Hypertens Suppl
– volume: 266
  start-page: 114
  year: 1993
  end-page: 120
  ident: bib353
  article-title: Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116)
  publication-title: J Pharmacol Exp Ther
– volume: 40
  start-page: 1355
  year: 2000
  end-page: 1364
  ident: bib374
  article-title: Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers
  publication-title: J Clin Pharmacol
– volume: 46
  start-page: 1074
  year: 2005
  end-page: 1079
  ident: bib11
  article-title: Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies
  publication-title: Am J Kidney Dis
– volume: 19
  start-page: S21
  year: 2001
  end-page: S32
  ident: bib217
  article-title: The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction
  publication-title: J Hypertens Suppl
– volume: 52
  start-page: 441
  year: 1997
  end-page: 449
  ident: bib282
  article-title: Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects
  publication-title: Eur J Clin Pharmacol
– volume: 10
  start-page: S101
  year: 1999
  end-page: S103
  ident: bib54
  article-title: Analysis of the effects of candesartan on responses to angiotensin II in the hindquarters vascular bed of the cat
  publication-title: J Am Soc Nephrol
– volume: 151
  start-page: 952
  year: 2007
  end-page: 962
  ident: bib220
  article-title: Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT
  publication-title: Br J Pharmacol
– volume: 13
  start-page: 126
  year: 2000
  end-page: 128
  ident: bib132
  article-title: Effect of valsartan on renal handling of uric acid in healthy subjects
  publication-title: J Nephrol
– volume: 126
  start-page: 1057
  year: 1999
  end-page: 1065
  ident: bib418
  article-title: Distinction between surmountable and insurmountable selective AT
  publication-title: Br J Pharmacol
– volume: 26
  start-page: 2252
  year: 2006
  end-page: 2259
  ident: bib284
  article-title: Angiotensin II type 1 receptor-mediated inflammation is required for choroidal neovascularization
  publication-title: Arterioscler Thromb Vasc Biol
– volume: 25
  start-page: 41
  year: 2005
  end-page: 46
  ident: bib183
  article-title: Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers
  publication-title: Int J Clin Pharmacol Res
– volume: 59
  start-page: 303
  year: 1995
  end-page: 311
  ident: bib82
  article-title: Binding of valsartan to mammalian angiotensin AT1 receptors
  publication-title: Regul Pept
– volume: 29
  start-page: 163
  year: 2012
  end-page: 177
  ident: bib188
  article-title: Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin
  publication-title: Adv Ther
– volume: 49
  start-page: 115
  year: 1995
  end-page: 119
  ident: bib130
  article-title: Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT
  publication-title: Eur J Clin Pharmacol
– volume: 113
  start-page: 331
  year: 1994
  end-page: 333
  ident: bib341
  article-title: Mutations in transmembrane segment VII of the AT1 receptor differentiate between closely related insurmountable and competitive angiotensin antagonists
  publication-title: Br J Pharmacol
– volume: 30
  start-page: 33
  year: 1993
  end-page: 39
  ident: bib232
  article-title: Functional evidence that the angiotensin antagonist losartan crosses the blood-brain barrier in the rat
  publication-title: Brain Res Bull
– volume: 9
  start-page: 1639
  year: 2001
  end-page: 1647
  ident: bib321
  article-title: Synthesis and study of a cyclic angiotensin II antagonist analogue reveals the role of π*—π* interactions in the C-terminal aromatic residue for agonist activity and its structure resemblance with AT(1) non-peptide antagonists
  publication-title: Bioorg Med Chem
– volume: 188
  start-page: 1030
  year: 1992
  end-page: 1039
  ident: bib63
  article-title: [
  publication-title: Biochem Biophys Res Commun
– volume: 281
  start-page: 19288
  year: 2006
  end-page: 19295
  ident: bib269
  article-title: Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor
  publication-title: J Biol Chem
– volume: 23
  start-page: 115
  year: 2008
  end-page: 119
  ident: bib201
  article-title: The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan
  publication-title: Drug Metab Pharmacokinet
– volume: 58
  start-page: 1499
  year: 2006
  end-page: 1505
  ident: bib458
  article-title: Inhibitory effects of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic anion transporter 4
  publication-title: J Pharm Pharmacol
– volume: 20
  start-page: 579
  year: 2007
  end-page: 586
  ident: bib173
  article-title: TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation
  publication-title: Am J Hypertens
– volume: 58
  start-page: 1883
  year: 1992
  end-page: 1888
  ident: bib323
  article-title: AT
  publication-title: J Neurochem
– volume: 59
  start-page: 1200
  year: 2010
  end-page: 1209
  ident: bib473
  article-title: Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-γ activation
  publication-title: Metabolism
– volume: 40
  start-page: 1312
  year: 2000
  end-page: 1322
  ident: bib367
  article-title: Absorption, metabolism, and excretion of intravenously and orally administered [
  publication-title: J Clin Pharmacol
– volume: 60
  start-page: 49
  year: 2012
  end-page: 54
  ident: bib195
  article-title: Influence of ABCC2, SLCO1B1, and ABCG2 polymorphisms on the pharmacokinetics of olmesartan
  publication-title: J Cardiovasc Pharmacol
– volume: 20
  start-page: 377
  year: 2010
  end-page: 388
  ident: bib12
  article-title: A single-nucleotide polymorphism of alanine to threonine at position 163 of the human angiotensin II type 1 receptor impairs Losartan affinity
  publication-title: Pharmacogenet Genomics
– volume: 198
  start-page: 22
  year: 2008
  end-page: 28
  ident: bib69
  article-title: Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells
  publication-title: Atherosclerosis
– volume: 43
  start-page: 661
  year: 1997
  end-page: 664
  ident: bib256
  article-title: Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers
  publication-title: Br J Clin Pharmacol
– volume: 79
  start-page: 131
  year: 1999
  end-page: 139
  ident: bib364
  article-title: Inhibition of the angiotensin II Type 1 receptor by TCV-116: quantitation by in vitro autoradiography
  publication-title: Jpn J Pharmacol
– volume: 76
  start-page: 763
  year: 2008
  end-page: 772
  ident: bib7
  article-title: The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan
  publication-title: Biochem Pharmacol
– volume: 41
  start-page: 1798
  year: 2010
  end-page: 1806
  ident: bib432
  article-title: Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator-activated receptor-γ activation in mice with chronic cerebral hypoperfusion
  publication-title: Stroke
– volume: 24
  start-page: 1891
  year: 2006
  end-page: 1898
  ident: bib235
  article-title: Telmisartan inhibits beta2-integrin MAC-1 expression in human T-lymphocytes
  publication-title: J Hypertens
– volume: 12
  start-page: 1
  year: 2011
  end-page: 7
  ident: bib270
  article-title: Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects
  publication-title: J Renin Angiotensin Aldosterone Syst
– volume: 271
  start-page: 91
  year: 1994
  end-page: 99
  ident: bib319
  article-title: In vitro N-glucuronidation of SB 47436 (BMS 186295), a new AT1 nonpeptide angiotensin II receptor antagonist, by rat, monkey and human hepatic microsomal fractions
  publication-title: J Pharmacol Exp Ther
– volume: 17
  start-page: 1482
  year: 2000
  end-page: 1488
  ident: bib419
  article-title: Inhibition of angiotensin II-induced inositol phosphate production by triacid nonpeptide antagonists in CHO cells expressing human AT1 receptors
  publication-title: Pharm Res
– volume: 41
  start-page: 6640
  year: 2002
  end-page: 6650
  ident: bib225
  article-title: Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662
  publication-title: Biochemistry
– volume: 8
  start-page: 1789
  year: 2011
  end-page: 1798
  ident: bib390
  article-title: The involvement of organic anion transporting polypeptide in the hepatic uptake of telmisartan in rats: PET studies with [¹¹C]telmisartan
  publication-title: Mol Pharm
– volume: 104
  start-page: 771
  year: 1991
  end-page: 772
  ident: bib365
  article-title: Access of peripherally administered DuP 753 to rat brain angiotensin II receptors
  publication-title: Br J Pharmacol
– volume: 11
  start-page: S29
  year: 1997
  end-page: S30
  ident: bib325
  article-title: Bioavailability of candesartan is unaffected by food in healthy volunteers administered candesartan cilexetil
  publication-title: J Hum Hypertens
– volume: 36
  start-page: 1230
  year: 1993
  end-page: 1238
  ident: bib258
  article-title: Molecular shape comparison of angiotensin II receptor antagonists
  publication-title: J Med Chem
– volume: 40
  start-page: 50
  year: 2002
  end-page: 57
  ident: bib20
  article-title: Prejunctional and postjunctional inhibitory actions of eprosartan and candesartan in the isolated rabbit mesenteric artery
  publication-title: J Cardiovasc Pharmacol
– volume: 34
  start-page: 3105
  year: 1991
  end-page: 3114
  ident: bib44
  article-title: Nonpeptidic angiotensin II antagonists: synthesis and in vitro activity of a series of novel naphthalene and tetrahydronaphthalene derivatives
  publication-title: J Med Chem
– volume: 34
  start-page: 1247
  year: 2006
  end-page: 1254
  ident: bib457
  article-title: Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans
  publication-title: Drug Metab Dispos
– volume: 55
  start-page: 869
  year: 2010
  end-page: 879
  ident: bib149
  article-title: Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-δ-dependent pathways
  publication-title: Hypertension
– volume: 34
  start-page: 1109
  year: 2006
  end-page: 1115
  ident: bib166
  article-title: Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans
  publication-title: Drug Metab Dispos
– volume: 262
  start-page: 595
  year: 1992
  end-page: 601
  ident: bib307
  article-title: The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism
  publication-title: J Pharmacol Exp Ther
– volume: 27
  start-page: 59
  year: 1997
  end-page: 71
  ident: bib429
  article-title: Pharmacokinetics, disposition and biotransformation of [
  publication-title: Xenobiotica
– volume: 273
  start-page: 816
  year: 1995
  end-page: 822
  ident: bib209
  article-title: Absorption and glucuronidation of the angiotensin II receptor antagonist losartan by the rat intestine
  publication-title: J Pharmacol Exp Ther
– volume: 252
  start-page: 711
  year: 1990
  end-page: 718
  ident: bib62
  article-title: Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent
  publication-title: J Pharmacol Exp Ther
– volume: 12
  start-page: 119
  year: 1994
  end-page: 128
  ident: bib438
  article-title: Effects on binding characteristics and renal function of the novel, non-peptide angiotensin II antagonist BIBR277 in the rat
  publication-title: J Hypertens
– volume: 245
  start-page: 63
  year: 1993
  end-page: 66
  ident: bib105
  article-title: Angiotensin AT1 receptors mediate a positive inotropic effect of angiotensin II in guinea pig atria
  publication-title: Eur J Pharmacol
– volume: 45
  start-page: 154
  year: 2006
  end-page: 162
  ident: bib97
  article-title: Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists
  publication-title: Vascul Pharmacol
– volume: 404
  start-page: 434
  year: 2011
  end-page: 437
  ident: bib308
  article-title: Unique “delta lock” structure of telmisartan is involved in its strongest binding affinity to angiotensin II type 1 receptor
  publication-title: Biochem Biophys Res Commun
– volume: 38
  start-page: 347
  year: 1998
  end-page: 356
  ident: bib253
  article-title: Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis
  publication-title: J Clin Pharmacol
– volume: 13
  start-page: 61
  year: 2009
  end-page: 65
  ident: bib394
  article-title: Pharmacokinetics of olmesartan medoxomil in hemodialysis patients: little effect of dialysis upon its pharmacokinetics
  publication-title: Clin Exp Nephrol
– reference: Tsukamoto O and Kitakaze M (2013) It is time to reconsider the cardiovascular protection afforded by RAAS blockade-overview of RAAS systems.
– volume: 26
  start-page: A12
  year: 2004
  end-page: A20
  ident: bib303
  article-title: Antagonizing the angiotensin II subtype I Receptor: a focus on olmesartan medoxomil
  publication-title: Clin Ther
– volume: 59
  start-page: 1079
  year: 2012
  end-page: 1088
  ident: bib265
  article-title: Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice
  publication-title: Hypertension
– volume: 30
  start-page: 583
  year: 1997
  end-page: 590
  ident: bib219
  article-title: Pharmacokinetic-pharmacodynamic relations of losartan and EXP3174 in a porcine animal model
  publication-title: J Cardiovasc Pharmacol
– volume: 39
  start-page: 323
  year: 1996
  end-page: 338
  ident: bib460
  article-title: Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds
  publication-title: J Med Chem
– volume: 76
  start-page: 133
  year: 1998
  end-page: 140
  ident: bib218
  article-title: Inhibitory effects of candesartan on responses to angiotensin peptides in the hindquarters vascular bed of the cat
  publication-title: Can J Physiol Pharmacol
– volume: 399
  start-page: 83
  year: 2009
  end-page: 87
  ident: bib267
  article-title: Telmisartan pharmacokinetics in Japanese renal transplant recipients
  publication-title: Clin Chim Acta
– volume: 63
  start-page: PL75
  year: 2012
  end-page: PL80
  ident: bib477
  article-title: Angiotensin II signaling activiates the NO-CGMP pathway in rat proximal tubules
  publication-title: Life Sci
– volume: 45
  start-page: 49
  year: 1998
  end-page: 55
  ident: bib389
  article-title: Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics
  publication-title: Br J Clin Pharmacol
– volume: 172
  start-page: 1195
  year: 1990
  end-page: 1202
  ident: bib60
  article-title: [
  publication-title: Biochem Biophys Res Commun
– volume: 54
  start-page: 1353
  year: 2009
  end-page: 1359
  ident: bib456
  article-title: Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-γ activation
  publication-title: Hypertension
– volume: 13
  start-page: 849
  year: 1993
  end-page: 861
  ident: bib4
  article-title: Characterization of [
  publication-title: J Recept Res
– volume: 32
  start-page: 1303
  year: 2011
  end-page: 1308
  ident: bib15
  article-title: Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics
  publication-title: Acta Pharmacol Sin
– volume: 23
  start-page: 720
  year: 2003
  end-page: 725
  ident: bib223
  article-title: Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals
  publication-title: Pharmacotherapy
– volume: 35
  start-page: 2658
  year: 1992
  end-page: 2667
  ident: bib234
  article-title: Nonpeptide angiotensin II receptor antagonists: synthetic and computational chemistry of N-[[4-[2-(2H-tetrazol-5-yl)-1-cycloalken-1- yl]phenyl]methyl]imidazole derivatives and their in vitro activity
  publication-title: J Med Chem
– volume: 13
  start-page: S75
  year: 1999
  end-page: S80
  ident: bib164
  article-title: Pharmacologic properties of candesartan cilexetil—possible mechanisms of long-acting antihypertensive action
  publication-title: J Hum Hypertens
– volume: 22
  start-page: 1186
  year: 2000
  end-page: 1203
  ident: bib251
  article-title: Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension
  publication-title: Clin Ther
– volume: 58
  start-page: 725
  year: 2011
  end-page: 732
  ident: bib17
  article-title: High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-γ target genes in patients with the metabolic syndrome
  publication-title: Hypertension
– volume: 31
  start-page: 150
  year: 2010
  end-page: 161
  ident: bib435
  article-title: Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters
  publication-title: Biopharm Drug Dispos
– volume: 40
  start-page: 1365
  year: 2000
  end-page: 1372
  ident: bib370
  article-title: Pharmacokinetics of single-dose telmisartan 120 mg given during and between hemodialysis in subjects with severe renal insufficiency: comparison with healthy volunteers
  publication-title: J Clin Pharmacol
– volume: 127
  start-page: 1876
  year: 1999
  end-page: 1882
  ident: bib136
  article-title: Action of AT
  publication-title: Br J Pharmacol
– volume: 2
  start-page: 193
  year: 2009
  end-page: 198
  ident: bib122
  article-title: Telmisartan as a peroxisome proliferator-activated receptor-γ ligand is a new target in the treatment of human renal cell carcinoma
  publication-title: Mol Med Report
– volume: 28
  start-page: 1083
  year: 2010
  end-page: 1090
  ident: bib339
  article-title: Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age
  publication-title: J Hypertens
– volume: 44
  start-page: 1329
  year: 2005
  end-page: 1342
  ident: bib471
  article-title: Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients
  publication-title: Clin Pharmacokinet
– volume: 343
  start-page: 297
  year: 1998
  end-page: 302
  ident: bib161
  article-title: Angiotensin II stimulation of the stress-activated protein kinases in renal mesangial cells is mediated by the angiotensin AT1 receptor subtype
  publication-title: Eur J Pharmacol
– volume: 132
  start-page: 11
  year: 1991
  end-page: 15
  ident: bib304
  article-title: Distribution of angiotensin II receptor subtypes in rat brain nuclei
  publication-title: Neurosci Lett
– volume: 11
  start-page: S27
  year: 1997
  end-page: S28
  ident: bib416
  article-title: Absorption, metabolism and excretion of 14C-candesartan and 14C-candesartan cilexetil in healthy volunteers
  publication-title: J Hum Hypertens
– volume: 33
  start-page: 1406
  year: 1999
  end-page: 1413
  ident: bib279
  article-title: Mechanistic differences of various AT
  publication-title: Hypertension
– volume: 272
  start-page: F515
  year: 1997
  end-page: F520
  ident: bib312
  article-title: Angiotensin II responses in AT1A receptor-deficient mice: a role for AT1B receptors in blood pressure regulation
  publication-title: Am J Physiol
– volume: 5
  start-page: 648
  year: 1992
  end-page: 656
  ident: bib227
  article-title: AT1 receptors mediate the release of prostaglandins in porcine smooth muscle cells and rat astrocytes
  publication-title: Am J Hypertens
– volume: 19
  start-page: 612
  year: 1999
  end-page: 619
  ident: bib207
  article-title: Pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal disease
  publication-title: Pharmacotherapy
– volume: 68
  start-page: 347
  year: 2005
  end-page: 355
  ident: bib104
  article-title: Single mutations at Asn
  publication-title: Mol Pharmacol
– volume: 3
  start-page: 247
  year: 2002
  end-page: 254
  ident: bib356
  article-title: The pharmacokinetics and pharmacodynamics of angiotensin-receptor blockers in end-stage renal disease
  publication-title: J Renin Angiotensin Aldosterone Syst
– reference: Challa VR, Ravindra Babu P, Challa SR, Johnson B, and Maheswari C (2013) Pharmacokinetic interaction study between quercetin and valsartan in rats and in vitro models.
– volume: 359
  start-page: 1811
  year: 2008
  end-page: 1821
  ident: bib102
  article-title: Uric acid and cardiovascular risk
  publication-title: N Engl J Med
– volume: 251
  start-page: 143
  year: 1994
  end-page: 150
  ident: bib151
  article-title: Effect of SR 47436, a novel angiotensin II AT1 receptor antagonist, on human vascular smooth muscle cells in vitro
  publication-title: Eur J Pharmacol
– volume: 53
  start-page: 451
  year: 1998
  end-page: 458
  ident: bib343
  article-title: An interaction study with cimetidine and the new angiotensin II antagonist valsartan
  publication-title: Eur J Clin Pharmacol
– volume: 37
  start-page: 981
  year: 2001
  end-page: 984
  ident: bib224
  article-title: Prevention of hypertension by irbesartan in Dahl S rats relates to central angiotensin II type 1 receptor blockade
  publication-title: Hypertension
– volume: 41
  start-page: 154
  year: 1992
  end-page: 162
  ident: bib74
  article-title: Angiotensin II receptor recognized by DuP753 regulates two distinct guanine nucleotide-binding protein signaling pathways
  publication-title: Mol Pharmacol
– volume: 70
  start-page: 716
  year: 1992
  end-page: 719
  ident: bib1
  article-title: Competitive antagonism of pressor responses to angiotensin II and angiotensin III by the angiotensin II-1 receptor ligand losartan
  publication-title: Can J Physiol Pharmacol
– volume: 44
  start-page: 341
  year: 1993
  end-page: 348
  ident: bib83
  article-title: Effect of pretreatment with the selective beta 1-adrenoceptor antagonist bisoprolol on the subsequent cardiovascular actions and beta-adrenoceptor subtype specific occupancy of celiprolol in healthy man
  publication-title: Eur J Clin Pharmacol
– volume: 32
  start-page: 129
  year: 2010
  end-page: 136
  ident: bib197
  article-title: Clinical and pharmacotherapeutic relevance of the double-chain domain of the angiotensin II type 1 receptor blocker olmesartan
  publication-title: Clin Exp Hypertens
– volume: 52
  start-page: 371
  year: 1997
  end-page: 378
  ident: bib35
  article-title: Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide
  publication-title: Eur J Clin Pharmacol
– volume: 39
  start-page: 1232
  year: 2012
  end-page: 1235
  ident: bib300
  article-title: Brain penetration of telmisartan, a unique centrally acting angiotensin II type 1 receptor blocker, studied by PET in conscious rhesus macaques
  publication-title: Nucl Med Biol
– volume: 61
  start-page: 277
  year: 2001
  end-page: 284
  ident: bib421
  article-title: A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists
  publication-title: Biochem Pharmacol
– volume: 130
  start-page: 3641
  year: 1992
  end-page: 3649
  ident: bib38
  article-title: Angiotensin-II-binding sites on hepatocyte nuclei
  publication-title: Endocrinology
– volume: 46
  start-page: 585
  year: 2005
  end-page: 593
  ident: bib266
  article-title: A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker
  publication-title: J Cardiovasc Pharmacol
– volume: 26
  start-page: 973
  year: 2008
  end-page: 980
  ident: bib26
  article-title: Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same?
  publication-title: J Hypertens
– volume: 43
  start-page: 527
  year: 2000
  end-page: 550
  ident: bib443
  article-title: The PPARs: from orphan receptors to drug discovery
  publication-title: J Med Chem
– volume: 54
  start-page: 183
  year: 2002
  end-page: 185
  ident: bib464
  article-title: Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity
  publication-title: Br J Clin Pharmacol
– volume: 35
  start-page: 482
  year: 2007
  end-page: 489
  ident: bib259
  article-title: Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-γ activation
  publication-title: J Int Med Res
– volume: 285
  start-page: 181
  year: 1995
  end-page: 188
  ident: bib275
  article-title: Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist
  publication-title: Eur J Pharmacol
– volume: 19
  start-page: 237
  year: 1998
  end-page: 244
  ident: bib360
  article-title: The effect of age on the pharmacokinetics of valsartan
  publication-title: Biopharm Drug Dispos
– volume: 35
  start-page: 589
  year: 2005
  end-page: 602
  ident: bib290
  article-title: Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes
  publication-title: Xenobiotica
– volume: 39
  start-page: 418
  year: 1999
  end-page: 424
  ident: bib262
  article-title: The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers
  publication-title: J Clin Pharmacol
– volume: 59
  start-page: 825
  year: 2001
  end-page: 836
  ident: bib47
  article-title: Direct effects of candesartan and eprosartan on human cloned potassium channels involved in cardiac repolarization
  publication-title: Mol Pharmacol
– volume: 55
  start-page: 597
  year: 2003
  end-page: 606
  ident: bib296
  article-title: International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology
  publication-title: Pharmacol Rev
– volume: 15
  start-page: 2815
  year: 2009
  end-page: 2832
  ident: bib327
  article-title: Are the pleiotropic effects of telmisartan clinically relevant?
  publication-title: Curr Pharm Des
– volume: 26
  start-page: 408
  year: 1998
  end-page: 417
  ident: bib57
  article-title: Biotransformation of irbesartan in man
  publication-title: Drug Metab Dispos
– volume: 62
  start-page: 272
  year: 1997
  end-page: 278
  ident: bib41
  article-title: Pharmacokinetics of valsartan in patients with liver disease
  publication-title: Clin Pharmacol Ther
– volume: 66
  start-page: 367
  year: 1999
  end-page: 373
  ident: bib24
  article-title: Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay
  publication-title: Clin Pharmacol Ther
– volume: 95
  start-page: 49
  year: 2011
  end-page: 67
  ident: bib450
  article-title: Brain renin-angiotensin—a new look at an old system
  publication-title: Prog Neurobiol
– volume: 14
  start-page: 577
  year: 2000
  end-page: 585
  ident: bib422
  article-title: Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptors
  publication-title: Fundam Clin Pharmacol
– volume: 271
  start-page: 804
  year: 1994
  end-page: 810
  ident: bib133
  article-title: Time course of losartan blockade of angiotensin II hypertension versus blockade of angiotensin II fast pressor effects
  publication-title: J Pharmacol Exp Ther
– volume: 576
  start-page: 492
  year: 2004
  end-page: 497
  ident: bib116
  article-title: An angiotensin II AT
  publication-title: FEBS Lett
– volume: 22
  start-page: 263
  year: 2004
  end-page: 284
  ident: bib127
  article-title: Candesartan
  publication-title: Cardiovasc Drug Rev
– volume: 261
  start-page: 96
  year: 1992
  end-page: 100
  ident: bib430
  article-title: Renin-angiotensin system inhibition reduces glycine-induced glomerular hyperfiltration in conscious rats
  publication-title: J Pharmacol Exp Ther
– volume: 62
  start-page: 782
  year: 2007
  end-page: 784
  ident: bib451
  article-title: Pharmacokinetics and urinary excretion of eprosartan in Chinese healthy volunteers of different gender
  publication-title: Pharmazie
– volume: 54
  start-page: 4219
  year: 2011
  end-page: 4233
  ident: bib50
  article-title: Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ
  publication-title: J Med Chem
– volume: 12
  start-page: 205
  year: 1997
  end-page: 208
  ident: bib392
  article-title: Regulation of cardiac angiotensinogen mRNA in vivo and in vitro
  publication-title: Heart Vessels
– volume: 264
  start-page: 307
  year: 1994
  end-page: 316
  ident: bib216
  article-title: Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT
  publication-title: Eur J Pharmacol
– volume: 265
  start-page: 826
  year: 1993
  end-page: 834
  ident: bib52
  article-title: Pharmacological characterization of SR 47436, a new nonpeptide AT
  publication-title: J Pharmacol Exp Ther
– volume: 5
  start-page: 7
  year: 1994
  end-page: 14
  ident: bib297
  article-title: Pharmacological profile of a novel nonpeptide angiotensin II subtype 1 receptor antagonist, TCV-116
  publication-title: Blood Press Suppl
– volume: 109
  start-page: 2054
  year: 2004
  end-page: 2057
  ident: bib346
  article-title: Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity
  publication-title: Circulation
– volume: 375
  start-page: 446
  year: 2008
  end-page: 449
  ident: bib276
  article-title: Telmisartan prevented cognitive decline partly due to PPAR-γ activation
  publication-title: Biochem Biophys Res Commun
– volume: 247
  start-page: 139
  year: 1993
  end-page: 144
  ident: bib88
  article-title: Characterization of cardiac angiotensin AT
  publication-title: Eur J Pharmacol
– volume: 3
  start-page: 197
  year: 2011
  end-page: 208
  ident: bib106
  article-title: Angiotensin II-inhibiting drugs have no effect on intraneuronal Aβ or oligomeric Aβ levels in a triple transgenic mouse model of Alzheimer’s disease
  publication-title: Am J Transl Res
– volume: 65
  start-page: 2
  year: 2004
  end-page: 11
  ident: bib193
  article-title: Efficacy as a vector: the relative prevalence and paucity of inverse agonism
  publication-title: Mol Pharmacol
– volume: 19
  start-page: 351
  year: 1998
  end-page: 356
  ident: bib398
  article-title: Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food
  publication-title: Biopharm Drug Dispos
– volume: 28
  start-page: 631
  year: 2006
  end-page: 643
  ident: bib158
  article-title: Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers
  publication-title: Clin Exp Hypertens
– volume: 42
  start-page: 333
  year: 1992
  end-page: 335
  ident: bib291
  article-title: Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects
  publication-title: Eur J Clin Pharmacol
– volume: 46
  start-page: 267
  year: 1998
  end-page: 270
  ident: bib399
  article-title: Effect of age and gender on the pharmacokinetics of eprosartan
  publication-title: Br J Clin Pharmacol
– volume: 35
  start-page: 906
  year: 2000
  end-page: 913
  ident: bib277
  article-title: Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation
  publication-title: J Cardiovasc Pharmacol
– volume: 27
  start-page: 288
  year: 1999
  end-page: 296
  ident: bib40
  article-title: Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes
  publication-title: Drug Metab Dispos
– volume: 345
  start-page: 673
  year: 1992
  end-page: 678
  ident: bib42
  article-title: Antihypertensive activity of the non-peptide angiotensin II receptor antagonist, SK&F 108566, in rats and dogs
  publication-title: Naunyn Schmiedebergs Arch Pharmacol
– volume: 272
  start-page: 619
  year: 1995
  end-page: 627
  ident: bib405
  article-title: Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure
  publication-title: J Pharmacol Exp Ther
– volume: 871
  start-page: 29
  year: 2000
  end-page: 38
  ident: bib298
  article-title: Chronic peripheral administration of the angiotensin II AT(
  publication-title: Brain Res
– volume: 48
  start-page: 823
  year: 2008
  end-page: 836
  ident: bib331
  article-title: Evaluation of population pharmacokinetics and exposure-response relationship with coadministration of amlodipine besylate and olmesartan medoxomil
  publication-title: J Clin Pharmacol
– volume: 47
  start-page: 38
  year: 2009
  end-page: 43
  ident: bib140
  article-title: No effect of MDR1 C3435T polymorphism on oral pharmacokinetics of telmisartan in 19 healthy Chinese male subjects
  publication-title: Clin Chem Lab Med
– volume: 40
  start-page: 605
  year: 2001
  end-page: 614
  ident: bib254
  article-title: Drug interactions with irbesartan
  publication-title: Clin Pharmacokinet
– volume: 15
  start-page: 823
  year: 1990
  end-page: 834
  ident: bib446
  article-title: Nonpeptide angiotensin II receptor antagonists. Studies with EXP9270 and DuP 753
  publication-title: Hypertension
– volume: 29
  start-page: 1051
  year: 2001
  end-page: 1056
  ident: bib466
  article-title: Role of CYP2C9 polymorphism in losartan oxidation
  publication-title: Drug Metab Dispos
– volume: 34
  start-page: 1514
  year: 1991
  end-page: 1517
  ident: bib434
  article-title: 1-(Carboxybenyl)imidazole-5-acrylic acids: potent and selective angiotensin receptor antagonists
  publication-title: J Med Chem
– volume: 68
  start-page: 1239
  year: 2008
  end-page: 1272
  ident: bib348
  article-title: Olmesartan medoxomil: a review of its use in the management of hypertension
  publication-title: Drugs
– volume: 52
  start-page: 115
  year: 1997
  end-page: 120
  ident: bib110
  article-title: Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man
  publication-title: Eur J Clin Pharmacol
– volume: 46
  start-page: 611
  year: 1998
  end-page: 613
  ident: bib414
  article-title: The effects of age and gender on the pharmacokinetics of irbesartan
  publication-title: Br J Clin Pharmacol
– volume: 57
  start-page: 1405
  year: 2008
  end-page: 1413
  ident: bib71
  article-title: Liver-specific peroxisome proliferator-activated receptor α target gene regulation by the angiotensin type 1 receptor blocker telmisartan
  publication-title: Diabetes
– volume: 268
  start-page: 1540
  year: 1994
  end-page: 1547
  ident: bib165
  article-title: Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (+-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats
  publication-title: J Pharmacol Exp Ther
– volume: 271
  start-page: 429
  year: 1994
  end-page: 437
  ident: bib383
  article-title: Angiotensin type 1 receptors mediate smooth muscle proliferation and endothelin biosynthesis in rat vascular smooth muscle
  publication-title: J Pharmacol Exp Ther
– volume: 52
  start-page: 451
  year: 1997
  end-page: 459
  ident: bib78
  article-title: Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol
  publication-title: Eur J Clin Pharmacol
– volume: 161
  start-page: 150
  year: 2010
  end-page: 161
  ident: bib336
  article-title: beta-Arrestin 1 and 2 stabilize the angiotensin II type I receptor in distinct high-affinity conformations
  publication-title: Br J Pharmacol
– volume: 20
  start-page: 1821
  year: 2002
  end-page: 1828
  ident: bib295
  article-title: Sympatholytic properties of several AT
  publication-title: J Hypertens
– volume: 20
  start-page: 45
  year: 2006
  end-page: 50
  ident: bib79
  article-title: Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population
  publication-title: J Hum Hypertens
– volume: 54
  start-page: 738
  year: 2009
  end-page: 743
  ident: bib186
  article-title: Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPARgamma activation
  publication-title: Hypertension
– volume: 410
  start-page: 508
  year: 2011
  end-page: 513
  ident: bib403
  article-title: Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-γ-dependent activity
  publication-title: Biochem Biophys Res Commun
– volume: 26
  start-page: 1209
  year: 2008
  end-page: 1215
  ident: bib382
  article-title: Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor-γ dependent pathway
  publication-title: J Hypertens
– volume: 38
  start-page: 702
  year: 1998
  end-page: 707
  ident: bib412
  article-title: Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers
  publication-title: J Clin Pharmacol
– volume: 34
  start-page: 1055
  year: 2006
  end-page: 1059
  ident: bib14
  article-title: Inhibitory action of telmisartan on constriction of rat mesenteric artery in vitro
  publication-title: Jpn Pharmacol Ther
– volume: 293
  start-page: E91
  year: 2007
  end-page: E95
  ident: bib476
  article-title: Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties
  publication-title: Am J Physiol Endocrinol Metab
– volume: 51
  start-page: 696
  year: 2008
  end-page: 703
  ident: bib338
  article-title: Effect of telmisartan on nitric oxide—asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor γ and peroxisome proliferator activated receptor γ signaling during endothelial aging
  publication-title: Hypertension
– volume: 103
  start-page: 176
  year: 2008
  end-page: 179
  ident: bib463
  article-title: Disposition of a CYP2C9 phenotyping agent, losartan, is not influenced by the common 3435C > T variation of the drug transporter gene ABCB1 (MDR1)
  publication-title: Basic Clin Pharmacol Toxicol
– volume: 19
  start-page: 2241
  year: 2001
  end-page: 2250
  ident: bib22
  article-title: Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan
  publication-title: J Hypertens
– volume: 19
  start-page: 1160
  year: 1991
  end-page: 1162
  ident: bib377
  article-title: Synthesis and identification of a novel tetrazole metabolite of the angiotensin II receptor antagonist DuP 753
  publication-title: Drug Metab Dispos
– volume: 54
  start-page: 3442
  year: 2005
  end-page: 3452
  ident: bib344
  article-title: Molecular characterization of new selective peroxisome proliferator-activated receptor γ modulators with angiotensin receptor blocking activity
  publication-title: Diabetes
– volume: 10
  start-page: 311S
  year: 1997
  end-page: 317S
  ident: bib43
  article-title: The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations
  publication-title: Am J Hypertens
– volume: 365
  start-page: 477
  year: 2002
  end-page: 483
  ident: bib128
  article-title: Peripherally applied candesartan inhibits central responses to angiotensin II in conscious rats
  publication-title: Naunyn Schmiedebergs Arch Pharmacol
– volume: 302
  start-page: 1089
  year: 2002
  end-page: 1095
  ident: bib248
  article-title: In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist
  publication-title: J Pharmacol Exp Ther
– volume: 38
  start-page: 751
  year: 2010
  end-page: 754
  ident: bib242
  article-title: [Effects of telmisartan on 4-Aminopyridine-sensitive voltage dependant potassium channel of lymphocyte derived from spontaneously hypertensive rat]
  publication-title: Zhonghua Xin Xue Guan Bing Za Zhi
– volume: 21
  start-page: 792
  year: 1993
  end-page: 799
  ident: bib160
  article-title: N-glucuronidation reactions. I. Tetrazole N-glucuronidation of selected angiotensin II receptor antagonists in hepatic microsomes from rats, dogs, monkeys, and humans
  publication-title: Drug Metab Dispos
– volume: 19
  start-page: 15
  year: 2004
  end-page: 23
  ident: bib396
  article-title: Pharmacokinetic comparison of an angiotensin II receptor antagonist, telmisartan, in Japanese and western hypertensive patients using population pharmacokinetic method
  publication-title: Drug Metab Pharmacokinet
– volume: 28
  start-page: 79
  year: 2000
  end-page: 88
  ident: bib80
  article-title: Disposition of irbesartan, an angiotensin II AT
  publication-title: Drug Metab Dispos
– volume: 39
  start-page: 5228
  year: 1996
  end-page: 5235
  ident: bib203
  article-title: Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres
  publication-title: J Med Chem
– volume: 72
  start-page: 238
  year: 2002
  end-page: 246
  ident: bib108
  article-title: Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers
  publication-title: Clin Pharmacol Ther
– volume: 23
  start-page: 285
  year: 1995
  end-page: 289
  ident: bib474
  article-title: Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174
  publication-title: Drug Metab Dispos
– volume: 59
  start-page: 308
  year: 2012
  end-page: 316
  ident: bib215
  article-title: Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade
  publication-title: Hypertension
– volume: 10
  start-page: 93
  year: 2008
  end-page: 98
  ident: bib51
  article-title: Local adipose tissue renin-angiotensin system
  publication-title: Curr Hypertens Rep
– volume: 133
  start-page: 1678
  year: 1993
  end-page: 1684
  ident: bib318
  article-title: The type 1 angiotensin-II receptor mediates intracellular calcium mobilization in rat luteal cells
  publication-title: Endocrinology
– volume: 53
  start-page: 899
  year: 2008
  end-page: 904
  ident: bib385
  article-title: Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism
  publication-title: J Hum Genet
– volume: 335
  start-page: 572
  year: 2010
  end-page: 579
  ident: bib423
  article-title: Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance
  publication-title: J Pharmacol Exp Ther
– volume: 99
  start-page: 331
  year: 2000
  end-page: 341
  ident: bib100
  article-title: Comparative in vivo effects of irbesartan and losartan on angiotensin II receptor binding in the rat kidney following oral administration
  publication-title: Clin Sci (Lond)
– volume: 12
  start-page: 1201
  year: 1999
  end-page: 1208
  ident: bib247
  article-title: Assessment of angiotensin II receptor blockade in humans using a standardized angiotensin II receptor-binding assay
  publication-title: Am J Hypertens
– volume: 65
  start-page: 585
  year: 2009
  end-page: 591
  ident: bib141
  article-title: Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers
  publication-title: Eur J Clin Pharmacol
– volume: 31
  start-page: 541
  year: 2010
  end-page: 550
  ident: bib361
  article-title: Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease
  publication-title: Am J Nephrol
– volume: 22
  start-page: 267
  year: 2007
  end-page: 275
  ident: bib185
  article-title: Inhibitory effects of angiotensin receptor blockers on CYP2C9 activity in human liver microsomes
  publication-title: Drug Metab Pharmacokinet
– volume: 68
  start-page: 501
  year: 2000
  end-page: 509
  ident: bib134
  article-title: Effect of angiotensin II infusion with and without angiotensin II type 1 receptor blockade on nitric oxide metabolism and endothelin in human beings: a placebo-controlled study in healthy volunteers
  publication-title: Clin Pharmacol Ther
– volume: 13
  start-page: 1123
  year: 2011
  end-page: 1129
  ident: bib481
  article-title: Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats
  publication-title: Diabetes Obes Metab
– volume: 56
  start-page: 569
  year: 2006
  end-page: 573
  ident: bib480
  article-title: Pharmacokinetics of telmisartan in healthy Chinese subjects after oral administration of two dosage levels.
  publication-title: Arzneimittelforschung
– volume: 29
  start-page: 913
  year: 2008
  end-page: 922
  ident: bib410
  article-title: Electropharmacological properties of telmisartan in blocking hKv1.5 and HERG potassium channels expressed on Xenopus laevis oocytes
  publication-title: Acta Pharmacol Sin
– volume: 36
  start-page: 237
  year: 2008
  end-page: 243
  ident: bib469
  article-title: Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-elicited hepatic insulin resistance via peroxisome proliferator-activated receptor-γ activation
  publication-title: J Int Med Res
– volume: 464
  start-page: 151
  year: 2009
  end-page: 155
  ident: bib144
  article-title: Cerebroprotective action of telmisartan by inhibition of macrophages/microglia expressing HMGB1 via a peroxisome proliferator-activated receptor gamma-dependent mechanism
  publication-title: Neurosci Lett
– volume: 62
  start-page: 539
  year: 2006
  end-page: 546
  ident: bib437
  article-title: Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo
  publication-title: Eur J Clin Pharmacol
– volume: 281
  start-page: 161
  year: 1995
  end-page: 171
  ident: bib68
  article-title: Effects of irbesartan (SR47436/BMS-186295) on angiotensin II-induced pressor responses in the pithed rat: potential mechanisms of action
  publication-title: Eur J Pharmacol
– volume: 52
  start-page: 1075
  year: 2000
  end-page: 1083
  ident: bib115
  article-title: Comparative pharmacodynamics and pharmacokinetics of candesartan and losartan in man
  publication-title: J Pharm Pharmacol
– volume: 35
  start-page: 2166
  year: 2007
  end-page: 2176
  ident: bib453
  article-title: Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor
  publication-title: Drug Metab Dispos
– volume: 260
  start-page: 933
  year: 1992
  end-page: 938
  ident: bib94
  article-title: Characterization of renal angiotensin II receptors using subtype selective antagonists
  publication-title: J Pharmacol Exp Ther
– volume: 11
  start-page: S19
  year: 1997
  end-page: S25
  ident: bib159
  article-title: Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers
  publication-title: J Hum Hypertens
– volume: 62
  start-page: 1
  year: 2010
  end-page: 96
  ident: bib198
  article-title: Xenobiotic, bile acid, and cholesterol transporters: function and regulation
  publication-title: Pharmacol Rev
– volume: 39
  start-page: 847
  year: 2012
  end-page: 853
  ident: bib355
  article-title: Whole-body distribution and radiation dosimetry of [
  publication-title: Nucl Med Biol
– volume: 29
  start-page: 2476
  year: 2011
  end-page: 2483
  ident: bib182
  article-title: Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker
  publication-title: J Hypertens
– volume: 48
  start-page: 4389
  year: 2005
  end-page: 4399
  ident: bib28
  article-title: Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT
  publication-title: J Med Chem
– volume: 43
  start-page: 84
  year: 2003
  end-page: 91
  ident: bib222
  article-title: Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans
  publication-title: J Clin Pharmacol
– volume: 39
  start-page: 820
  year: 2011
  end-page: 829
  ident: bib86
  article-title: Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach
  publication-title: Drug Metab Dispos
– volume: 240
  start-page: 147
  year: 1993
  end-page: 154
  ident: bib239
  article-title: Antagonist effect of losartan on angiotensin II induced contraction in five isolated smooth muscle assays
  publication-title: Eur J Pharmacol
– volume: 24
  start-page: 362
  year: 2011
  end-page: 368
  ident: bib317
  article-title: Blockade of AT1 receptors protects the blood-brain barrier and improves cognition in Dahl salt-sensitive hypertensive rats
  publication-title: Am J Hypertens
– volume: 110
  start-page: 761
  year: 1993
  end-page: 771
  ident: bib75
  article-title: Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype
  publication-title: Br J Pharmacol
– volume: 52
  start-page: 25
  year: 1996
  end-page: 29
  ident: bib444
  article-title: Nonpeptide angiotensin II receptor antagonist: pharmacokinetics and pharmacodynamics in rats of EXP3174, an active metabolite of losartan
  publication-title: Pharmacology
– volume: 33
  start-page: 850
  year: 1999
  end-page: 855
  ident: bib261
  article-title: Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT
  publication-title: Hypertension
– volume: 150
  start-page: 1056
  year: 1993
  end-page: 1059
  ident: bib393
  article-title: Angiotensin II receptors in the rat urinary bladder smooth muscle: type 1 subtype receptors mediate contractile responses
  publication-title: J Urol
– volume: 253
  start-page: 27
  year: 1994
  end-page: 34
  ident: bib427
  article-title: Effect of an angiotensin II receptor antagonist, CV-11974, and its prodrug, TCV-116, on production of aldosterone
  publication-title: Eur J Pharmacol
– volume: 31
  start-page: 1549
  year: 2008
  end-page: 1557
  ident: bib468
  article-title: Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan
  publication-title: Hypertens Res
– volume: 272
  start-page: 963
  year: 1995
  end-page: 969
  ident: bib192
  article-title: Pharmacologic characterization of CI-996, a new angiotensin receptor antagonist
  publication-title: J Pharmacol Exp Ther
– volume: 37
  start-page: 214
  year: 1997
  end-page: 221
  ident: bib72
  article-title: Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist
  publication-title: J Clin Pharmacol
– volume: 352
  start-page: 1
  year: 1995
  end-page: 10
  ident: bib264
  article-title: Classification of alpha 1-adrenoceptor subtypes
  publication-title: Naunyn Schmiedebergs Arch Pharmacol
– volume: 19
  start-page: 221
  year: 1992
  end-page: 227
  ident: bib155
  article-title: Aldosterone regulation of gene transcription leading to control of ion transport
  publication-title: Hypertension
– volume: 1
  start-page: 336
  year: 2000
  end-page: 341
  ident: bib23
  article-title: The pharmacological potency of various AT(
  publication-title: J Renin Angiotensin Aldosterone Syst
– volume: 41
  start-page: 515
  year: 2001
  end-page: 527
  ident: bib347
  article-title: Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects
  publication-title: J Clin Pharmacol
– volume: 685
  start-page: 91
  year: 2012
  end-page: 98
  ident: bib402
  article-title: Telmisartan inhibits vascular dysfunction and inflammation via activation of peroxisome proliferator-activated receptor-γ in subtotal nephrectomized rat
  publication-title: Eur J Pharmacol
– volume: 113
  start-page: 179
  year: 1994
  end-page: 189
  ident: bib91
  article-title: BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174
  publication-title: Br J Pharmacol
– volume: 291
  start-page: 417
  year: 1995
  end-page: 425
  ident: bib170
  article-title: A long-term receptor stimulation is requisite for angiotensin II-dependent DNA synthesis in vascular smooth muscle cells from spontaneously hypertensive rats
  publication-title: Eur J Pharmacol
– volume: 16
  start-page: 789
  year: 2010
  end-page: 798
  ident: bib228
  article-title: Characterization of the binding of angiotensin II receptor blockers to human serum albumin using docking and molecular dynamics simulation
  publication-title: J Mol Model
– volume: 23
  start-page: 285
  year: 2003
  end-page: 296
  ident: bib294
  article-title: AT(
  publication-title: Auton Autacoid Pharmacol
– volume: 78
  start-page: 983
  year: 2010
  end-page: 992
  ident: bib315
  article-title: Functional selectivity in adrenergic and angiotensin signaling systems
  publication-title: Mol Pharmacol
– volume: 111
  start-page: 227
  year: 2009
  end-page: 234
  ident: bib31
  article-title: Constitutively active mutant N111G of angiotensin II type 1 (AT(1)) receptor induces homologous internalization through mediation of AT(1)-receptor antagonist
  publication-title: J Pharmacol Sci
– volume: 18
  start-page: 127
  year: 2000
  end-page: 156
  ident: bib439
  article-title: A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist
  publication-title: Cardiovasc Drug Rev
– volume: 23
  start-page: 631
  year: 2007
  end-page: 640
  ident: bib384
  article-title: Evaluation of a pharmacokinetic interaction between valsartan and simvastatin in healthy subjects
  publication-title: Curr Med Res Opin
– volume: 33
  start-page: 247
  year: 2008
  end-page: 252
  ident: bib212
  article-title: Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan, a AT
  publication-title: Eur J Drug Metab Pharmacokinet
– volume: 43
  start-page: 251
  year: 2001
  end-page: 255
  ident: bib280
  article-title: Central inhibition of AT
  publication-title: Pharmacol Res
– volume: 134
  start-page: 225
  year: 2005
  end-page: 231
  ident: bib156
  article-title: Angiotensin type 1 receptor blockage improves ischemic injury following transient focal cerebral ischemia
  publication-title: Neuroscience
– volume: 41
  start-page: 742
  year: 2001
  end-page: 749
  ident: bib334
  article-title: The pharmacokinetics of irbesartan in hypertensive children and adolescents
  publication-title: J Clin Pharmacol
– volume: 62
  start-page: 1345
  year: 2002
  end-page: 1353
  ident: bib431
  article-title: Olmesartan medoxomil
  publication-title: Drugs
– volume: 21
  start-page: 523
  year: 2011
  end-page: 530
  ident: bib452
  article-title: The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers
  publication-title: Pharmacogenet Genomics
– volume: 246
  start-page: 328
  year: 1988
  end-page: 337
  ident: bib436
  article-title: Beta adrenoceptor subtype binding activity in plasma and beta blockade by propranolol and beta-1 selective bisoprolol in humans. Evaluation with Schild-plots
  publication-title: J Pharmacol Exp Ther
– volume: 86
  start-page: 52
  year: 2010
  end-page: 58
  ident: bib184
  article-title: Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes
  publication-title: Life Sci
– volume: 63
  start-page: 316
  year: 1998
  end-page: 323
  ident: bib442
  article-title: Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers
  publication-title: Clin Pharmacol Ther
– volume: 247
  start-page: 193
  year: 1993
  end-page: 198
  ident: bib59
  article-title: Characterization of [
  publication-title: Eur J Pharmacol
– volume: 32
  start-page: 765
  year: 2009
  end-page: 769
  ident: bib288
  article-title: Telmisartan inhibits cytokine-induced nuclear factor-kappaB activation independently of the peroxisome proliferator-activated receptor-γ
  publication-title: Hypertens Res
– volume: 55
  start-page: 244
  year: 1997
  end-page: 251
  ident: bib306
  article-title: Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade
  publication-title: Pharmacology
– volume: 40
  start-page: 35
  year: 2002
  end-page: 40
  ident: bib349
  article-title: Bioequivalence study of a valsartan tablet and a capsule formulation after single dosing in healthy volunteers using a replicated crossover design
  publication-title: Int J Clin Pharmacol Ther
– volume: 32
  start-page: 416
  year: 2009
  end-page: 420
  ident: bib34
  article-title: Telmisartan increases the permeability of endothelial cells through zonula occludens-1
  publication-title: Biol Pharm Bull
– volume: 43
  start-page: 2685
  year: 2000
  end-page: 2697
  ident: bib221
  article-title: Synthesis and pharmacological evaluation of new pyrazolidine-3, 5-diones as AT(
  publication-title: J Med Chem
– volume: 74
  start-page: 505
  year: 2003
  end-page: 508
  ident: bib411
  article-title: Altered pharmacokinetics and excessive hypotensive effect of candesartan in a patient with the CYP2C91/3 genotype
  publication-title: Clin Pharmacol Ther
– volume: 64
  start-page: 323
  year: 2009
  end-page: 326
  ident: bib179
  article-title: Pharmacokinetic and safety profile of olmesartan medoxomil in healthy Chinese subjects after single and multiple administrations
  publication-title: Pharmazie
– volume: 83
  start-page: 1333
  year: 1991
  end-page: 1342
  ident: bib67
  article-title: Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II
  publication-title: Circulation
– volume: 385
  start-page: 13
  year: 2012
  end-page: 26
  ident: bib73
  article-title: Local renin-angiotensin systems in the genitourinary tract
  publication-title: Naunyn Schmiedebergs Arch Pharmacol
– volume: 49
  start-page: 235
  year: 2009
  end-page: 241
  ident: bib37
  article-title: Pharmacokinetics of valsartan in pediatric and adolescent subjects with hypertension
  publication-title: J Clin Pharmacol
– volume: 106
  start-page: 233
  year: 1992
  end-page: 241
  ident: bib240
  article-title: Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible and syntopic action
  publication-title: Br J Pharmacol
– volume: 12
  start-page: 159
  year: 1994
  end-page: 162
  ident: bib245
  article-title: Effects of losartan (DuP753) and enalaprilat on the mean arterial pressure response to phenylephrine
  publication-title: J Hypertens
– volume: 36
  start-page: 796
  year: 2008
  end-page: 805
  ident: bib167
  article-title: Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide
  publication-title: Drug Metab Dispos
– volume: 294
  start-page: 179
  year: 2000
  end-page: 186
  ident: bib352
  article-title: Differential inhibition of the prejunctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan
  publication-title: J Pharmacol Exp Ther
– volume: 71
  start-page: 89
  year: 2002
  end-page: 98
  ident: bib465
  article-title: Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype
  publication-title: Clin Pharmacol Ther
– volume: 46
  start-page: 594
  year: 1996
  end-page: 600
  ident: bib205
  article-title: Disposition of the new angiotensin II receptor antagonist candesartan cilexetil in rats and dogs
  publication-title: Arzneimittelforschung
– volume: 22
  start-page: 2253
  year: 2004
  end-page: 2261
  ident: bib213
  article-title: Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system
  publication-title: J Hypertens
– volume: 276
  start-page: 125
  year: 1996
  end-page: 129
  ident: bib95
  article-title: Interaction of nonpeptide angiotensin II receptor antagonists with the urate transporter in rat renal brush-border membranes
  publication-title: J Pharmacol Exp Ther
– volume: 14
  start-page: 179
  year: 2012
  end-page: 188
  ident: bib236
  article-title: Regulation of uric acid excretion by the kidney
  publication-title: Curr Rheumatol Rep
– volume: 143
  start-page: 299
  year: 1963
  end-page: 330
  ident: bib417
  article-title: Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters
  publication-title: Arch Int Pharmacodyn Ther
– volume: 336
  start-page: 801
  year: 2011
  end-page: 808
  ident: bib310
  article-title: In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies
  publication-title: J Pharmacol Exp Ther
– volume: 169
  start-page: 997
  year: 1990
  end-page: 1006
  ident: bib366
  article-title: Discrimination of two angiotensin II receptor subtypes with a selective agonist analogue of angiotensin II, p-aminophenylalanine6 angiotensin II
  publication-title: Biochem Biophys Res Commun
– volume: 40
  start-page: 1347
  year: 2000
  end-page: 1354
  ident: bib369
  article-title: Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers
  publication-title: J Clin Pharmacol
– volume: 24
  start-page: 2023
  year: 2006
  end-page: 2031
  ident: bib172
  article-title: The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage
  publication-title: J Hypertens
– volume: 24
  start-page: 467
  year: 1994
  end-page: 473
  ident: bib199
  article-title: Modification of pressure natriuresis by long-term losartan in spontaneously hypertensive rats
  publication-title: Hypertension
– volume: 37
  start-page: 165
  year: 2009
  end-page: 168
  ident: bib229
  article-title: [Effects of telmisartan on voltage-gated Kv1.3 and Kv1.5 potassium channels expressed in Xenopus oocytes]
  publication-title: Zhonghua Xin Xue Guan Bing Za Zhi
– volume: 35
  start-page: 715
  year: 2012
  end-page: 719
  ident: bib8
  article-title: Structural basis for telmisartan-mediated partial activation of PPAR gamma
  publication-title: Hypertens Res
– volume: 58
  start-page: 641
  year: 1995
  end-page: 649
  ident: bib241
  article-title: Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans
  publication-title: Clin Pharmacol Ther
– volume: 40
  start-page: 1323
  year: 2000
  end-page: 1330
  ident: bib472
  article-title: Multiple-dose pharmacokinetics of telmisartan and of hydrochlorothiazide following concurrent administration in healthy subjects
  publication-title: J Clin Pharmacol
– volume: 320
  start-page: 211
  year: 2007
  end-page: 217
  ident: bib174
  article-title: Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter
  publication-title: J Pharmacol Exp Ther
– volume: 25
  start-page: 639
  year: 2008
  end-page: 646
  ident: bib337
  article-title: Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers
  publication-title: Pharm Res
– volume: 29
  start-page: 2422
  year: 2011
  end-page: 2439
  ident: bib187
  article-title: Morning blood pressure surge, morning platelet aggregation, and silent cerebral infarction in older Japanese hypertensive patients
  publication-title: J Hypertens
– volume: 30
  start-page: 1260
  year: 1997
  end-page: 1266
  ident: bib56
  article-title: Analysis of the effects of candesartan in the mesenteric vascular bed of the cat
  publication-title: Hypertension
– volume: 7
  start-page: 140
  year: 2007
  end-page: 145
  ident: bib98
  article-title: Metabolic actions of angiotensin receptor antagonists: PPAR-γ agonist actions or a class effect?
  publication-title: Curr Opin Pharmacol
– volume: 19
  start-page: 561
  year: 2001
  end-page: 566
  ident: bib121
  article-title: The angiotensin II AT
  publication-title: J Hypertens
– volume: 6
  start-page: 863
  year: 2010
  end-page: 871
  ident: bib90
  article-title: Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties
  publication-title: Expert Opin Drug Metab Toxicol
– volume: 347
  start-page: 220
  year: 1993
  end-page: 224
  ident: bib479
  article-title: Characterization of the angiotensin II-receptor subtype in the longitudinal smooth muscle of the rat portal vein
  publication-title: Naunyn Schmiedebergs Arch Pharmacol
– volume: 369
  start-page: 69
  year: 2004
  end-page: 77
  ident: bib126
  article-title: Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution
  publication-title: Naunyn Schmiedebergs Arch Pharmacol
– volume: 24
  start-page: 2255
  year: 2006
  end-page: 2261
  ident: bib101
  article-title: Synergistic protective effects of erythropoietin and olmesartan on ischemic stroke survival and post-stroke memory dysfunctions in the gerbil
  publication-title: J Hypertens
– volume: 269
  start-page: 16533
  year: 1994
  end-page: 16536
  ident: bib178
  article-title: Differential structural requirements for specific binding of nonpeptide and peptide antagonists to the AT
  publication-title: J Biol Chem
– volume: 14
  start-page: 432
  year: 1999
  end-page: 436
  ident: bib354
  article-title: Pharmacokinetics of
  publication-title: Xenobio Metabol Dispos
– volume: 289
  start-page: 399
  year: 1995
  end-page: 402
  ident: bib111
  article-title: Effects of TCV-116 and CV-11974 on angiotensin II-induced responses in vascular smooth muscle cells
  publication-title: Eur J Pharmacol
– volume: 15
  start-page: 850
  year: 2008
  end-page: 853
  ident: bib455
  article-title: Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gammaactivation
  publication-title: Protein Pept Lett
– volume: 36
  start-page: 3371
  year: 1993
  end-page: 3380
  ident: bib29
  article-title: A new series of imidazolones: highly specific and potent nonpeptide AT
  publication-title: J Med Chem
– volume: 81
  start-page: 819
  year: 1994
  end-page: 822
  ident: bib420
  article-title: Influence of Losartan, an angiotensin receptor antagonist, on neointimal proliferation in cultured human saphenous vein
  publication-title: Br J Surg
– volume: 255
  start-page: 211
  year: 1990
  end-page: 217
  ident: bib448
  article-title: Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent
  publication-title: J Pharmacol Exp Ther
– volume: 10
  start-page: 1463
  year: 1992
  end-page: 1469
  ident: bib243
  article-title: Angiotensin II increases proto-oncogene expression and phosphoinositide turnover in vascular smooth muscle cells via the angiotensin II AT
  publication-title: J Hypertens
– volume: 45
  start-page: 567
  year: 1998
  end-page: 573
  ident: bib250
  article-title: Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man
  publication-title: Br J Clin Pharmacol
– volume: 326
  start-page: 983
  year: 2008
  end-page: 990
  ident: bib2
  article-title: In vitro biliary clearance of angiotensin II receptor blockers and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in sandwich-cultured rat hepatocytes: comparison with in vivo biliary clearance
  publication-title: J Pharmacol Exp Ther
– volume: 51
  start-page: 259
  year: 2008
  end-page: 266
  ident: bib428
  article-title: Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-γ
  publication-title: Hypertension
– volume: 19
  start-page: S3
  year: 2001
  end-page: S14
  ident: bib204
  article-title: In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist
  publication-title: J Hypertens Suppl
– volume: 26
  start-page: 490
  year: 1995
  end-page: 494
  ident: bib305
  article-title: Persistent inhibition of the pressor and aldosterone responses to angiotensin-II by TCV-116 in normotensive subjects
  publication-title: J Cardiovasc Pharmacol
– volume: 363
  start-page: 509
  year: 2001
  end-page: 514
  ident: bib138
  article-title: Differential effects of eprosartan and losartan at prejunctional angiotensin II receptors
  publication-title: Naunyn Schmiedebergs Arch Pharmacol
– volume: 37
  start-page: 226
  year: 2012
  end-page: 231
  ident: bib461
  article-title: Pharmacokinetics of losartan and its active carboxylic acid metabolite E-3174 in five ethnic populations of China
  publication-title: J Clin Pharm Ther
– volume: 59
  start-page: 589
  year: 2003
  end-page: 592
  ident: bib350
  article-title: Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects
  publication-title: Eur J Clin Pharmacol
– volume: 409
  start-page: 275
  year: 2011
  end-page: 279
  ident: bib408
  article-title: Irbesartan attenuates ischemic brain damage by inhibition of MCP-1/CCR2 signaling pathway beyond AT₁ receptor blockade
  publication-title: Biochem Biophys Res Commun
– volume: 319
  start-page: 137
  year: 1997
  end-page: 146
  ident: bib311
  article-title: Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor
  publication-title: Eur J Pharmacol
– volume: 52
  start-page: 3455
  year: 2007
  end-page: 3464
  ident: bib118
  article-title: Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats
  publication-title: Dig Dis Sci
– volume: 39
  start-page: 1031
  year: 2011
  end-page: 1038
  ident: bib433
  article-title: Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments
  publication-title: Drug Metab Dispos
– volume: 16
  start-page: 478
  year: 1999
  end-page: 485
  ident: bib363
  article-title: Grapefruit juice activates P-glycoprotein-mediated drug transport
  publication-title: Pharm Res
– volume: 41
  start-page: 809
  year: 1992
  end-page: 815
  ident: bib39
  article-title: Modulation of angiotensin II binding affinity by allosteric interaction of polyvinyl sulfate with an intracellular domain of the DuP-753-sensitive angiotensin II receptor of bovine adrenal glomerulosa
  publication-title: Mol Pharmacol
– volume: 20
  start-page: 1151
  year: 2002
  end-page: 1156
  ident: bib89
  article-title: Comparison of the vascular and antiadrenergic activities of four angiotensin II type 1 antagonists in the pithed rat
  publication-title: J Hypertens
– volume: 30
  start-page: 87
  year: 2012
  end-page: 96
  ident: bib314
  article-title: Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-γ activation in human monocytes
  publication-title: J Hypertens
– volume: 52
  start-page: 415
  year: 2000
  end-page: 472
  ident: bib81
  article-title: International union of pharmacology. XXIII. The angiotensin II receptors
  publication-title: Pharmacol Rev
– volume: 268
  start-page: 1199
  year: 1994
  end-page: 1205
  ident: bib66
  article-title: The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dog
  publication-title: J Pharmacol Exp Ther
– volume: 40
  start-page: 1338
  year: 2000
  end-page: 1346
  ident: bib371
  article-title: Pharmacokinetics of acetaminophen and ibuprofen when coadministered with telmisartan in healthy volunteers
  publication-title: J Clin Pharmacol
– reference: .
– volume: 34
  start-page: 1976
  year: 2006
  end-page: 1984
  ident: bib58
  article-title: Rapid identification of P-glycoprotein substrates and inhibitors
  publication-title: Drug Metab Dispos
– volume: 1
  start-page: 33
  year: 1990
  end-page: 40
  ident: bib61
  article-title: Angiotensin II receptor subtypes and their selective nonpeptide ligands
  publication-title: Receptor
– volume: 64
  start-page: 712
  year: 2010
  end-page: 717
  ident: bib119
  article-title: The angiotensin receptor blocker, telmisartan, reduces and stabilizes atherosclerosis in ApoE and AT1aR double deficient mice
  publication-title: Biomed Pharmacother
– volume: 28
  start-page: 543
  year: 2008
  end-page: 548
  ident: bib462
  article-title: Telmisartan but not valsartan inhibits TGF-β-mediated accumulation of extracellular matrix via activation of PPARgamma
  publication-title: J Huazhong Univ Sci Technolog Med Sci
– volume: 61
  start-page: 627
  year: 2005
  end-page: 634
  ident: bib154
  article-title: CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population
  publication-title: Eur J Clin Pharmacol
– volume: 71
  start-page: 68
  year: 2002
  end-page: 76
  ident: bib249
  article-title: Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing
  publication-title: Clin Pharmacol Ther
– volume: 28
  start-page: 1730
  year: 2010
  end-page: 1737
  ident: bib175
  article-title: Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-γ activation in diabetic mice
  publication-title: J Hypertens
– volume: 35
  start-page: 940
  year: 2012
  end-page: 946
  ident: bib196
  article-title: Sympathoinhibition caused by orally administered telmisartan through inhibition of the AT₁ receptor in the rostral ventrolateral medulla of hypertensive rats
  publication-title: Hypertens Res
– volume: 39
  start-page: 788
  year: 2009
  end-page: 793
  ident: bib233
  article-title: Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects
  publication-title: Xenobiotica
– volume: 31
  start-page: 1268
  year: 2011
  end-page: 1275
  ident: bib260
  article-title: Telmisartan exerts antiatherosclerotic effects by activating peroxisome proliferator-activated receptor-γ in macrophages
  publication-title: Arterioscler Thromb Vasc Biol
– volume: 85
  start-page: 136
  year: 2009
  end-page: 140
  ident: bib33
  article-title: Binding sites of valsartan, candesartan and losartan with angiotensin II receptor 1 subtype by molecular modeling
  publication-title: Life Sci
– volume: 101
  start-page: 755
  year: 1998
  end-page: 760
  ident: bib406
  article-title: Murine double nullizygotes of the angiotensin type 1A and 1B receptor genes duplicate severe abnormal phenotypes of angiotensinogen nullizygotes
  publication-title: J Clin Invest
– volume: 263
  start-page: C750
  year: 1992
  end-page: C758
  ident: bib320
  article-title: Effects of angiotensin II and nonpeptide receptor antagonists on transduction pathways in rat proximal tubule
  publication-title: Am J Physiol
– volume: 47
  start-page: 255
  year: 1995
  end-page: 266
  ident: bib177
  article-title: International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. IX. Recommendations on terms and symbols in quantitative pharmacology
  publication-title: Pharmacol Rev
– volume: 26
  start-page: 937
  year: 2003
  end-page: 943
  ident: bib274
  article-title: Molecular analysis of the structure and function of the angiotensin II type 1 receptor
  publication-title: Hypertens Res
– volume: 10
  start-page: 743
  year: 2008
  end-page: 750
  ident: bib404
  article-title: Efficacy, safety, and pharmacokientics of candesartan cilexetil in hypertensive children aged 5 to 17 years
  publication-title: J Clin Hypertens (Greeenwich)
– volume: 120
  start-page: 488
  year: 1997
  end-page: 494
  ident: bib424
  article-title: In vitro and in vivo effects of UP 269-6, a new potent orally active nonpeptide angiotensin II receptor antagonist, on vascular smooth muscle cell proliferation
  publication-title: Br J Pharmacol
– volume: 367
  start-page: 413
  year: 1999
  end-page: 422
  ident: bib107
  article-title: Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-transfected [correction of tranfected] Chinese hamster ovary cells
  publication-title: Eur J Pharmacol
– volume: 185
  start-page: 271
  year: 2010
  end-page: 280
  ident: bib135
  article-title: Modulation of PPAR-gamma by telmisartan protects the heart against myocardial infarction in experimental diabetes
  publication-title: Chem Biol Interact
– volume: 129
  start-page: 1235
  year: 2000
  end-page: 1243
  ident: bib362
  article-title: Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers
  publication-title: Br J Pharmacol
– volume: 18
  start-page: 42
  year: 1998
  end-page: 50
  ident: bib397
  article-title: Effect of hepatic disease on the pharmacokinetics and plasma protein binding of eprosartan
  publication-title: Pharmacotherapy
– volume: 41
  start-page: 1081
  year: 1992
  end-page: 1088
  ident: bib441
  article-title: Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies
  publication-title: Mol Pharmacol
– volume: 40
  start-page: 1373
  year: 2000
  end-page: 1379
  ident: bib368
  article-title: The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers
  publication-title: J Clin Pharmacol
– volume: 101
  start-page: 1199
  year: 2000
  end-page: 1205
  ident: bib48
  article-title: Losartan and its metabolite E3174 modify cardiac delayed rectifier K(
  publication-title: Circulation
– volume: 21
  start-page: 2175
  year: 2003
  end-page: 2182
  ident: bib137
  article-title: Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats
  publication-title: J Hypertens
– volume: 49
  start-page: 3094
  year: 2006
  end-page: 3099
  ident: bib470
  article-title: Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation
  publication-title: Diabetologia
– volume: 13
  start-page: 227
  year: 1996
  end-page: 233
  ident: bib324
  article-title: Effects of structural modifications on the intestinal permeability of angiotensin II receptor antagonists and the correlation of in vitro, in situ, and in vivo absorption
  publication-title: Pharm Res
– volume: 26
  start-page: 29
  year: 2006
  end-page: 34
  ident: bib208
  article-title: Pharmacokinetics of olmesartan medoxomil plus hydrochlorothiazide combination in healthy subjects
  publication-title: Clin Drug Investig
– volume: 25
  start-page: 14
  year: 1995
  end-page: 21
  ident: bib87
  article-title: Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers
  publication-title: Hypertension
– volume: 325
  start-page: 349
  year: 2008
  end-page: 356
  ident: bib238
  article-title: Progress in brain penetration evaluation in drug discovery and development
  publication-title: J Pharmacol Exp Ther
– volume: 113
  start-page: 57
  year: 2010
  end-page: 65
  ident: bib30
  article-title: Engineered mutation of some important amino acids in angiotensin II type 1 (AT1) receptor increases the binding affinity of AT1-receptor antagonists
  publication-title: J Pharmacol Sci
– volume: 46
  start-page: 2261
  year: 2003
  end-page: 2270
  ident: bib342
  article-title: Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites
  publication-title: J Med Chem
– volume: 14
  start-page: 48
  year: 1959
  end-page: 58
  ident: bib13
  article-title: Some quantitative uses of drug antagonists
  publication-title: Br J Pharmacol
– volume: 47
  start-page: 295
  year: 2007
  end-page: 304
  ident: bib18
  article-title: Pharmacokinetics of oral doses of telmisartan and nisoldipine, given alone and in combination, in patients with essential hypertension
  publication-title: J Clin Pharmacol
– volume: 54
  start-page: 782
  year: 2009
  end-page: 787
  ident: bib409
  article-title: Cognitive deficit in amyloid-β-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-γ activation
  publication-title: Hypertension
– volume: 285
  start-page: 11892
  year: 2010
  end-page: 11902
  ident: bib168
  article-title: Human carboxymethylenebutenolidase as a bioactivating hydrolase of olmesartan medoxomil in liver and intestine
  publication-title: J Biol Chem
– volume: 32
  start-page: 986
  year: 2010
  end-page: 991
  ident: bib211
  article-title: Ang II enhances tubular cell Ets-1 expression and associated down stream signaling is mediated through AT1 receptors
  publication-title: Ren Fail
– volume: 11
  start-page: S31
  year: 1997
  end-page: S35
  ident: bib181
  article-title: Pharmacokinetic drug interaction studies with candesartan cilexetil
  publication-title: J Hum Hypertens
– volume: 38
  start-page: 141
  year: 2001
  end-page: 148
  ident: bib19
  article-title: Effect of the AT
  publication-title: J Cardiovasc Pharmacol
– volume: 53
  start-page: 798
  year: 2009
  end-page: 804
  ident: bib401
  article-title: Inhibition of tumor necrosis factor-α-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator-activated receptor-γ with nuclear factor kappaB and CCAAT/enhancer-binding protein-β
  publication-title: Hypertension
– volume: 53
  start-page: 445
  year: 1998
  end-page: 449
  ident: bib189
  article-title: Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174
  publication-title: Eur J Clin Pharmacol
– volume: 298
  start-page: 62
  year: 2001
  end-page: 70
  ident: bib129
  article-title: AT
  publication-title: J Pharmacol Exp Ther
– volume: 35
  start-page: 1008
  year: 1995
  end-page: 1015
  ident: bib206
  article-title: Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin
  publication-title: J Clin Pharmacol
– volume: 73
  start-page: 459
  year: 1995
  end-page: 464
  ident: bib257
  article-title: Inhibition by BMS 186295, a selective nonpeptide AT1 antagonist, of adrenal catecholamine release induced by angiotensin II in the dog in vivo
  publication-title: Can J Physiol Pharmacol
– volume: 391
  start-page: 85
  year: 2010
  end-page: 90
  ident: bib272
  article-title: Molecular mechanisms of the antagonistic action between AT
  publication-title: Biochem Biophys Res Commun
– volume: 110
  start-page: 245
  year: 1993
  end-page: 252
  ident: bib440
  article-title: Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277
  publication-title: Br J Pharmacol
– volume: 23
  start-page: 207
  year: 1995
  end-page: 215
  ident: bib376
  article-title: Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members
  publication-title: Drug Metab Dispos
– volume: 46
  start-page: 137
  year: 2005
  end-page: 143
  ident: bib70
  article-title: PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin
  publication-title: Hypertension
– volume: 40
  start-page: 571
  year: 1995
  end-page: 575
  ident: bib84
  article-title: Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers
  publication-title: Br J Clin Pharmacol
– volume: 53
  start-page: 417
  year: 1997
  end-page: 421
  ident: bib200
  article-title: Angiotensin type-1 (AT
  publication-title: Biochem Pharmacol
– volume: 34
  start-page: 862
  year: 2006
  end-page: 869
  ident: bib285
  article-title: OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker
  publication-title: Drug Metab Dispos
– volume: 38
  start-page: 433
  year: 1998
  end-page: 436
  ident: bib413
  article-title: Lack of effect of food on the oral bioavailability of irbesartan in healthy male volunteers
  publication-title: J Clin Pharmacol
– volume: 36
  start-page: 4040
  year: 1993
  end-page: 4051
  ident: bib326
  article-title: 6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: synthesis, biological activity, and structure-activity relationships
  publication-title: J Med Chem
– volume: 47
  start-page: 425
  year: 1995
  end-page: 431
  ident: bib340
  article-title: Interaction between the nonpeptide angiotensin antagonist SKF-108,566 and histidine 256 (HisVI:16) of the angiotensin type 1 receptor
  publication-title: Mol Pharmacol
– volume: 12
  start-page: 746
  year: 2010
  end-page: 752
  ident: bib157
  article-title: Telmisartan effects on insulin resistance in obese or overweight adults without diabetes or hypertension
  publication-title: J Clin Hypertens (Greenwich)
– volume: 38
  start-page: 820
  year: 2008
  end-page: 826
  ident: bib380
  article-title: Angiotensin inhibition stimulates PPARgamma and the release of visfatin
  publication-title: Eur J Clin Invest
– volume: 35
  start-page: 515
  year: 1995
  end-page: 520
  ident: bib65
  article-title: Human plasma protein binding of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) and its pharmacologically active metabolite EXP3174
  publication-title: J Clin Pharmacol
– volume: 367
  start-page: 255
  year: 1999
  end-page: 265
  ident: bib77
  article-title: Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats
  publication-title: Eur J Pharmacol
– volume: 38
  start-page: 649
  year: 1998
  end-page: 653
  ident: bib191
  article-title: Eprosartan does not affect the pharmacodynamics of warfarin
  publication-title: J Clin Pharmacol
– volume: 47
  start-page: 2574
  year: 2004
  end-page: 2586
  ident: bib49
  article-title: Design, synthesis, structural studies, biological evaluation, and computational simulations of novel potent AT1 angiotensin II receptor antagonists based on the 4-phenylquinoline structure
  publication-title: J Med Chem
– volume: 51
  start-page: 513
  year: 1992
  end-page: 521
  ident: bib283
  article-title: Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist
  publication-title: Clin Pharmacol Ther
– volume: 28
  start-page: 149
  year: 2000
  end-page: 167
  ident: bib373
  article-title: Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients
  publication-title: J Int Med Res
– volume: 25
  start-page: 1643
  year: 2007
  end-page: 1649
  ident: bib351
  article-title: Receptor-independent intracellular radical scavenging activity of an angiotensin II receptor blocker
  publication-title: J Hypertens
– volume: 38
  start-page: 519
  year: 2000
  end-page: 526
  ident: bib357
  article-title: Pharmacokinetics and blood pressure response of losartan in end-stage renal disease
  publication-title: Clin Pharmacokinet
– volume: 34
  start-page: 683
  year: 2009
  end-page: 692
  ident: bib268
  article-title: Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients
  publication-title: J Clin Pharm Ther
– volume: 24
  start-page: 376
  year: 2009
  end-page: 388
  ident: bib395
  article-title: Comparative pharmacodynamics of olmesartan and azelnidipine in patients with hypertension: a population pharmacokinetic/pharmacodynamic analysis
  publication-title: Drug Metab Pharmacokinet
– volume: 59
  start-page: 268
  year: 1996
  end-page: 274
  ident: bib131
  article-title: Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174
  publication-title: Clin Pharmacol Ther
– volume: 114
  start-page: 115
  year: 2010
  end-page: 118
  ident: bib287
  article-title: Concentration-dependent inhibitory effect of irbesartan on renal uric acid transporters
  publication-title: J Pharmacol Sci
– volume: 44
  start-page: 407
  year: 1999
  end-page: 415
  ident: bib244
  article-title: Vasoconstriction by in situ formed angiotensin II: role of ACE and chymase
  publication-title: Cardiovasc Res
– volume: 40
  start-page: 374
  year: 2012
  end-page: 380
  ident: bib169
  article-title: Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism
  publication-title: Drug Metab Dispos
– volume: 103
  start-page: 904
  year: 2001
  end-page: 912
  ident: bib46
  article-title: Angiotensin II type 1 receptor blockers
  publication-title: Circulation
– volume: 14
  start-page: 133
  year: 2007
  end-page: 141
  ident: bib293
  article-title: Telmisartan enhances cholesterol efflux from THP-1 macrophages by activating PPARgamma
  publication-title: J Atheroscler Thromb
– volume: 50
  start-page: 137
  year: 1994
  end-page: 145
  ident: bib329
  article-title: Modulation of tachyphylaxis to angiotensin II in rabbit isolated aorta by the angiotensin AT
  publication-title: Regul Pept
– volume: 154
  start-page: 133
  year: 1997
  end-page: 138
  ident: bib124
  article-title: Characterization of the AT
  publication-title: J Endocrinol
– volume: 36
  start-page: 1275
  year: 2008
  end-page: 1282
  ident: bib120
  article-title: Effect of plasma protein binding on in vitro-in vivo correlation of biliary excretion of drugs evaluated by sandwich-cultured rat hepatocytes
  publication-title: Drug Metab Dispos
– volume: 38
  start-page: 672
  year: 2001
  end-page: 685
  ident: bib375
  article-title: Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge
  publication-title: J Cardiovasc Pharmacol
– volume: 62
  start-page: 610
  year: 1997
  end-page: 618
  ident: bib359
  article-title: The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis
  publication-title: Clin Pharmacol Ther
– volume: 39
  start-page: 1930
  year: 2011
  end-page: 1938
  ident: bib125
  article-title: The impact of hepatic uptake on the pharmacokinetics of organic anions
  publication-title: Drug Metab Dispos
– volume: 44
  start-page: 89
  year: 1992
  end-page: 99
  ident: bib237
  article-title: DuP 753, the selective angiotensin II receptor blocker, is a competitive antagonist to human platelet thromboxane A
  publication-title: Prostaglandins
– volume: 270
  start-page: 12846
  year: 1995
  end-page: 12850
  ident: bib103
  article-title: The docking of Arg2 of angiotensin II with Asp281 of AT1 receptor is essential for full agonism
  publication-title: J Biol Chem
– volume: 36
  start-page: 555
  year: 1995
  end-page: 562
  ident: bib263
  article-title: Local action of the renin angiotensin system in the porcine ophthalmic circulation: effects of ACE-inhibitors and angiotensin receptor antagonists
  publication-title: Invest Ophthalmol Vis Sci
– volume: 36
  start-page: 1772
  year: 1993
  end-page: 1784
  ident: bib210
  article-title: Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazoles
  publication-title: J Med Chem
– volume: 112
  start-page: 459
  year: 2010
  end-page: 462
  ident: bib32
  article-title: Internalization of constitutively active N111G MUTANT of AT1 receptor induced by angiotensin II-receptor antagonists candesartan, losartan, and telmisartan: comparison with valsartan
  publication-title: J Pharmacol Sci
– volume: 79
  start-page: 427
  year: 2006
  end-page: 439
  ident: bib246
  article-title: Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril
  publication-title: Clin Pharmacol Ther
– volume: 35
  start-page: 16435
  year: 1996
  end-page: 16442
  ident: bib301
  article-title: The active state of the AT1 angiotensin receptor is generated by angiotensin II induction
  publication-title: Biochemistry
– volume: 352
  start-page: 15
  year: 1998
  end-page: 21
  ident: bib322
  article-title: Evaluation of the ability of irbesartan to cross the blood-brain barrier following acute intragastric treatment
  publication-title: Eur J Pharmacol
– volume: 43
  start-page: 271
  year: 1992
  end-page: 280
  ident: bib313
  article-title: Characterization and coupling of angiotensin-II receptor subtypes in cultured bovine adrenal fasciculata cells
  publication-title: J Steroid Biochem Mol Biol
– volume: 40
  start-page: 389
  year: 2000
  end-page: 395
  ident: bib316
  article-title: The pharmacokinetics and pharmacodynamics of losartan in continuous ambulatory peritoneal dialysis
  publication-title: J Clin Pharmacol
– volume: 76
  start-page: 113
  year: 2004
  end-page: 118
  ident: bib5
  article-title: Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans
  publication-title: Clin Pharmacol Ther
– volume: 48
  start-page: 85
  year: 2008
  end-page: 95
  ident: bib150
  article-title: Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects
  publication-title: J Clin Pharmacol
– volume: 33
  start-page: 1044
  year: 2010
  end-page: 1052
  ident: bib117
  article-title: A small difference in the molecular structure of angiotensin II receptor blockers induces AT₁ receptor-dependent and -independent beneficial effects
  publication-title: Hypertens Res
– volume: 32
  start-page: 304
  year: 1998
  end-page: 308
  ident: bib400
  article-title: Effect of ranitidine on the pharmacokinetics of orally administered eprosartan, an angiotensin II antagonist, in healthy male volunteers
  publication-title: Ann Pharmacother
– volume: 57
  start-page: 531
  year: 2012
  end-page: 544
  ident: bib96
  article-title: Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure
  publication-title: J Hum Genet
– volume: 267
  start-page: H2297
  year: 1994
  end-page: H2304
  ident: bib286
  article-title: Chronic administration of angiotensin II receptor antagonist, TCV-116, in cardiomyopathic hamsters
  publication-title: Am J Physiol
– volume: 21
  start-page: 576
  year: 2008
  end-page: 581
  ident: bib202
  article-title: Cardioprotective mechanism of telmisartan via PPAR-γ-eNOS pathway in dahl salt-sensitive hypertensive rats
  publication-title: Am J Hypertens
– volume: 40
  start-page: 547
  year: 1997
  end-page: 558
  ident: bib6
  article-title: Synthesis and structure-activity relationship of a new series of potent AT
  publication-title: J Med Chem
– volume: 34
  start-page: 138
  year: 1999
  end-page: 143
  ident: bib113
  article-title: Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats
  publication-title: Hypertension
– volume: 36
  start-page: 134
  year: 2013
  end-page: 139
  ident: bib273
  article-title: Unique Binding Behavior of the Recently Approved Angiotensin II Receptor Blocker Azilsartan Compared With That of Candesartan
  publication-title: Hypertens Res
– volume: 15
  start-page: 1490
  year: 1998
  end-page: 1494
  ident: bib467
  article-title: Correlating partitioning and caco-2 cell permeability of structurally diverse small molecular weight compounds
  publication-title: Pharm Res
– volume: 11
  start-page: S45
  year: 1997
  end-page: S47
  ident: bib25
  article-title: Inhibition of angiotensin II pressor response and ex vivo angiotensin II radioligand binding by candesartan cilexetil and losartan in healthy human volunteers
  publication-title: J Hum Hypertens
– volume: 51
  start-page: 2137
  year: 2008
  end-page: 2146
  ident: bib490
  article-title: Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems
  publication-title: J Med Chem
– volume: 46
  start-page: 311
  year: 1993
  end-page: 318
  ident: bib302
  article-title: Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist
  publication-title: Biochem Pharmacol
– volume: 23
  start-page: 369
  year: 2001
  end-page: 373
  ident: bib475
  article-title: Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers
  publication-title: Ther Drug Monit
– volume: 384
  start-page: 81
  year: 1999
  end-page: 89
  ident: bib152
  article-title: The angiotensin AT(
  publication-title: Eur J Pharmacol
– volume: 60
  start-page: 513
  year: 2008
  end-page: 535
  ident: bib333
  article-title: Pharmacogenomics of G protein-coupled receptor ligands in cardiovascular medicine
  publication-title: Pharmacol Rev
– volume: 111
  start-page: 145
  year: 1994
  end-page: 150
  ident: bib330
  article-title: A pharmacodynamic study of SR 47436, a selective AT1 receptor antagonist, on blood pressure in conscious cynomolgus monkeys
  publication-title: Br J Pharmacol
– volume: 274
  start-page: E115
  year: 1998
  end-page: E123
  ident: bib55
  article-title: Responses to angiotensin peptides are mediated by AT1 receptors in the rat
  publication-title: Am J Physiol
– volume: 30
  start-page: 607
  year: 1997
  end-page: 615
  ident: bib391
  article-title: Pharmacologic profiles of KRH-594, a novel nonpeptide angiotensin II-receptor antagonist
  publication-title: J Cardiovasc Pharmacol
– volume: 35
  start-page: 290
  year: 1993
  end-page: 297
  ident: bib309
  article-title: Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans
  publication-title: Br J Clin Pharmacol
– year: 1987
  ident: bib194
  article-title: Pharmacological Analysis of Drug-Receptor Interaction
– volume: 105
  start-page: 686
  year: 1992
  end-page: 690
  ident: bib147
  article-title: Pharmacological characterization of angiotensin-induced depolarizations of rat superior cervical ganglion in vitro
  publication-title: Br J Pharmacol
– volume: 15
  start-page: 208
  year: 2012
  end-page: 220
  ident: bib459
  article-title: Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats
  publication-title: J Pharm Pharm Sci
– volume: 584
  start-page: 613
  year: 2007
  end-page: 623
  ident: bib449
  article-title: Involvement of an enterocyte renin-angiotensin system in the local control of SGLT1-dependent glucose uptake across the rat small intestinal brush border membrane
  publication-title: J Physiol
– volume: 24
  start-page: 65
  year: 2001
  end-page: 74
  ident: bib386
  article-title: Acute effects of E-3174, a human active metabolite of losartan, on the cardiovascular system in tachycardia-induced canine heart failure
  publication-title: Hypertens Res
– volume: 13
  start-page: S49
  year: 1995
  end-page: S52
  ident: bib358
  article-title: The pharmacokinetics of losartan in renal insufficiency
  publication-title: J Hypertens Suppl
– volume: 205
  start-page: 376
  year: 2009
  end-page: 384
  ident: bib153
  article-title: Telmisartan induces proliferation of human endothelial progenitor cells via PPARgamma-dependent PI3K/Akt pathway
  publication-title: Atherosclerosis
– volume: 22
  start-page: 139
  year: 2008
  end-page: 146
  ident: bib271
  article-title: Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state
  publication-title: Mol Endocrinol
– volume: 348
  start-page: 101
  year: 1998
  end-page: 114
  ident: bib146
  article-title: Characterization and distribution of angiotensin II receptor subtypes in the mouse brain
  publication-title: Eur J Pharmacol
– volume: 2
  start-page: 62
  year: 1996
  end-page: 66
  ident: bib292
  article-title: The clinical pharmacology of losartan in Japanese subjects and patients
  publication-title: Blood Press Suppl
– volume: 8
  start-page: 343
  year: 1997
  end-page: 350
  ident: bib289
  article-title: Role of the angiotensin II type 1 receptor in preconditioning against infarction
  publication-title: Coron Artery Dis
– volume: 38
  start-page: 129
  year: 1998
  end-page: 137
  ident: bib255
  article-title: Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment
  publication-title: J Clin Pharmacol
– volume: 28
  start-page: 1146
  year: 2000
  end-page: 1148
  ident: bib299
  article-title: Both cMOAT/MRP2 and another unknown transporter(s) are responsible for the biliary excretion of glucuronide conjugate of the nonpeptide angiotensin II antagonist, telmisaltan
  publication-title: Drug Metab Dispos
– volume: 79
  start-page: 169
  year: 2008
  end-page: 178
  ident: bib454
  article-title: Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT
  publication-title: Cardiovasc Res
– volume: 669
  start-page: 84
  year: 2011
  end-page: 93
  ident: bib214
  article-title: Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models
  publication-title: Eur J Pharmacol
– volume: 50
  start-page: 683
  year: 2012
  end-page: 689
  ident: bib16
  article-title: Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174
  publication-title: Int J Clin Pharmacol Ther
– volume: 61
  start-page: 35
  year: 1997
  end-page: 44
  ident: bib278
  article-title: The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects
  publication-title: Clin Pharmacol Ther
– volume: 47
  start-page: 231
  year: 1994
  end-page: 245
  ident: bib281
  article-title: Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects
  publication-title: Eur J Clin Pharmacol
– volume: 15
  start-page: 143
  year: 2001
  end-page: 150
  ident: bib231
  article-title: Different types of antagonism by losartan and irbesartan on the effects of angiotensin II and its degradation products in rabbit arteries
  publication-title: Fundam Clin Pharmacol
– volume: 41
  start-page: 893
  year: 2009
  end-page: 898
  ident: bib112
  article-title: Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients
  publication-title: Horm Metab Res
– volume: 75
  start-page: 259
  year: 1997
  end-page: 266
  ident: bib180
  article-title: Pharmacological profiles of a novel non-peptide angiotensin II type I receptor antagonist HR720 in vitro and in vivo
  publication-title: Jpn J Pharmacol
– volume: 11
  start-page: S37
  year: 1997
  end-page: S42
  ident: bib85
  article-title: Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment
  publication-title: J Hum Hypertens
– volume: 54
  start-page: 1295
  year: 2002
  end-page: 1310
  ident: bib114
  article-title: The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans
  publication-title: Adv Drug Deliv Rev
– volume: 14
  start-page: 1645
  year: 2010
  end-page: 1656
  ident: bib379
  article-title: Synergistic effects of telmisartan and simvastatin on endothelial progenitor cells
  publication-title: J Cell Mol Med
– volume: 345
  start-page: 673
  year: 1992
  ident: 10.1124/pr.112.007278_bib42
  article-title: Antihypertensive activity of the non-peptide angiotensin II receptor antagonist, SK&F 108566, in rats and dogs
  publication-title: Naunyn Schmiedebergs Arch Pharmacol
  doi: 10.1007/BF00164582
– volume: 103
  start-page: 904
  year: 2001
  ident: 10.1124/pr.112.007278_bib46
  article-title: Angiotensin II type 1 receptor blockers
  publication-title: Circulation
  doi: 10.1161/01.CIR.103.6.904
– volume: 29
  start-page: 1051
  year: 2001
  ident: 10.1124/pr.112.007278_bib466
  article-title: Role of CYP2C9 polymorphism in losartan oxidation
  publication-title: Drug Metab Dispos
– volume: 19
  start-page: 351
  year: 1998
  ident: 10.1124/pr.112.007278_bib398
  article-title: Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food
  publication-title: Biopharm Drug Dispos
  doi: 10.1002/(SICI)1099-081X(199809)19:6<351::AID-BDD115>3.0.CO;2-V
– volume: 15
  start-page: 1490
  year: 1998
  ident: 10.1124/pr.112.007278_bib467
  article-title: Correlating partitioning and caco-2 cell permeability of structurally diverse small molecular weight compounds
  publication-title: Pharm Res
  doi: 10.1023/A:1011930411574
– volume: 64
  start-page: 712
  year: 2010
  ident: 10.1124/pr.112.007278_bib119
  article-title: The angiotensin receptor blocker, telmisartan, reduces and stabilizes atherosclerosis in ApoE and AT1aR double deficient mice
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2010.09.014
– volume: 47
  start-page: 38
  year: 2009
  ident: 10.1124/pr.112.007278_bib140
  article-title: No effect of MDR1 C3435T polymorphism on oral pharmacokinetics of telmisartan in 19 healthy Chinese male subjects
  publication-title: Clin Chem Lab Med
  doi: 10.1515/CCLM.2009.019
– volume: 40
  start-page: 35
  year: 2002
  ident: 10.1124/pr.112.007278_bib349
  article-title: Bioequivalence study of a valsartan tablet and a capsule formulation after single dosing in healthy volunteers using a replicated crossover design
  publication-title: Int J Clin Pharmacol Ther
  doi: 10.5414/CPP40035
– volume: 246
  start-page: 328
  year: 1988
  ident: 10.1124/pr.112.007278_bib436
  article-title: Beta adrenoceptor subtype binding activity in plasma and beta blockade by propranolol and beta-1 selective bisoprolol in humans. Evaluation with Schild-plots
  publication-title: J Pharmacol Exp Ther
  doi: 10.1016/S0022-3565(25)21024-2
– volume: 268
  start-page: 1199
  year: 1994
  ident: 10.1124/pr.112.007278_bib66
  article-title: The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dog
  publication-title: J Pharmacol Exp Ther
  doi: 10.1016/S0022-3565(25)38613-1
– volume: 21
  start-page: 576
  year: 2008
  ident: 10.1124/pr.112.007278_bib202
  article-title: Cardioprotective mechanism of telmisartan via PPAR-γ-eNOS pathway in dahl salt-sensitive hypertensive rats
  publication-title: Am J Hypertens
  doi: 10.1038/ajh.2008.27
– volume: 151
  start-page: 952
  year: 2007
  ident: 10.1124/pr.112.007278_bib220
  article-title: Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor
  publication-title: Br J Pharmacol
  doi: 10.1038/sj.bjp.0707323
– volume: 79
  start-page: 131
  year: 1999
  ident: 10.1124/pr.112.007278_bib364
  article-title: Inhibition of the angiotensin II Type 1 receptor by TCV-116: quantitation by in vitro autoradiography
  publication-title: Jpn J Pharmacol
  doi: 10.1254/jjp.79.131
– volume: 39
  start-page: 847
  year: 2012
  ident: 10.1124/pr.112.007278_bib355
  article-title: Whole-body distribution and radiation dosimetry of [11C]telmisartan as a biomarker for hepatic organic anion transporting polypeptide (OATP) 1B3
  publication-title: Nucl Med Biol
  doi: 10.1016/j.nucmedbio.2012.01.008
– volume: 41
  start-page: 809
  year: 1992
  ident: 10.1124/pr.112.007278_bib39
  article-title: Modulation of angiotensin II binding affinity by allosteric interaction of polyvinyl sulfate with an intracellular domain of the DuP-753-sensitive angiotensin II receptor of bovine adrenal glomerulosa
  publication-title: Mol Pharmacol
  doi: 10.1016/S0026-895X(25)09072-8
– volume: 54
  start-page: 3442
  year: 2005
  ident: 10.1124/pr.112.007278_bib344
  article-title: Molecular characterization of new selective peroxisome proliferator-activated receptor γ modulators with angiotensin receptor blocking activity
  publication-title: Diabetes
  doi: 10.2337/diabetes.54.12.3442
– volume: 13
  start-page: S49
  year: 1995
  ident: 10.1124/pr.112.007278_bib358
  article-title: The pharmacokinetics of losartan in renal insufficiency
  publication-title: J Hypertens Suppl
  doi: 10.1097/00004872-199507001-00007
– volume: 326
  start-page: 983
  year: 2008
  ident: 10.1124/pr.112.007278_bib2
  article-title: In vitro biliary clearance of angiotensin II receptor blockers and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in sandwich-cultured rat hepatocytes: comparison with in vivo biliary clearance
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.108.138073
– volume: 154
  start-page: 133
  year: 1997
  ident: 10.1124/pr.112.007278_bib124
  article-title: Characterization of the AT1 angiotensin II receptor expressed in guinea pig liver
  publication-title: J Endocrinol
  doi: 10.1677/joe.0.1540133
– volume: 36
  start-page: 134
  year: 2013
  ident: 10.1124/pr.112.007278_bib273
  article-title: Unique Binding Behavior of the Recently Approved Angiotensin II Receptor Blocker Azilsartan Compared With That of Candesartan
  publication-title: Hypertens Res
  doi: 10.1038/hr.2012.147
– volume: 25
  start-page: 14
  year: 1995
  ident: 10.1124/pr.112.007278_bib87
  article-title: Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers
  publication-title: Hypertension
  doi: 10.1161/01.HYP.25.1.14
– volume: 352
  start-page: 1
  year: 1995
  ident: 10.1124/pr.112.007278_bib264
  article-title: Classification of alpha 1-adrenoceptor subtypes
  publication-title: Naunyn Schmiedebergs Arch Pharmacol
  doi: 10.1007/BF00169183
– volume: 19
  start-page: S3
  year: 2001
  ident: 10.1124/pr.112.007278_bib204
  article-title: In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist
  publication-title: J Hypertens Suppl
  doi: 10.1097/00004872-200106001-00002
– volume: 11
  start-page: S31
  issue: Suppl 2
  year: 1997
  ident: 10.1124/pr.112.007278_bib181
  article-title: Pharmacokinetic drug interaction studies with candesartan cilexetil
  publication-title: J Hum Hypertens
– volume: 24
  start-page: 467
  year: 1994
  ident: 10.1124/pr.112.007278_bib199
  article-title: Modification of pressure natriuresis by long-term losartan in spontaneously hypertensive rats
  publication-title: Hypertension
  doi: 10.1161/01.HYP.24.4.467
– volume: 39
  start-page: 1031
  year: 2011
  ident: 10.1124/pr.112.007278_bib433
  article-title: Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.110.036129
– volume: 72
  start-page: 184
  year: 2006
  ident: 10.1124/pr.112.007278_bib163
  article-title: Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor γ
  publication-title: Cardiovasc Res
  doi: 10.1016/j.cardiores.2006.07.014
– volume: 30
  start-page: 607
  year: 1997
  ident: 10.1124/pr.112.007278_bib391
  article-title: Pharmacologic profiles of KRH-594, a novel nonpeptide angiotensin II-receptor antagonist
  publication-title: J Cardiovasc Pharmacol
  doi: 10.1097/00005344-199711000-00011
– volume: 43
  start-page: 661
  year: 1997
  ident: 10.1124/pr.112.007278_bib256
  article-title: Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers
  publication-title: Br J Clin Pharmacol
  doi: 10.1046/j.1365-2125.1997.00608.x
– volume: 23
  start-page: 369
  year: 2001
  ident: 10.1124/pr.112.007278_bib475
  article-title: Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers
  publication-title: Ther Drug Monit
  doi: 10.1097/00007691-200108000-00008
– volume: 247
  start-page: 193
  year: 1993
  ident: 10.1124/pr.112.007278_bib59
  article-title: Characterization of [3H]losartan receptors in isolated rat glomeruli
  publication-title: Eur J Pharmacol
  doi: 10.1016/0922-4106(93)90077-M
– volume: 42
  start-page: 333
  year: 1992
  ident: 10.1124/pr.112.007278_bib291
  article-title: Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/BF00266358
– volume: 53
  start-page: 899
  year: 2008
  ident: 10.1124/pr.112.007278_bib385
  article-title: Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism
  publication-title: J Hum Genet
  doi: 10.1007/s10038-008-0324-9
– volume: 367
  start-page: 255
  year: 1999
  ident: 10.1124/pr.112.007278_bib77
  article-title: Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats
  publication-title: Eur J Pharmacol
  doi: 10.1016/S0014-2999(98)00983-2
– volume: 273
  start-page: 816
  year: 1995
  ident: 10.1124/pr.112.007278_bib209
  article-title: Absorption and glucuronidation of the angiotensin II receptor antagonist losartan by the rat intestine
  publication-title: J Pharmacol Exp Ther
  doi: 10.1016/S0022-3565(25)09579-5
– volume: 24
  start-page: 65
  year: 2001
  ident: 10.1124/pr.112.007278_bib386
  article-title: Acute effects of E-3174, a human active metabolite of losartan, on the cardiovascular system in tachycardia-induced canine heart failure
  publication-title: Hypertens Res
  doi: 10.1291/hypres.24.65
– volume: 365
  start-page: 477
  year: 2002
  ident: 10.1124/pr.112.007278_bib128
  article-title: Peripherally applied candesartan inhibits central responses to angiotensin II in conscious rats
  publication-title: Naunyn Schmiedebergs Arch Pharmacol
  doi: 10.1007/s00210-002-0545-y
– volume: 40
  start-page: 1331
  year: 2000
  ident: 10.1124/pr.112.007278_bib372
  article-title: Steady-state pharmacodynamics and pharmacokinetics of warfarin in the presence and absence of telmisartan in healthy male volunteers
  publication-title: J Clin Pharmacol
  doi: 10.1177/009127000004001204
– volume: 871
  start-page: 29
  year: 2000
  ident: 10.1124/pr.112.007278_bib298
  article-title: Chronic peripheral administration of the angiotensin II AT(1) receptor antagonist candesartan blocks brain AT(1) receptors
  publication-title: Brain Res
  doi: 10.1016/S0006-8993(00)02377-5
– volume: 51
  start-page: 513
  year: 1992
  ident: 10.1124/pr.112.007278_bib283
  article-title: Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/clpt.1992.56
– volume: 24
  start-page: 2023
  year: 2006
  ident: 10.1124/pr.112.007278_bib172
  article-title: The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage
  publication-title: J Hypertens
  doi: 10.1097/01.hjh.0000244952.54738.f6
– volume: 267
  start-page: H2297
  year: 1994
  ident: 10.1124/pr.112.007278_bib286
  article-title: Chronic administration of angiotensin II receptor antagonist, TCV-116, in cardiomyopathic hamsters
  publication-title: Am J Physiol
– volume: 35
  start-page: 482
  year: 2007
  ident: 10.1124/pr.112.007278_bib259
  publication-title: J Int Med Res
  doi: 10.1177/147323000703500407
– volume: 32
  start-page: 765
  year: 2009
  ident: 10.1124/pr.112.007278_bib288
  article-title: Telmisartan inhibits cytokine-induced nuclear factor-kappaB activation independently of the peroxisome proliferator-activated receptor-γ
  publication-title: Hypertens Res
  doi: 10.1038/hr.2009.95
– volume: 70
  start-page: 716
  year: 1992
  ident: 10.1124/pr.112.007278_bib1
  article-title: Competitive antagonism of pressor responses to angiotensin II and angiotensin III by the angiotensin II-1 receptor ligand losartan
  publication-title: Can J Physiol Pharmacol
  doi: 10.1139/y92-093
– volume: 79
  start-page: 427
  year: 2006
  ident: 10.1124/pr.112.007278_bib246
  article-title: Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/j.clpt.2006.01.011
– volume: 47
  start-page: 295
  year: 2007
  ident: 10.1124/pr.112.007278_bib18
  article-title: Pharmacokinetics of oral doses of telmisartan and nisoldipine, given alone and in combination, in patients with essential hypertension
  publication-title: J Clin Pharmacol
  doi: 10.1177/0091270006297225
– volume: 685
  start-page: 91
  year: 2012
  ident: 10.1124/pr.112.007278_bib402
  article-title: Telmisartan inhibits vascular dysfunction and inflammation via activation of peroxisome proliferator-activated receptor-γ in subtotal nephrectomized rat
  publication-title: Eur J Pharmacol
  doi: 10.1016/j.ejphar.2012.01.026
– volume: 29
  start-page: 913
  year: 2008
  ident: 10.1124/pr.112.007278_bib410
  article-title: Electropharmacological properties of telmisartan in blocking hKv1.5 and HERG potassium channels expressed on Xenopus laevis oocytes
  publication-title: Acta Pharmacol Sin
  doi: 10.1111/j.1745-7254.2008.00839.x
– volume: 49
  start-page: 235
  year: 2009
  ident: 10.1124/pr.112.007278_bib37
  article-title: Pharmacokinetics of valsartan in pediatric and adolescent subjects with hypertension
  publication-title: J Clin Pharmacol
  doi: 10.1177/0091270008329547
– volume: 219
  start-page: 147
  year: 1992
  ident: 10.1124/pr.112.007278_bib45
  article-title: Losartan potassium, a nonpeptide antagonist of angiotensin II, chronically administered p.o. does not readily cross the blood-brain barrier
  publication-title: Eur J Pharmacol
  doi: 10.1016/0014-2999(92)90593-S
– volume: 253
  start-page: 27
  year: 1994
  ident: 10.1124/pr.112.007278_bib427
  article-title: Effect of an angiotensin II receptor antagonist, CV-11974, and its prodrug, TCV-116, on production of aldosterone
  publication-title: Eur J Pharmacol
  doi: 10.1016/0014-2999(94)90753-6
– volume: 19
  start-page: 561
  year: 2001
  ident: 10.1124/pr.112.007278_bib121
  article-title: The angiotensin II AT1 receptor antagonist irbesartan prevents thromboxane A2-induced vasoconstriction in the rat hind-limb vascular bed in vivo
  publication-title: J Hypertens
  doi: 10.1097/00004872-200103001-00007
– volume: 101
  start-page: 755
  year: 1998
  ident: 10.1124/pr.112.007278_bib406
  article-title: Murine double nullizygotes of the angiotensin type 1A and 1B receptor genes duplicate severe abnormal phenotypes of angiotensinogen nullizygotes
  publication-title: J Clin Invest
  doi: 10.1172/JCI1899
– ident: 10.1124/pr.112.007278_bib407
  doi: 10.1007/s10557-011-6361-1
– volume: 46
  start-page: 585
  year: 2005
  ident: 10.1124/pr.112.007278_bib266
  article-title: A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker
  publication-title: J Cardiovasc Pharmacol
  doi: 10.1097/01.fjc.0000180902.78230.fd
– volume: 271
  start-page: 91
  year: 1994
  ident: 10.1124/pr.112.007278_bib319
  article-title: In vitro N-glucuronidation of SB 47436 (BMS 186295), a new AT1 nonpeptide angiotensin II receptor antagonist, by rat, monkey and human hepatic microsomal fractions
  publication-title: J Pharmacol Exp Ther
  doi: 10.1016/S0022-3565(25)22844-0
– volume: 21
  start-page: 2175
  year: 2003
  ident: 10.1124/pr.112.007278_bib137
  article-title: Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats
  publication-title: J Hypertens
  doi: 10.1097/00004872-200311000-00028
– volume: 34
  start-page: 1055
  year: 2006
  ident: 10.1124/pr.112.007278_bib14
  article-title: Inhibitory action of telmisartan on constriction of rat mesenteric artery in vitro
  publication-title: Jpn Pharmacol Ther
– volume: 40
  start-page: 1338
  year: 2000
  ident: 10.1124/pr.112.007278_bib371
  article-title: Pharmacokinetics of acetaminophen and ibuprofen when coadministered with telmisartan in healthy volunteers
  publication-title: J Clin Pharmacol
  doi: 10.1177/009127000004001205
– volume: 343
  start-page: 297
  year: 1998
  ident: 10.1124/pr.112.007278_bib161
  article-title: Angiotensin II stimulation of the stress-activated protein kinases in renal mesangial cells is mediated by the angiotensin AT1 receptor subtype
  publication-title: Eur J Pharmacol
  doi: 10.1016/S0014-2999(97)01542-2
– volume: 293
  start-page: E91
  year: 2007
  ident: 10.1124/pr.112.007278_bib476
  article-title: Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties
  publication-title: Am J Physiol Endocrinol Metab
  doi: 10.1152/ajpendo.00024.2007
– volume: 2
  start-page: 62
  year: 1996
  ident: 10.1124/pr.112.007278_bib292
  article-title: The clinical pharmacology of losartan in Japanese subjects and patients
  publication-title: Blood Press Suppl
– volume: 23
  start-page: 207
  year: 1995
  ident: 10.1124/pr.112.007278_bib376
  article-title: Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members
  publication-title: Drug Metab Dispos
  doi: 10.1016/S0090-9556(25)06520-1
– volume: 90
  start-page: 53
  year: 1992
  ident: 10.1124/pr.112.007278_bib3
  article-title: Role of angiotensin II receptor subtypes on the regulation of aldosterone secretion in the adrenal glomerulosa zone in the rat
  publication-title: Mol Cell Endocrinol
  doi: 10.1016/0303-7207(92)90101-B
– volume: 40
  start-page: 571
  year: 1995
  ident: 10.1124/pr.112.007278_bib84
  article-title: Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers
  publication-title: Br J Clin Pharmacol
  doi: 10.1111/j.1365-2125.1995.tb05802.x
– volume: 120
  start-page: 488
  year: 1997
  ident: 10.1124/pr.112.007278_bib424
  article-title: In vitro and in vivo effects of UP 269-6, a new potent orally active nonpeptide angiotensin II receptor antagonist, on vascular smooth muscle cell proliferation
  publication-title: Br J Pharmacol
  doi: 10.1038/sj.bjp.0700897
– volume: 576
  start-page: 492
  year: 2004
  ident: 10.1124/pr.112.007278_bib116
  article-title: An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes
  publication-title: FEBS Lett
  doi: 10.1016/j.febslet.2004.09.027
– volume: 37
  start-page: 165
  year: 2009
  ident: 10.1124/pr.112.007278_bib229
  article-title: [Effects of telmisartan on voltage-gated Kv1.3 and Kv1.5 potassium channels expressed in Xenopus oocytes]
  publication-title: Zhonghua Xin Xue Guan Bing Za Zhi
– volume: 262
  start-page: 595
  year: 1992
  ident: 10.1124/pr.112.007278_bib307
  article-title: The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism
  publication-title: J Pharmacol Exp Ther
  doi: 10.1016/S0022-3565(25)10800-8
– volume: 39
  start-page: 1930
  year: 2011
  ident: 10.1124/pr.112.007278_bib125
  article-title: The impact of hepatic uptake on the pharmacokinetics of organic anions
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.111.039842
– volume: 46
  start-page: 594
  year: 1996
  ident: 10.1124/pr.112.007278_bib205
  article-title: Disposition of the new angiotensin II receptor antagonist candesartan cilexetil in rats and dogs
  publication-title: Arzneimittelforschung
– volume: 112
  start-page: 459
  year: 2010
  ident: 10.1124/pr.112.007278_bib32
  article-title: Internalization of constitutively active N111G MUTANT of AT1 receptor induced by angiotensin II-receptor antagonists candesartan, losartan, and telmisartan: comparison with valsartan
  publication-title: J Pharmacol Sci
  doi: 10.1254/jphs.09343SC
– volume: 8
  start-page: 343
  year: 1997
  ident: 10.1124/pr.112.007278_bib289
  article-title: Role of the angiotensin II type 1 receptor in preconditioning against infarction
  publication-title: Coron Artery Dis
  doi: 10.1097/00019501-199706000-00003
– volume: 6
  start-page: 863
  year: 2010
  ident: 10.1124/pr.112.007278_bib90
  article-title: Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties
  publication-title: Expert Opin Drug Metab Toxicol
  doi: 10.1517/17425255.2010.494597
– volume: 40
  start-page: 1355
  year: 2000
  ident: 10.1124/pr.112.007278_bib374
  article-title: Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers
  publication-title: J Clin Pharmacol
  doi: 10.1177/009127000004001207
– volume: 35
  start-page: 940
  year: 2012
  ident: 10.1124/pr.112.007278_bib196
  article-title: Sympathoinhibition caused by orally administered telmisartan through inhibition of the AT₁ receptor in the rostral ventrolateral medulla of hypertensive rats
  publication-title: Hypertens Res
  doi: 10.1038/hr.2012.63
– volume: 58
  start-page: 1499
  year: 2006
  ident: 10.1124/pr.112.007278_bib458
  article-title: Inhibitory effects of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic anion transporter 4
  publication-title: J Pharm Pharmacol
  doi: 10.1211/jpp.58.11.0011
– volume: 404
  start-page: 434
  year: 2011
  ident: 10.1124/pr.112.007278_bib308
  article-title: Unique “delta lock” structure of telmisartan is involved in its strongest binding affinity to angiotensin II type 1 receptor
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2010.11.139
– volume: 68
  start-page: 1239
  year: 2008
  ident: 10.1124/pr.112.007278_bib348
  article-title: Olmesartan medoxomil: a review of its use in the management of hypertension
  publication-title: Drugs
  doi: 10.2165/00003495-200868090-00005
– volume: 31
  start-page: 1549
  year: 2008
  ident: 10.1124/pr.112.007278_bib468
  article-title: Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan
  publication-title: Hypertens Res
  doi: 10.1291/hypres.31.1549
– volume: 56
  start-page: 569
  year: 2006
  ident: 10.1124/pr.112.007278_bib480
  article-title: Pharmacokinetics of telmisartan in healthy Chinese subjects after oral administration of two dosage levels.
  publication-title: Arzneimittelforschung
– volume: 20
  start-page: 579
  year: 2007
  ident: 10.1124/pr.112.007278_bib173
  article-title: TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation
  publication-title: Am J Hypertens
  doi: 10.1016/j.amjhyper.2006.12.010
– volume: 289
  start-page: 267
  year: 1995
  ident: 10.1124/pr.112.007278_bib143
  article-title: Kinetic studies on the interaction of nonlabeled antagonists with the angiotensin II receptor
  publication-title: Eur J Pharmacol
  doi: 10.1016/0922-4106(95)90103-5
– volume: 20
  start-page: 377
  year: 2010
  ident: 10.1124/pr.112.007278_bib12
  article-title: A single-nucleotide polymorphism of alanine to threonine at position 163 of the human angiotensin II type 1 receptor impairs Losartan affinity
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/FPC.0b013e32833a6d4a
– volume: 336
  start-page: 801
  year: 2011
  ident: 10.1124/pr.112.007278_bib310
  article-title: In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.110.176636
– volume: 59
  start-page: 825
  year: 2001
  ident: 10.1124/pr.112.007278_bib47
  article-title: Direct effects of candesartan and eprosartan on human cloned potassium channels involved in cardiac repolarization
  publication-title: Mol Pharmacol
  doi: 10.1016/S0026-895X(24)09251-4
– volume: 198
  start-page: 22
  year: 2008
  ident: 10.1124/pr.112.007278_bib69
  article-title: Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells
  publication-title: Atherosclerosis
  doi: 10.1016/j.atherosclerosis.2007.09.013
– volume: 110
  start-page: 761
  year: 1993
  ident: 10.1124/pr.112.007278_bib75
  article-title: Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype
  publication-title: Br J Pharmacol
  doi: 10.1111/j.1476-5381.1993.tb13877.x
– volume: 132
  start-page: 11
  year: 1991
  ident: 10.1124/pr.112.007278_bib304
  article-title: Distribution of angiotensin II receptor subtypes in rat brain nuclei
  publication-title: Neurosci Lett
  doi: 10.1016/0304-3940(91)90420-X
– volume: 62
  start-page: 782
  year: 2007
  ident: 10.1124/pr.112.007278_bib451
  article-title: Pharmacokinetics and urinary excretion of eprosartan in Chinese healthy volunteers of different gender
  publication-title: Pharmazie
– volume: 54
  start-page: 738
  year: 2009
  ident: 10.1124/pr.112.007278_bib186
  article-title: Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPARgamma activation
  publication-title: Hypertension
  doi: 10.1161/HYPERTENSIONAHA.109.132886
– volume: 33
  start-page: 1044
  year: 2010
  ident: 10.1124/pr.112.007278_bib117
  article-title: A small difference in the molecular structure of angiotensin II receptor blockers induces AT₁ receptor-dependent and -independent beneficial effects
  publication-title: Hypertens Res
  doi: 10.1038/hr.2010.135
– volume: 13
  start-page: 1123
  year: 2011
  ident: 10.1124/pr.112.007278_bib481
  article-title: Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats
  publication-title: Diabetes Obes Metab
  doi: 10.1111/j.1463-1326.2011.01471.x
– volume: 47
  start-page: 2574
  year: 2004
  ident: 10.1124/pr.112.007278_bib49
  article-title: Design, synthesis, structural studies, biological evaluation, and computational simulations of novel potent AT1 angiotensin II receptor antagonists based on the 4-phenylquinoline structure
  publication-title: J Med Chem
  doi: 10.1021/jm031100t
– volume: 302
  start-page: 237
  year: 2009
  ident: 10.1124/pr.112.007278_bib415
  article-title: Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism
  publication-title: Mol Cell Endocrinol
  doi: 10.1016/j.mce.2008.06.006
– volume: 375
  start-page: 446
  year: 2008
  ident: 10.1124/pr.112.007278_bib276
  article-title: Telmisartan prevented cognitive decline partly due to PPAR-γ activation
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2008.08.032
– volume: 265
  start-page: 826
  year: 1993
  ident: 10.1124/pr.112.007278_bib52
  article-title: Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist
  publication-title: J Pharmacol Exp Ther
  doi: 10.1016/S0022-3565(25)38210-8
– volume: 30
  start-page: 259
  year: 2009
  ident: 10.1124/pr.112.007278_bib482
  article-title: Transport characteristics of candesartan in human intestinal Caco-2 cell line
  publication-title: Biopharm Drug Dispos
  doi: 10.1002/bdd.664
– volume: 10
  start-page: 93
  year: 2008
  ident: 10.1124/pr.112.007278_bib51
  article-title: Local adipose tissue renin-angiotensin system
  publication-title: Curr Hypertens Rep
  doi: 10.1007/s11906-008-0019-9
– volume: 43
  start-page: 2685
  year: 2000
  ident: 10.1124/pr.112.007278_bib221
  article-title: Synthesis and pharmacological evaluation of new pyrazolidine-3, 5-diones as AT(1) angiotensin II receptor antagonists
  publication-title: J Med Chem
  doi: 10.1021/jm9904147
– volume: 76
  start-page: 763
  year: 2008
  ident: 10.1124/pr.112.007278_bib7
  article-title: The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan
  publication-title: Biochem Pharmacol
  doi: 10.1016/j.bcp.2008.07.006
– volume: 27
  start-page: 288
  year: 1999
  ident: 10.1124/pr.112.007278_bib40
  article-title: Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes
  publication-title: Drug Metab Dispos
  doi: 10.1016/S0090-9556(24)15292-0
– volume: 294
  start-page: 179
  year: 2000
  ident: 10.1124/pr.112.007278_bib352
  article-title: Differential inhibition of the prejunctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan
  publication-title: J Pharmacol Exp Ther
  doi: 10.1016/S0022-3565(24)39054-8
– volume: 30
  start-page: 1260
  year: 1997
  ident: 10.1124/pr.112.007278_bib56
  article-title: Analysis of the effects of candesartan in the mesenteric vascular bed of the cat
  publication-title: Hypertension
  doi: 10.1161/01.HYP.30.5.1260
– volume: 15
  start-page: 208
  year: 2012
  ident: 10.1124/pr.112.007278_bib459
  article-title: Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats
  publication-title: J Pharm Pharm Sci
  doi: 10.18433/J3SK5V
– volume: 74
  start-page: 505
  year: 2003
  ident: 10.1124/pr.112.007278_bib411
  article-title: Altered pharmacokinetics and excessive hypotensive effect of candesartan in a patient with the CYP2C91/3 genotype
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/j.clpt.2003.08.001
– volume: 584
  start-page: 613
  year: 2007
  ident: 10.1124/pr.112.007278_bib449
  article-title: Involvement of an enterocyte renin-angiotensin system in the local control of SGLT1-dependent glucose uptake across the rat small intestinal brush border membrane
  publication-title: J Physiol
  doi: 10.1113/jphysiol.2007.138578
– volume: 40
  start-page: 1347
  year: 2000
  ident: 10.1124/pr.112.007278_bib369
  article-title: Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers
  publication-title: J Clin Pharmacol
  doi: 10.1177/009127000004001206
– volume: 260
  start-page: 933
  year: 1992
  ident: 10.1124/pr.112.007278_bib94
  article-title: Characterization of renal angiotensin II receptors using subtype selective antagonists
  publication-title: J Pharmacol Exp Ther
  doi: 10.1016/S0022-3565(25)11466-3
– volume: 62
  start-page: 1345
  year: 2002
  ident: 10.1124/pr.112.007278_bib431
  article-title: Olmesartan medoxomil
  publication-title: Drugs
  doi: 10.2165/00003495-200262090-00005
– volume: 292
  start-page: 238
  year: 2000
  ident: 10.1124/pr.112.007278_bib230
  article-title: Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation
  publication-title: J Pharmacol Exp Ther
  doi: 10.1016/S0022-3565(24)35282-6
– volume: 58
  start-page: 725
  year: 2011
  ident: 10.1124/pr.112.007278_bib17
  article-title: High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-γ target genes in patients with the metabolic syndrome
  publication-title: Hypertension
  doi: 10.1161/HYPERTENSIONAHA.111.173542
– volume: 30
  start-page: 583
  year: 1997
  ident: 10.1124/pr.112.007278_bib219
  article-title: Pharmacokinetic-pharmacodynamic relations of losartan and EXP3174 in a porcine animal model
  publication-title: J Cardiovasc Pharmacol
  doi: 10.1097/00005344-199711000-00008
– volume: 40
  start-page: 1373
  year: 2000
  ident: 10.1124/pr.112.007278_bib368
  article-title: The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers
  publication-title: J Clin Pharmacol
  doi: 10.1177/009127000004001209
– volume: 399
  start-page: 83
  year: 2009
  ident: 10.1124/pr.112.007278_bib267
  article-title: Telmisartan pharmacokinetics in Japanese renal transplant recipients
  publication-title: Clin Chim Acta
  doi: 10.1016/j.cca.2008.09.020
– volume: 11
  start-page: S27
  issue: Suppl 2
  year: 1997
  ident: 10.1124/pr.112.007278_bib416
  article-title: Absorption, metabolism and excretion of 14C-candesartan and 14C-candesartan cilexetil in healthy volunteers
  publication-title: J Hum Hypertens
– volume: 51
  start-page: 259
  year: 2008
  ident: 10.1124/pr.112.007278_bib428
  article-title: Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-γ
  publication-title: Hypertension
  doi: 10.1161/HYPERTENSIONAHA.107.099028
– volume: 384
  start-page: 81
  year: 1999
  ident: 10.1124/pr.112.007278_bib152
  article-title: The angiotensin AT(1) receptor antagonist irbesartan has near-peptide affinity and potently blocks receptor signaling
  publication-title: Eur J Pharmacol
  doi: 10.1016/S0014-2999(99)00662-7
– volume: 205
  start-page: 376
  year: 2009
  ident: 10.1124/pr.112.007278_bib153
  article-title: Telmisartan induces proliferation of human endothelial progenitor cells via PPARgamma-dependent PI3K/Akt pathway
  publication-title: Atherosclerosis
  doi: 10.1016/j.atherosclerosis.2008.12.036
– volume: 143
  start-page: 299
  year: 1963
  ident: 10.1124/pr.112.007278_bib417
  article-title: Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters
  publication-title: Arch Int Pharmacodyn Ther
– volume: 409
  start-page: 275
  year: 2011
  ident: 10.1124/pr.112.007278_bib408
  article-title: Irbesartan attenuates ischemic brain damage by inhibition of MCP-1/CCR2 signaling pathway beyond AT₁ receptor blockade
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2011.04.142
– volume: 263
  start-page: C750
  year: 1992
  ident: 10.1124/pr.112.007278_bib320
  article-title: Effects of angiotensin II and nonpeptide receptor antagonists on transduction pathways in rat proximal tubule
  publication-title: Am J Physiol
  doi: 10.1152/ajpcell.1992.263.4.C750
– volume: 271
  start-page: 804
  year: 1994
  ident: 10.1124/pr.112.007278_bib133
  article-title: Time course of losartan blockade of angiotensin II hypertension versus blockade of angiotensin II fast pressor effects
  publication-title: J Pharmacol Exp Ther
  doi: 10.1016/S0022-3565(25)23835-6
– volume: 50
  start-page: 683
  year: 2012
  ident: 10.1124/pr.112.007278_bib16
  article-title: Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174
  publication-title: Int J Clin Pharmacol Ther
  doi: 10.5414/CP201467
– volume: 38
  start-page: 702
  year: 1998
  ident: 10.1124/pr.112.007278_bib412
  article-title: Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers
  publication-title: J Clin Pharmacol
  doi: 10.1002/j.1552-4604.1998.tb04809.x
– volume: 29
  start-page: 284
  year: 1997
  ident: 10.1124/pr.112.007278_bib145
  article-title: The pharmacologic profile of 606A, a novel angiotensin II receptor antagonist
  publication-title: J Cardiovasc Pharmacol
  doi: 10.1097/00005344-199702000-00019
– volume: 126
  start-page: 1057
  year: 1999
  ident: 10.1124/pr.112.007278_bib418
  article-title: Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors
  publication-title: Br J Pharmacol
  doi: 10.1038/sj.bjp.0702398
– volume: 20
  start-page: 1151
  year: 2002
  ident: 10.1124/pr.112.007278_bib89
  article-title: Comparison of the vascular and antiadrenergic activities of four angiotensin II type 1 antagonists in the pithed rat
  publication-title: J Hypertens
  doi: 10.1097/00004872-200206000-00027
– volume: 13
  start-page: 227
  year: 1996
  ident: 10.1124/pr.112.007278_bib324
  article-title: Effects of structural modifications on the intestinal permeability of angiotensin II receptor antagonists and the correlation of in vitro, in situ, and in vivo absorption
  publication-title: Pharm Res
  doi: 10.1023/A:1016086930019
– volume: 391
  start-page: 85
  year: 2010
  ident: 10.1124/pr.112.007278_bib272
  article-title: Molecular mechanisms of the antagonistic action between AT1 and AT2 receptors
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2009.11.008
– volume: 20
  start-page: 1821
  year: 2002
  ident: 10.1124/pr.112.007278_bib295
  article-title: Sympatholytic properties of several AT1-receptor antagonists in the isolated rabbit thoracic aorta
  publication-title: J Hypertens
  doi: 10.1097/00004872-200209000-00028
– volume: 41
  start-page: 154
  year: 1992
  ident: 10.1124/pr.112.007278_bib74
  article-title: Angiotensin II receptor recognized by DuP753 regulates two distinct guanine nucleotide-binding protein signaling pathways
  publication-title: Mol Pharmacol
  doi: 10.1016/S0026-895X(25)08819-4
– volume: 26
  start-page: 973
  year: 2008
  ident: 10.1124/pr.112.007278_bib26
  article-title: Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same?
  publication-title: J Hypertens
  doi: 10.1097/HJH.0b013e3282f56ba5
– volume: 54
  start-page: 4219
  year: 2011
  ident: 10.1124/pr.112.007278_bib50
  article-title: Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ
  publication-title: J Med Chem
  doi: 10.1021/jm200409s
– volume: 38
  start-page: 519
  year: 2000
  ident: 10.1124/pr.112.007278_bib357
  article-title: Pharmacokinetics and blood pressure response of losartan in end-stage renal disease
  publication-title: Clin Pharmacokinet
  doi: 10.2165/00003088-200038060-00005
– volume: 75
  start-page: 259
  year: 1997
  ident: 10.1124/pr.112.007278_bib180
  article-title: Pharmacological profiles of a novel non-peptide angiotensin II type I receptor antagonist HR720 in vitro and in vivo
  publication-title: Jpn J Pharmacol
  doi: 10.1254/jjp.75.259
– volume: 52
  start-page: 25
  year: 1996
  ident: 10.1124/pr.112.007278_bib444
  article-title: Nonpeptide angiotensin II receptor antagonist: pharmacokinetics and pharmacodynamics in rats of EXP3174, an active metabolite of losartan
  publication-title: Pharmacology
  doi: 10.1159/000139357
– volume: 36
  start-page: 4040
  year: 1993
  ident: 10.1124/pr.112.007278_bib326
  article-title: 6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: synthesis, biological activity, and structure-activity relationships
  publication-title: J Med Chem
  doi: 10.1021/jm00077a007
– volume: 36
  start-page: 237
  year: 2008
  ident: 10.1124/pr.112.007278_bib469
  article-title: Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-elicited hepatic insulin resistance via peroxisome proliferator-activated receptor-γ activation
  publication-title: J Int Med Res
  doi: 10.1177/147323000803600204
– volume: 45
  start-page: 49
  year: 1998
  ident: 10.1124/pr.112.007278_bib389
  article-title: Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics
  publication-title: Br J Clin Pharmacol
  doi: 10.1046/j.1365-2125.1998.00636.x
– volume: 110
  start-page: 245
  year: 1993
  ident: 10.1124/pr.112.007278_bib440
  article-title: Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277
  publication-title: Br J Pharmacol
  doi: 10.1111/j.1476-5381.1993.tb13800.x
– volume: 267
  start-page: 1521
  year: 1993
  ident: 10.1124/pr.112.007278_bib226
  article-title: Characterization of angiotensin II receptors in smooth muscle preparations of the guinea pig in vitro
  publication-title: J Pharmacol Exp Ther
  doi: 10.1016/S0022-3565(25)39603-5
– volume: 23
  start-page: 285
  year: 2003
  ident: 10.1124/pr.112.007278_bib294
  article-title: AT(1)-receptor blockade and sympathetic neurotransmission in cardiovascular disease
  publication-title: Auton Autacoid Pharmacol
  doi: 10.1111/j.1474-8673.2004.00301.x
– volume: 14
  start-page: 1645
  issue: 6B
  year: 2010
  ident: 10.1124/pr.112.007278_bib379
  article-title: Synergistic effects of telmisartan and simvastatin on endothelial progenitor cells
  publication-title: J Cell Mol Med
  doi: 10.1111/j.1582-4934.2009.00829.x
– volume: 63
  start-page: PL75
  year: 2012
  ident: 10.1124/pr.112.007278_bib477
  article-title: Angiotensin II signaling activiates the NO-CGMP pathway in rat proximal tubules
  publication-title: Life Sci
  doi: 10.1016/S0024-3205(98)00278-1
– volume: 10
  start-page: S101
  issue: Suppl 11
  year: 1999
  ident: 10.1124/pr.112.007278_bib54
  article-title: Analysis of the effects of candesartan on responses to angiotensin II in the hindquarters vascular bed of the cat
  publication-title: J Am Soc Nephrol
– volume: 68
  start-page: 149
  year: 2012
  ident: 10.1124/pr.112.007278_bib64
  article-title: CYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s00228-011-1098-0
– volume: 111
  start-page: 227
  year: 2009
  ident: 10.1124/pr.112.007278_bib31
  article-title: Constitutively active mutant N111G of angiotensin II type 1 (AT(1)) receptor induces homologous internalization through mediation of AT(1)-receptor antagonist
  publication-title: J Pharmacol Sci
  doi: 10.1254/jphs.09202FP
– volume: 61
  start-page: 277
  year: 2001
  ident: 10.1124/pr.112.007278_bib421
  article-title: A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists
  publication-title: Biochem Pharmacol
  doi: 10.1016/S0006-2952(00)00546-3
– volume: 16
  start-page: S64
  issue: Suppl 3
  year: 2002
  ident: 10.1124/pr.112.007278_bib76
  article-title: The renin-angiotensin system in the brain: possible therapeutic implications for AT(1)-receptor blockers
  publication-title: J Hum Hypertens
  doi: 10.1038/sj.jhh.1001442
– volume: 26
  start-page: 964
  year: 2008
  ident: 10.1124/pr.112.007278_bib162
  article-title: Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-γ-modulating activity, on nitric oxide bioavailability and atherosclerotic change
  publication-title: J Hypertens
  doi: 10.1097/HJH.0b013e3282f52c36
– volume: 39
  start-page: 788
  year: 2009
  ident: 10.1124/pr.112.007278_bib233
  article-title: Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects
  publication-title: Xenobiotica
  doi: 10.1080/00498250903134435
– volume: 35
  start-page: 515
  year: 1995
  ident: 10.1124/pr.112.007278_bib65
  article-title: Human plasma protein binding of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) and its pharmacologically active metabolite EXP3174
  publication-title: J Clin Pharmacol
  doi: 10.1002/j.1552-4604.1995.tb04097.x
– volume: 33
  start-page: 247
  year: 2008
  ident: 10.1124/pr.112.007278_bib212
  article-title: Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan, a AT1 receptor antagonist, from animal data
  publication-title: Eur J Drug Metab Pharmacokinet
  doi: 10.1007/BF03190880
– volume: 285
  start-page: 181
  year: 1995
  ident: 10.1124/pr.112.007278_bib275
  article-title: Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist
  publication-title: Eur J Pharmacol
  doi: 10.1016/0014-2999(95)00401-6
– volume: 5
  start-page: 7
  year: 1994
  ident: 10.1124/pr.112.007278_bib297
  article-title: Pharmacological profile of a novel nonpeptide angiotensin II subtype 1 receptor antagonist, TCV-116
  publication-title: Blood Press Suppl
– volume: 22
  start-page: 139
  year: 2008
  ident: 10.1124/pr.112.007278_bib271
  article-title: Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state
  publication-title: Mol Endocrinol
  doi: 10.1210/me.2007-0312
– volume: 31
  start-page: 150
  year: 2010
  ident: 10.1124/pr.112.007278_bib435
  article-title: Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters
  publication-title: Biopharm Drug Dispos
  doi: 10.1002/bdd.699
– volume: 41
  start-page: 6640
  year: 2002
  ident: 10.1124/pr.112.007278_bib225
  article-title: Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662
  publication-title: Biochemistry
  doi: 10.1021/bi0159581
– volume: 24
  start-page: 1891
  year: 2006
  ident: 10.1124/pr.112.007278_bib235
  article-title: Telmisartan inhibits beta2-integrin MAC-1 expression in human T-lymphocytes
  publication-title: J Hypertens
  doi: 10.1097/01.hjh.0000242415.73406.17
– volume: 268
  start-page: 1540
  year: 1994
  ident: 10.1124/pr.112.007278_bib165
  publication-title: J Pharmacol Exp Ther
  doi: 10.1016/S0022-3565(25)38647-7
– volume: 12
  start-page: 159
  year: 1994
  ident: 10.1124/pr.112.007278_bib245
  article-title: Effects of losartan (DuP753) and enalaprilat on the mean arterial pressure response to phenylephrine
  publication-title: J Hypertens
  doi: 10.1097/00004872-199402000-00008
– volume: 43
  start-page: 993
  year: 2004
  ident: 10.1124/pr.112.007278_bib27
  article-title: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity
  publication-title: Hypertension
  doi: 10.1161/01.HYP.0000123072.34629.57
– volume: 28
  start-page: 1730
  year: 2010
  ident: 10.1124/pr.112.007278_bib175
  article-title: Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-γ activation in diabetic mice
  publication-title: J Hypertens
  doi: 10.1097/HJH.0b013e32833a551a
– volume: 34
  start-page: 138
  year: 1999
  ident: 10.1124/pr.112.007278_bib113
  article-title: Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats
  publication-title: Hypertension
  doi: 10.1161/01.HYP.34.1.138
– volume: 18
  start-page: 127
  year: 2000
  ident: 10.1124/pr.112.007278_bib439
  article-title: A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist
  publication-title: Cardiovasc Drug Rev
  doi: 10.1111/j.1527-3466.2000.tb00039.x
– volume: 52
  start-page: 441
  year: 1997
  ident: 10.1124/pr.112.007278_bib282
  article-title: Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s002280050317
– volume: 38
  start-page: 246
  year: 1998
  ident: 10.1124/pr.112.007278_bib252
  article-title: Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects
  publication-title: J Clin Pharmacol
  doi: 10.1002/j.1552-4604.1998.tb04422.x
– volume: 73
  start-page: 459
  year: 1995
  ident: 10.1124/pr.112.007278_bib257
  article-title: Inhibition by BMS 186295, a selective nonpeptide AT1 antagonist, of adrenal catecholamine release induced by angiotensin II in the dog in vivo
  publication-title: Can J Physiol Pharmacol
  doi: 10.1139/y95-058
– volume: 26
  start-page: 2252
  year: 2006
  ident: 10.1124/pr.112.007278_bib284
  article-title: Angiotensin II type 1 receptor-mediated inflammation is required for choroidal neovascularization
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/01.ATV.0000240050.15321.fe
– volume: 28
  start-page: 1083
  year: 2010
  ident: 10.1124/pr.112.007278_bib339
  article-title: Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age
  publication-title: J Hypertens
  doi: 10.1097/HJH.0b013e328336b86b
– volume: 48
  start-page: 85
  year: 2008
  ident: 10.1124/pr.112.007278_bib150
  article-title: Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects
  publication-title: J Clin Pharmacol
  doi: 10.1177/0091270007307880
– volume: 57
  start-page: 531
  year: 2012
  ident: 10.1124/pr.112.007278_bib96
  article-title: Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure
  publication-title: J Hum Genet
  doi: 10.1038/jhg.2012.63
– volume: 47
  start-page: 231
  year: 1994
  ident: 10.1124/pr.112.007278_bib281
  article-title: Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/BF02570503
– volume: 133
  start-page: 1678
  year: 1993
  ident: 10.1124/pr.112.007278_bib318
  article-title: The type 1 angiotensin-II receptor mediates intracellular calcium mobilization in rat luteal cells
  publication-title: Endocrinology
  doi: 10.1210/endo.133.4.8404609
– volume: 38
  start-page: 751
  year: 2010
  ident: 10.1124/pr.112.007278_bib242
  article-title: [Effects of telmisartan on 4-Aminopyridine-sensitive voltage dependant potassium channel of lymphocyte derived from spontaneously hypertensive rat]
  publication-title: Zhonghua Xin Xue Guan Bing Za Zhi
– volume: 24
  start-page: 2255
  year: 2006
  ident: 10.1124/pr.112.007278_bib101
  article-title: Synergistic protective effects of erythropoietin and olmesartan on ischemic stroke survival and post-stroke memory dysfunctions in the gerbil
  publication-title: J Hypertens
  doi: 10.1097/01.hjh.0000249704.34607.4c
– volume: 19
  start-page: 612
  year: 1999
  ident: 10.1124/pr.112.007278_bib207
  article-title: Pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal disease
  publication-title: Pharmacotherapy
  doi: 10.1592/phco.19.8.612.31518
– volume: 50
  start-page: 137
  year: 1994
  ident: 10.1124/pr.112.007278_bib329
  article-title: Modulation of tachyphylaxis to angiotensin II in rabbit isolated aorta by the angiotensin AT1 receptor antagonist, losartan
  publication-title: Regul Pept
  doi: 10.1016/0167-0115(94)90029-9
– volume: 19
  start-page: 15
  year: 2004
  ident: 10.1124/pr.112.007278_bib396
  article-title: Pharmacokinetic comparison of an angiotensin II receptor antagonist, telmisartan, in Japanese and western hypertensive patients using population pharmacokinetic method
  publication-title: Drug Metab Pharmacokinet
  doi: 10.2133/dmpk.19.15
– volume: 274
  start-page: E115
  year: 1998
  ident: 10.1124/pr.112.007278_bib55
  article-title: Responses to angiotensin peptides are mediated by AT1 receptors in the rat
  publication-title: Am J Physiol
– volume: 46
  start-page: 137
  year: 2005
  ident: 10.1124/pr.112.007278_bib70
  article-title: PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin
  publication-title: Hypertension
  doi: 10.1161/01.HYP.0000168046.19884.6a
– volume: 62
  start-page: 272
  year: 1997
  ident: 10.1124/pr.112.007278_bib41
  article-title: Pharmacokinetics of valsartan in patients with liver disease
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/S0009-9236(97)90029-1
– volume: 46
  start-page: 267
  year: 1998
  ident: 10.1124/pr.112.007278_bib399
  article-title: Effect of age and gender on the pharmacokinetics of eprosartan
  publication-title: Br J Clin Pharmacol
  doi: 10.1046/j.1365-2125.1998.00778.x
– volume: 43
  start-page: 251
  year: 2001
  ident: 10.1124/pr.112.007278_bib280
  article-title: Central inhibition of AT1receptors by eprosartan—in vitro autoradiography in the brain
  publication-title: Pharmacol Res
  doi: 10.1006/phrs.2000.0767
– volume: 113
  start-page: 57
  year: 2010
  ident: 10.1124/pr.112.007278_bib30
  article-title: Engineered mutation of some important amino acids in angiotensin II type 1 (AT1) receptor increases the binding affinity of AT1-receptor antagonists
  publication-title: J Pharmacol Sci
  doi: 10.1254/jphs.09361FP
– volume: 35
  start-page: 16435
  year: 1996
  ident: 10.1124/pr.112.007278_bib301
  article-title: The active state of the AT1 angiotensin receptor is generated by angiotensin II induction
  publication-title: Biochemistry
  doi: 10.1021/bi961593m
– volume: 19
  start-page: 2241
  year: 2001
  ident: 10.1124/pr.112.007278_bib22
  article-title: Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan
  publication-title: J Hypertens
  doi: 10.1097/00004872-200112000-00018
– volume: 52
  start-page: 451
  year: 1997
  ident: 10.1124/pr.112.007278_bib78
  article-title: Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s002280050318
– volume: 12
  start-page: 205
  issue: Suppl 12
  year: 1997
  ident: 10.1124/pr.112.007278_bib392
  article-title: Regulation of cardiac angiotensinogen mRNA in vivo and in vitro
  publication-title: Heart Vessels
– volume: 34
  start-page: 862
  year: 2006
  ident: 10.1124/pr.112.007278_bib285
  article-title: OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.105.008888
– volume: 5
  start-page: 648
  year: 1992
  ident: 10.1124/pr.112.007278_bib227
  article-title: AT1 receptors mediate the release of prostaglandins in porcine smooth muscle cells and rat astrocytes
  publication-title: Am J Hypertens
  doi: 10.1093/ajh/5.9.648
– volume: 76
  start-page: 113
  year: 2004
  ident: 10.1124/pr.112.007278_bib5
  article-title: Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/j.clpt.2004.04.001
– volume: 14
  start-page: 133
  year: 2007
  ident: 10.1124/pr.112.007278_bib293
  article-title: Telmisartan enhances cholesterol efflux from THP-1 macrophages by activating PPARgamma
  publication-title: J Atheroscler Thromb
  doi: 10.5551/jat.14.133
– volume: 59
  start-page: 303
  year: 1995
  ident: 10.1124/pr.112.007278_bib82
  article-title: Binding of valsartan to mammalian angiotensin AT1 receptors
  publication-title: Regul Pept
  doi: 10.1016/0167-0115(95)00085-P
– ident: 10.1124/pr.112.007278_bib53
  doi: 10.3109/03639045.2012.693502
– volume: 10
  start-page: 311S
  issue: 12 Pt 2, Suppl
  year: 1997
  ident: 10.1124/pr.112.007278_bib43
  article-title: The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations
  publication-title: Am J Hypertens
  doi: 10.1016/S0895-7061(97)00391-9
– volume: 35
  start-page: 1008
  year: 1995
  ident: 10.1124/pr.112.007278_bib206
  article-title: Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin
  publication-title: J Clin Pharmacol
  doi: 10.1002/j.1552-4604.1995.tb04018.x
– volume: 15
  start-page: 2815
  year: 2009
  ident: 10.1124/pr.112.007278_bib327
  article-title: Are the pleiotropic effects of telmisartan clinically relevant?
  publication-title: Curr Pharm Des
  doi: 10.2174/138161209788923859
– volume: 49
  start-page: 115
  year: 1995
  ident: 10.1124/pr.112.007278_bib130
  article-title: Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/BF00192369
– volume: 40
  start-page: 1365
  year: 2000
  ident: 10.1124/pr.112.007278_bib370
  article-title: Pharmacokinetics of single-dose telmisartan 120 mg given during and between hemodialysis in subjects with severe renal insufficiency: comparison with healthy volunteers
  publication-title: J Clin Pharmacol
  doi: 10.1177/009127000004001208
– volume: 111
  start-page: 145
  year: 1994
  ident: 10.1124/pr.112.007278_bib330
  article-title: A pharmacodynamic study of SR 47436, a selective AT1 receptor antagonist, on blood pressure in conscious cynomolgus monkeys
  publication-title: Br J Pharmacol
  doi: 10.1111/j.1476-5381.1994.tb14036.x
– volume: 68
  start-page: 347
  year: 2005
  ident: 10.1124/pr.112.007278_bib104
  article-title: Single mutations at Asn295 and Leu305 in the cytoplasmic half of transmembrane α-helix domain 7 of the AT1 receptor induce promiscuous agonist specificity for angiotensin II fragments: a pseudo-constitutive activity
  publication-title: Mol Pharmacol
  doi: 10.1124/mol.105.011601
– volume: 10
  start-page: 1463
  year: 1992
  ident: 10.1124/pr.112.007278_bib243
  article-title: Angiotensin II increases proto-oncogene expression and phosphoinositide turnover in vascular smooth muscle cells via the angiotensin II AT1 receptor
  publication-title: J Hypertens
  doi: 10.1097/00004872-199210120-00005
– volume: 66
  start-page: 367
  year: 1999
  ident: 10.1124/pr.112.007278_bib24
  article-title: Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay
  publication-title: Clin Pharmacol Ther
  doi: 10.1053/cp.1999.v66.a101162
– volume: 25
  start-page: 1643
  year: 2007
  ident: 10.1124/pr.112.007278_bib351
  article-title: Receptor-independent intracellular radical scavenging activity of an angiotensin II receptor blocker
  publication-title: J Hypertens
  doi: 10.1097/HJH.0b013e328165d159
– volume: 40
  start-page: 547
  year: 1997
  ident: 10.1124/pr.112.007278_bib6
  article-title: Synthesis and structure-activity relationship of a new series of potent AT1 selective angiotensin II receptor antagonists: 5-(biphenyl-4-ylmethyl)pyrazoles
  publication-title: J Med Chem
  doi: 10.1021/jm9604383
– volume: 79
  start-page: 169
  year: 2008
  ident: 10.1124/pr.112.007278_bib454
  article-title: Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization
  publication-title: Cardiovasc Res
  doi: 10.1093/cvr/cvn064
– volume: 44
  start-page: 407
  year: 1999
  ident: 10.1124/pr.112.007278_bib244
  article-title: Vasoconstriction by in situ formed angiotensin II: role of ACE and chymase
  publication-title: Cardiovasc Res
  doi: 10.1016/S0008-6363(99)00249-7
– volume: 270
  start-page: 12846
  year: 1995
  ident: 10.1124/pr.112.007278_bib103
  article-title: The docking of Arg2 of angiotensin II with Asp281 of AT1 receptor is essential for full agonism
  publication-title: J Biol Chem
  doi: 10.1074/jbc.270.21.12846
– volume: 19
  start-page: 221
  year: 1992
  ident: 10.1124/pr.112.007278_bib155
  article-title: Aldosterone regulation of gene transcription leading to control of ion transport
  publication-title: Hypertension
  doi: 10.1161/01.HYP.19.3.221
– volume: 34
  start-page: 1976
  year: 2006
  ident: 10.1124/pr.112.007278_bib58
  article-title: Rapid identification of P-glycoprotein substrates and inhibitors
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.106.012351
– volume: 47
  start-page: 425
  year: 1995
  ident: 10.1124/pr.112.007278_bib340
  article-title: Interaction between the nonpeptide angiotensin antagonist SKF-108,566 and histidine 256 (HisVI:16) of the angiotensin type 1 receptor
  publication-title: Mol Pharmacol
  doi: 10.1016/S0026-895X(25)08561-X
– volume: 21
  start-page: 523
  year: 2011
  ident: 10.1124/pr.112.007278_bib452
  article-title: The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/FPC.0b013e3283482502
– volume: 367
  start-page: 413
  year: 1999
  ident: 10.1124/pr.112.007278_bib107
  article-title: Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-transfected [correction of tranfected] Chinese hamster ovary cells
  publication-title: Eur J Pharmacol
  doi: 10.1016/S0014-2999(98)00965-0
– volume: 34
  start-page: 1109
  year: 2006
  ident: 10.1124/pr.112.007278_bib166
  article-title: Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.105.009175
– volume: 26
  start-page: 937
  year: 2003
  ident: 10.1124/pr.112.007278_bib274
  article-title: Molecular analysis of the structure and function of the angiotensin II type 1 receptor
  publication-title: Hypertens Res
  doi: 10.1291/hypres.26.937
– volume: 26
  start-page: 29
  year: 2006
  ident: 10.1124/pr.112.007278_bib208
  article-title: Pharmacokinetics of olmesartan medoxomil plus hydrochlorothiazide combination in healthy subjects
  publication-title: Clin Drug Investig
  doi: 10.2165/00044011-200626010-00004
– volume: 269
  start-page: 16533
  year: 1994
  ident: 10.1124/pr.112.007278_bib178
  article-title: Differential structural requirements for specific binding of nonpeptide and peptide antagonists to the AT1 angiotensin receptor. Identification of amino acid residues that determine binding of the antihypertensive drug losartan
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(19)89420-6
– volume: 272
  start-page: F515
  year: 1997
  ident: 10.1124/pr.112.007278_bib312
  article-title: Angiotensin II responses in AT1A receptor-deficient mice: a role for AT1B receptors in blood pressure regulation
  publication-title: Am J Physiol
– volume: 36
  start-page: 796
  year: 2008
  ident: 10.1124/pr.112.007278_bib167
  article-title: Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.107.018903
– volume: 59
  start-page: 89
  year: 1999
  ident: 10.1124/pr.112.007278_bib123
  article-title: Effects of eprosartan on glomerular injury in rats with reduced renal mass
  publication-title: Pharmacology
  doi: 10.1159/000028308
– volume: 46
  start-page: 311
  year: 1993
  ident: 10.1124/pr.112.007278_bib302
  article-title: Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist
  publication-title: Biochem Pharmacol
  doi: 10.1016/0006-2952(93)90420-2
– volume: 22
  start-page: 1186
  year: 2000
  ident: 10.1124/pr.112.007278_bib251
  article-title: Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension
  publication-title: Clin Ther
  doi: 10.1016/S0149-2918(00)83062-3
– volume: 59
  start-page: 1079
  year: 2012
  ident: 10.1124/pr.112.007278_bib265
  article-title: Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice
  publication-title: Hypertension
  doi: 10.1161/HYPERTENSIONAHA.112.192401
– volume: 72
  start-page: 238
  year: 2002
  ident: 10.1124/pr.112.007278_bib108
  article-title: Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers
  publication-title: Clin Pharmacol Ther
  doi: 10.1067/mcp.2002.127945
– volume: 32
  start-page: 304
  year: 1998
  ident: 10.1124/pr.112.007278_bib400
  article-title: Effect of ranitidine on the pharmacokinetics of orally administered eprosartan, an angiotensin II antagonist, in healthy male volunteers
  publication-title: Ann Pharmacother
  doi: 10.1345/aph.17188
– volume: 39
  start-page: 5228
  year: 1996
  ident: 10.1124/pr.112.007278_bib203
  article-title: Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres
  publication-title: J Med Chem
  doi: 10.1021/jm960547h
– volume: 363
  start-page: 509
  year: 2001
  ident: 10.1124/pr.112.007278_bib138
  article-title: Differential effects of eprosartan and losartan at prejunctional angiotensin II receptors
  publication-title: Naunyn Schmiedebergs Arch Pharmacol
  doi: 10.1007/s002100100396
– volume: 245
  start-page: 63
  year: 1993
  ident: 10.1124/pr.112.007278_bib105
  article-title: Angiotensin AT1 receptors mediate a positive inotropic effect of angiotensin II in guinea pig atria
  publication-title: Eur J Pharmacol
  doi: 10.1016/0922-4106(93)90170-E
– volume: 53
  start-page: 798
  year: 2009
  ident: 10.1124/pr.112.007278_bib401
  article-title: Inhibition of tumor necrosis factor-α-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator-activated receptor-γ with nuclear factor kappaB and CCAAT/enhancer-binding protein-β
  publication-title: Hypertension
  doi: 10.1161/HYPERTENSIONAHA.108.126656
– volume: 252
  start-page: 337
  year: 1994
  ident: 10.1124/pr.112.007278_bib478
  article-title: A non-competitive type of angiotensin-receptor antagonism by losartan in renal artery preparations
  publication-title: Eur J Pharmacol
  doi: 10.1016/0014-2999(94)90183-X
– volume: 53
  start-page: 1727
  year: 2010
  ident: 10.1124/pr.112.007278_bib332
  article-title: Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice
  publication-title: Diabetologia
  doi: 10.1007/s00125-010-1744-6
– volume: 113
  start-page: 179
  year: 1994
  ident: 10.1124/pr.112.007278_bib91
  article-title: BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174
  publication-title: Br J Pharmacol
  doi: 10.1111/j.1476-5381.1994.tb16191.x
– volume: 19
  start-page: 237
  year: 1998
  ident: 10.1124/pr.112.007278_bib360
  article-title: The effect of age on the pharmacokinetics of valsartan
  publication-title: Biopharm Drug Dispos
  doi: 10.1002/(SICI)1099-081X(199805)19:4<237::AID-BDD100>3.0.CO;2-7
– volume: 26
  start-page: 408
  year: 1998
  ident: 10.1124/pr.112.007278_bib57
  article-title: Biotransformation of irbesartan in man
  publication-title: Drug Metab Dispos
– volume: 19
  start-page: 75
  year: 1996
  ident: 10.1124/pr.112.007278_bib426
  article-title: Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats
  publication-title: Hypertens Res
  doi: 10.1291/hypres.19.75
– volume: 20
  start-page: 45
  year: 2006
  ident: 10.1124/pr.112.007278_bib79
  article-title: Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population
  publication-title: J Hum Hypertens
  doi: 10.1038/sj.jhh.1001941
– volume: 95
  start-page: 49
  year: 2011
  ident: 10.1124/pr.112.007278_bib450
  article-title: Brain renin-angiotensin—a new look at an old system
  publication-title: Prog Neurobiol
  doi: 10.1016/j.pneurobio.2011.07.001
– volume: 15
  start-page: 143
  year: 2001
  ident: 10.1124/pr.112.007278_bib231
  article-title: Different types of antagonism by losartan and irbesartan on the effects of angiotensin II and its degradation products in rabbit arteries
  publication-title: Fundam Clin Pharmacol
  doi: 10.1046/j.1472-8206.2001.00018.x
– volume: 44
  start-page: 341
  year: 1993
  ident: 10.1124/pr.112.007278_bib83
  article-title: Effect of pretreatment with the selective beta 1-adrenoceptor antagonist bisoprolol on the subsequent cardiovascular actions and beta-adrenoceptor subtype specific occupancy of celiprolol in healthy man
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/BF00316470
– volume: 35
  start-page: 906
  year: 2000
  ident: 10.1124/pr.112.007278_bib277
  article-title: Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation
  publication-title: J Cardiovasc Pharmacol
  doi: 10.1097/00005344-200006000-00012
– volume: 40
  start-page: 605
  year: 2001
  ident: 10.1124/pr.112.007278_bib254
  article-title: Drug interactions with irbesartan
  publication-title: Clin Pharmacokinet
  doi: 10.2165/00003088-200140080-00004
– volume: 46
  start-page: 1074
  year: 2005
  ident: 10.1124/pr.112.007278_bib11
  article-title: Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies
  publication-title: Am J Kidney Dis
  doi: 10.1053/j.ajkd.2005.08.034
– volume: 28
  start-page: 149
  year: 2000
  ident: 10.1124/pr.112.007278_bib373
  article-title: Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients
  publication-title: J Int Med Res
  doi: 10.1177/147323000002800401
– volume: 19
  start-page: 1160
  year: 1991
  ident: 10.1124/pr.112.007278_bib377
  article-title: Synthesis and identification of a novel tetrazole metabolite of the angiotensin II receptor antagonist DuP 753
  publication-title: Drug Metab Dispos
  doi: 10.1016/S0090-9556(25)09049-X
– volume: 263
  start-page: F411
  year: 1992
  ident: 10.1124/pr.112.007278_bib99
  article-title: Angiotensin II receptor subtypes in cultured rat renal mesangial cells
  publication-title: Am J Physiol
– volume: 81
  start-page: 819
  year: 1994
  ident: 10.1124/pr.112.007278_bib420
  article-title: Influence of Losartan, an angiotensin receptor antagonist, on neointimal proliferation in cultured human saphenous vein
  publication-title: Br J Surg
  doi: 10.1002/bjs.1800810609
– volume: 39
  start-page: 418
  year: 1999
  ident: 10.1124/pr.112.007278_bib262
  article-title: The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers
  publication-title: J Clin Pharmacol
  doi: 10.1177/00912709922007886
– volume: 10
  start-page: 743
  year: 2008
  ident: 10.1124/pr.112.007278_bib404
  article-title: Efficacy, safety, and pharmacokientics of candesartan cilexetil in hypertensive children aged 5 to 17 years
  publication-title: J Clin Hypertens (Greeenwich)
  doi: 10.1111/j.1751-7176.2008.00022.x
– volume: 109
  start-page: 2054
  year: 2004
  ident: 10.1124/pr.112.007278_bib346
  article-title: Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity
  publication-title: Circulation
  doi: 10.1161/01.CIR.0000127955.36250.65
– volume: 12
  start-page: 1
  year: 2011
  ident: 10.1124/pr.112.007278_bib270
  article-title: Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects
  publication-title: J Renin Angiotensin Aldosterone Syst
  doi: 10.1177/1470320310370852
– volume: 59
  start-page: 1200
  year: 2010
  ident: 10.1124/pr.112.007278_bib473
  article-title: Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-γ activation
  publication-title: Metabolism
  doi: 10.1016/j.metabol.2009.11.013
– volume: 40
  start-page: 374
  year: 2012
  ident: 10.1124/pr.112.007278_bib169
  article-title: Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.111.041475
– volume: 48
  start-page: 4389
  year: 2005
  ident: 10.1124/pr.112.007278_bib28
  article-title: Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists
  publication-title: J Med Chem
  doi: 10.1021/jm049024x
– volume: 61
  start-page: 35
  year: 1997
  ident: 10.1124/pr.112.007278_bib278
  article-title: The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/S0009-9236(97)90180-6
– volume: 15
  start-page: 459
  year: 1990
  ident: 10.1124/pr.112.007278_bib447
  article-title: Hypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Nonpeptide angiotensin II receptor antagonists: X
  publication-title: Hypertension
  doi: 10.1161/01.HYP.15.5.459
– volume: 320
  start-page: 211
  year: 2007
  ident: 10.1124/pr.112.007278_bib174
  article-title: Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.106.112755
– volume: 105
  start-page: 686
  year: 1992
  ident: 10.1124/pr.112.007278_bib147
  article-title: Pharmacological characterization of angiotensin-induced depolarizations of rat superior cervical ganglion in vitro
  publication-title: Br J Pharmacol
  doi: 10.1111/j.1476-5381.1992.tb09039.x
– volume: 12
  start-page: 119
  year: 1994
  ident: 10.1124/pr.112.007278_bib438
  article-title: Effects on binding characteristics and renal function of the novel, non-peptide angiotensin II antagonist BIBR277 in the rat
  publication-title: J Hypertens
  doi: 10.1097/00004872-199402000-00003
– volume: 25
  start-page: 639
  year: 2008
  ident: 10.1124/pr.112.007278_bib337
  article-title: Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers
  publication-title: Pharm Res
  doi: 10.1007/s11095-007-9401-6
– volume: 29
  start-page: 2476
  year: 2011
  ident: 10.1124/pr.112.007278_bib182
  article-title: Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker
  publication-title: J Hypertens
  doi: 10.1097/HJH.0b013e32834c46fd
– volume: 59
  start-page: 268
  year: 1996
  ident: 10.1124/pr.112.007278_bib131
  article-title: Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/S0009-9236(96)80004-X
– volume: 335
  start-page: 572
  year: 2010
  ident: 10.1124/pr.112.007278_bib423
  article-title: Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.110.173005
– volume: 32
  start-page: 1303
  year: 2011
  ident: 10.1124/pr.112.007278_bib15
  article-title: Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics
  publication-title: Acta Pharmacol Sin
  doi: 10.1038/aps.2011.100
– volume: 47
  start-page: 255
  year: 1995
  ident: 10.1124/pr.112.007278_bib177
  article-title: International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. IX. Recommendations on terms and symbols in quantitative pharmacology
  publication-title: Pharmacol Rev
  doi: 10.1016/S0031-6997(25)06844-9
– volume: 28
  start-page: 125
  year: 2002
  ident: 10.1124/pr.112.007278_bib483
  article-title: Structure elucidation and conformational properties of eprosartan, a non peptide angiotensin II AT1 antagonist
  publication-title: J Pharm Biomed Anal
  doi: 10.1016/S0731-7085(01)00603-3
– volume: 36
  start-page: 3371
  year: 1993
  ident: 10.1124/pr.112.007278_bib29
  article-title: A new series of imidazolones: highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists
  publication-title: J Med Chem
  doi: 10.1021/jm00074a018
– volume: 111
  start-page: 145
  year: 2006
  ident: 10.1124/pr.112.007278_bib139
  article-title: Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance
  publication-title: Pharmacol Ther
  doi: 10.1016/j.pharmthera.2005.10.009
– volume: 52
  start-page: 115
  year: 1997
  ident: 10.1124/pr.112.007278_bib110
  article-title: Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s002280050259
– volume: 264
  start-page: 307
  year: 1994
  ident: 10.1124/pr.112.007278_bib216
  article-title: Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models
  publication-title: Eur J Pharmacol
  doi: 10.1016/0014-2999(94)00484-6
– volume: 28
  start-page: 543
  year: 2008
  ident: 10.1124/pr.112.007278_bib462
  article-title: Telmisartan but not valsartan inhibits TGF-β-mediated accumulation of extracellular matrix via activation of PPARgamma
  publication-title: J Huazhong Univ Sci Technolog Med Sci
  doi: 10.1007/s11596-008-0512-z
– volume: 54
  start-page: 1353
  year: 2009
  ident: 10.1124/pr.112.007278_bib456
  article-title: Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-γ activation
  publication-title: Hypertension
  doi: 10.1161/HYPERTENSIONAHA.109.138750
– volume: 15
  start-page: 823
  year: 1990
  ident: 10.1124/pr.112.007278_bib446
  article-title: Nonpeptide angiotensin II receptor antagonists. Studies with EXP9270 and DuP 753
  publication-title: Hypertension
  doi: 10.1161/01.HYP.15.6.823
– volume: 38
  start-page: 347
  year: 1998
  ident: 10.1124/pr.112.007278_bib253
  article-title: Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis
  publication-title: J Clin Pharmacol
  doi: 10.1002/j.1552-4604.1998.tb04434.x
– volume: 62
  start-page: 417
  year: 1997
  ident: 10.1124/pr.112.007278_bib190
  article-title: Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/S0009-9236(97)90120-X
– volume: 169
  start-page: 997
  year: 1990
  ident: 10.1124/pr.112.007278_bib366
  article-title: Discrimination of two angiotensin II receptor subtypes with a selective agonist analogue of angiotensin II, p-aminophenylalanine6 angiotensin II
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/0006-291X(90)91993-3
– volume: 172
  start-page: 1195
  year: 1990
  ident: 10.1124/pr.112.007278_bib60
  article-title: [3H]DUP 753, a highly potent and specific radioligand for the angiotensin II-1 receptor subtype
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/0006-291X(90)91575-D
– volume: 35
  start-page: 2658
  year: 1992
  ident: 10.1124/pr.112.007278_bib234
  article-title: Nonpeptide angiotensin II receptor antagonists: synthetic and computational chemistry of N-[[4-[2-(2H-tetrazol-5-yl)-1-cycloalken-1- yl]phenyl]methyl]imidazole derivatives and their in vitro activity
  publication-title: J Med Chem
  doi: 10.1021/jm00092a017
– volume: 43
  start-page: 84
  year: 2003
  ident: 10.1124/pr.112.007278_bib222
  article-title: Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans
  publication-title: J Clin Pharmacol
  doi: 10.1177/0091270002239710
– volume: 15
  start-page: 364
  year: 1994
  ident: 10.1124/pr.112.007278_bib328
  article-title: Agonist-antagonist interactions at angiotensin receptors: application of a two-state receptor model
  publication-title: Trends Pharmacol Sci
  doi: 10.1016/0165-6147(94)90156-2
– volume: 11
  start-page: S19
  issue: Suppl 2
  year: 1997
  ident: 10.1124/pr.112.007278_bib159
  article-title: Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers
  publication-title: J Hum Hypertens
– volume: 127
  start-page: 1876
  year: 1999
  ident: 10.1124/pr.112.007278_bib136
  article-title: Action of AT1 receptor antagonists on angiotensin II-induced tone in human isolated subcutaneous resistance arteries
  publication-title: Br J Pharmacol
  doi: 10.1038/sj.bjp.0702722
– volume: 9
  start-page: 1639
  year: 2001
  ident: 10.1124/pr.112.007278_bib321
  article-title: Synthesis and study of a cyclic angiotensin II antagonist analogue reveals the role of π*—π* interactions in the C-terminal aromatic residue for agonist activity and its structure resemblance with AT(1) non-peptide antagonists
  publication-title: Bioorg Med Chem
  doi: 10.1016/S0968-0896(01)00059-1
– volume: 31
  start-page: 541
  year: 2010
  ident: 10.1124/pr.112.007278_bib361
  article-title: Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease
  publication-title: Am J Nephrol
  doi: 10.1159/000313363
– volume: 114
  start-page: 115
  year: 2010
  ident: 10.1124/pr.112.007278_bib287
  article-title: Concentration-dependent inhibitory effect of irbesartan on renal uric acid transporters
  publication-title: J Pharmacol Sci
  doi: 10.1254/jphs.10064SC
– volume: 17
  start-page: 1482
  year: 2000
  ident: 10.1124/pr.112.007278_bib419
  article-title: Inhibition of angiotensin II-induced inositol phosphate production by triacid nonpeptide antagonists in CHO cells expressing human AT1 receptors
  publication-title: Pharm Res
  doi: 10.1023/A:1007600924033
– volume: 46
  start-page: 611
  year: 1998
  ident: 10.1124/pr.112.007278_bib414
  article-title: The effects of age and gender on the pharmacokinetics of irbesartan
  publication-title: Br J Clin Pharmacol
  doi: 10.1046/j.1365-2125.1998.00837.x
– volume: 40
  start-page: 1323
  year: 2000
  ident: 10.1124/pr.112.007278_bib472
  article-title: Multiple-dose pharmacokinetics of telmisartan and of hydrochlorothiazide following concurrent administration in healthy subjects
  publication-title: J Clin Pharmacol
  doi: 10.1177/009127000004001203
– volume: 18
  start-page: 69
  year: 1995
  ident: 10.1124/pr.112.007278_bib171
  article-title: Effects of the non-peptide angiotensin II receptor antagonist TCV-116 on systemic and renal hemodynamics in dogs with renal hypertension
  publication-title: Hypertens Res
  doi: 10.1291/hypres.18.69
– year: 1987
  ident: 10.1124/pr.112.007278_bib194
– volume: 63
  start-page: 316
  year: 1998
  ident: 10.1124/pr.112.007278_bib442
  article-title: Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/S0009-9236(98)90163-1
– volume: 31
  start-page: 1268
  year: 2011
  ident: 10.1124/pr.112.007278_bib260
  article-title: Telmisartan exerts antiatherosclerotic effects by activating peroxisome proliferator-activated receptor-γ in macrophages
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/ATVBAHA.110.222067
– volume: 113
  start-page: 331
  year: 1994
  ident: 10.1124/pr.112.007278_bib341
  article-title: Mutations in transmembrane segment VII of the AT1 receptor differentiate between closely related insurmountable and competitive angiotensin antagonists
  publication-title: Br J Pharmacol
  doi: 10.1111/j.1476-5381.1994.tb16899.x
– volume: 59
  start-page: 589
  year: 2003
  ident: 10.1124/pr.112.007278_bib350
  article-title: Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s00228-003-0664-5
– volume: 289
  start-page: 399
  year: 1995
  ident: 10.1124/pr.112.007278_bib111
  article-title: Effects of TCV-116 and CV-11974 on angiotensin II-induced responses in vascular smooth muscle cells
  publication-title: Eur J Pharmacol
  doi: 10.1016/0922-4106(95)90121-3
– volume: 56
  start-page: 135
  year: 2000
  ident: 10.1124/pr.112.007278_bib387
  article-title: In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s002280050731
– volume: 19
  start-page: 465
  year: 2001
  ident: 10.1124/pr.112.007278_bib21
  article-title: Inhibition of angiotensin II-induced facilitation of sympathetic neurotransmission in the pithed rat: a comparison between losartan, irbesartan, telmisartan, and captopril
  publication-title: J Hypertens
  doi: 10.1097/00004872-200103000-00015
– volume: 37
  start-page: 226
  year: 2012
  ident: 10.1124/pr.112.007278_bib461
  article-title: Pharmacokinetics of losartan and its active carboxylic acid metabolite E-3174 in five ethnic populations of China
  publication-title: J Clin Pharm Ther
  doi: 10.1111/j.1365-2710.2011.01279.x
– volume: 51
  start-page: 2137
  year: 2008
  ident: 10.1124/pr.112.007278_bib490
  article-title: Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems
  publication-title: J Med Chem
  doi: 10.1021/jm7011563
– volume: 188
  start-page: 1030
  year: 1992
  ident: 10.1124/pr.112.007278_bib63
  article-title: [125I]EXP985: a highly potent and specific nonpeptide radioligand antagonist for the AT1 angiotensin receptor
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/0006-291X(92)91335-N
– volume: 41
  start-page: 1081
  year: 1992
  ident: 10.1124/pr.112.007278_bib441
  article-title: Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies
  publication-title: Mol Pharmacol
  doi: 10.1016/S0026-895X(25)09255-7
– volume: 53
  start-page: 417
  year: 1997
  ident: 10.1124/pr.112.007278_bib200
  article-title: Angiotensin type-1 (AT1) receptor gene expression in primarily cultured human arterial umbilical endothelial cells
  publication-title: Biochem Pharmacol
  doi: 10.1016/S0006-2952(96)00691-0
– volume: 58
  start-page: 1883
  year: 1992
  ident: 10.1124/pr.112.007278_bib323
  article-title: AT1 angiotensin receptors mobilize intracellular calcium in a subclone of NG108-15 neuroblastoma cells
  publication-title: J Neurochem
  doi: 10.1111/j.1471-4159.1992.tb10065.x
– volume: 13
  start-page: 849
  year: 1993
  ident: 10.1124/pr.112.007278_bib4
  article-title: Characterization of [3H]SK&F 108566 as a radioligand for angiotensin type-1 receptor
  publication-title: J Recept Res
  doi: 10.3109/10799899309073697
– volume: 55
  start-page: 869
  year: 2010
  ident: 10.1124/pr.112.007278_bib149
  article-title: Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-δ-dependent pathways
  publication-title: Hypertension
  doi: 10.1161/HYPERTENSIONAHA.109.143958
– volume: 285
  start-page: 11892
  year: 2010
  ident: 10.1124/pr.112.007278_bib168
  article-title: Human carboxymethylenebutenolidase as a bioactivating hydrolase of olmesartan medoxomil in liver and intestine
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M109.072629
– volume: 41
  start-page: 1798
  year: 2010
  ident: 10.1124/pr.112.007278_bib432
  article-title: Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator-activated receptor-γ activation in mice with chronic cerebral hypoperfusion
  publication-title: Stroke
  doi: 10.1161/STROKEAHA.110.583948
– volume: 32
  start-page: 416
  year: 2009
  ident: 10.1124/pr.112.007278_bib34
  article-title: Telmisartan increases the permeability of endothelial cells through zonula occludens-1
  publication-title: Biol Pharm Bull
  doi: 10.1248/bpb.32.416
– volume: 14
  start-page: 48
  year: 1959
  ident: 10.1124/pr.112.007278_bib13
  article-title: Some quantitative uses of drug antagonists
  publication-title: Br J Pharmacol
– volume: 32
  start-page: 986
  year: 2010
  ident: 10.1124/pr.112.007278_bib211
  article-title: Ang II enhances tubular cell Ets-1 expression and associated down stream signaling is mediated through AT1 receptors
  publication-title: Ren Fail
  doi: 10.3109/0886022X.2010.501936
– volume: 283
  start-page: 26834
  year: 2008
  ident: 10.1124/pr.112.007278_bib10
  article-title: Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans
  publication-title: J Biol Chem
  doi: 10.1074/jbc.C800156200
– volume: 34
  start-page: 3105
  year: 1991
  ident: 10.1124/pr.112.007278_bib44
  article-title: Nonpeptidic angiotensin II antagonists: synthesis and in vitro activity of a series of novel naphthalene and tetrahydronaphthalene derivatives
  publication-title: J Med Chem
  doi: 10.1021/jm00114a021
– volume: 71
  start-page: 68
  year: 2002
  ident: 10.1124/pr.112.007278_bib249
  article-title: Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing
  publication-title: Clin Pharmacol Ther
  doi: 10.1067/mcp.2002.121425
– volume: 41
  start-page: 742
  year: 2001
  ident: 10.1124/pr.112.007278_bib334
  article-title: The pharmacokinetics of irbesartan in hypertensive children and adolescents
  publication-title: J Clin Pharmacol
  doi: 10.1177/00912700122010645
– volume: 247
  start-page: 139
  year: 1993
  ident: 10.1124/pr.112.007278_bib88
  article-title: Characterization of cardiac angiotensin AT1 receptors by [3H]SR 47436
  publication-title: Eur J Pharmacol
  doi: 10.1016/0922-4106(93)90071-G
– volume: 52
  start-page: 3455
  year: 2007
  ident: 10.1124/pr.112.007278_bib118
  article-title: Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats
  publication-title: Dig Dis Sci
  doi: 10.1007/s10620-007-9741-4
– volume: 76
  start-page: 133
  year: 1998
  ident: 10.1124/pr.112.007278_bib218
  article-title: Inhibitory effects of candesartan on responses to angiotensin peptides in the hindquarters vascular bed of the cat
  publication-title: Can J Physiol Pharmacol
  doi: 10.1139/y98-002
– volume: 28
  start-page: 79
  year: 2000
  ident: 10.1124/pr.112.007278_bib80
  article-title: Disposition of irbesartan, an angiotensin II AT1-receptor antagonist, in mice, rats, rabbits, and macaques
  publication-title: Drug Metab Dispos
  doi: 10.1016/S0090-9556(24)15006-4
– volume: 11
  start-page: S37
  issue: Suppl 2
  year: 1997
  ident: 10.1124/pr.112.007278_bib85
  article-title: Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment
  publication-title: J Hum Hypertens
– volume: 54
  start-page: 1295
  year: 2002
  ident: 10.1124/pr.112.007278_bib114
  article-title: The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/S0169-409X(02)00064-9
– volume: 60
  start-page: 49
  year: 2012
  ident: 10.1124/pr.112.007278_bib195
  article-title: Influence of ABCC2, SLCO1B1, and ABCG2 polymorphisms on the pharmacokinetics of olmesartan
  publication-title: J Cardiovasc Pharmacol
  doi: 10.1097/FJC.0b013e3182576098
– volume: 49
  start-page: 3094
  year: 2006
  ident: 10.1124/pr.112.007278_bib470
  article-title: Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation
  publication-title: Diabetologia
  doi: 10.1007/s00125-006-0437-7
– volume: 101
  start-page: 1199
  year: 2000
  ident: 10.1124/pr.112.007278_bib48
  article-title: Losartan and its metabolite E3174 modify cardiac delayed rectifier K(+) currents
  publication-title: Circulation
  doi: 10.1161/01.CIR.101.10.1199
– volume: 20
  start-page: 903
  year: 2010
  ident: 10.1124/pr.112.007278_bib92
  article-title: Antihypertensive treatments, cognitive decline, and dementia
  publication-title: J Alzheimers Dis
  doi: 10.3233/JAD-2010-091552
– volume: 240
  start-page: 147
  year: 1993
  ident: 10.1124/pr.112.007278_bib239
  article-title: Antagonist effect of losartan on angiotensin II induced contraction in five isolated smooth muscle assays
  publication-title: Eur J Pharmacol
  doi: 10.1016/0014-2999(93)90892-L
– volume: 34
  start-page: 1514
  year: 1991
  ident: 10.1124/pr.112.007278_bib434
  article-title: 1-(Carboxybenyl)imidazole-5-acrylic acids: potent and selective angiotensin receptor antagonists
  publication-title: J Med Chem
  doi: 10.1021/jm00108a043
– volume: 52
  start-page: 371
  year: 1997
  ident: 10.1124/pr.112.007278_bib35
  article-title: Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s002280050303
– volume: 38
  start-page: 820
  year: 2008
  ident: 10.1124/pr.112.007278_bib380
  article-title: Angiotensin inhibition stimulates PPARgamma and the release of visfatin
  publication-title: Eur J Clin Invest
  doi: 10.1111/j.1365-2362.2008.02025.x
– volume: 34
  start-page: 1247
  year: 2006
  ident: 10.1124/pr.112.007278_bib457
  article-title: Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.105.008938
– volume: 28
  start-page: 631
  year: 2006
  ident: 10.1124/pr.112.007278_bib158
  article-title: Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers
  publication-title: Clin Exp Hypertens
  doi: 10.1080/10641960600946171
– volume: 14
  start-page: 179
  year: 2012
  ident: 10.1124/pr.112.007278_bib236
  article-title: Regulation of uric acid excretion by the kidney
  publication-title: Curr Rheumatol Rep
  doi: 10.1007/s11926-012-0240-z
– volume: 252
  start-page: 711
  year: 1990
  ident: 10.1124/pr.112.007278_bib62
  article-title: Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent
  publication-title: J Pharmacol Exp Ther
  doi: 10.1016/S0022-3565(25)19981-3
– volume: 45
  start-page: 154
  year: 2006
  ident: 10.1124/pr.112.007278_bib97
  article-title: Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists
  publication-title: Vascul Pharmacol
  doi: 10.1016/j.vph.2006.05.002
– volume: 22
  start-page: 263
  year: 2004
  ident: 10.1124/pr.112.007278_bib127
  article-title: Candesartan
  publication-title: Cardiovasc Drug Rev
  doi: 10.1111/j.1527-3466.2004.tb00146.x
– volume: 161
  start-page: 150
  year: 2010
  ident: 10.1124/pr.112.007278_bib336
  article-title: beta-Arrestin 1 and 2 stabilize the angiotensin II type I receptor in distinct high-affinity conformations
  publication-title: Br J Pharmacol
  doi: 10.1111/j.1476-5381.2010.00875.x
– volume: 54
  start-page: 183
  year: 2002
  ident: 10.1124/pr.112.007278_bib464
  article-title: Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity
  publication-title: Br J Clin Pharmacol
  doi: 10.1046/j.1365-2125.2002.01646.x
– volume: 32
  start-page: 129
  year: 2010
  ident: 10.1124/pr.112.007278_bib197
  article-title: Clinical and pharmacotherapeutic relevance of the double-chain domain of the angiotensin II type 1 receptor blocker olmesartan
  publication-title: Clin Exp Hypertens
  doi: 10.3109/10641960903254430
– volume: 13
  start-page: 126
  year: 2000
  ident: 10.1124/pr.112.007278_bib132
  article-title: Effect of valsartan on renal handling of uric acid in healthy subjects
  publication-title: J Nephrol
– volume: 199
  start-page: 295
  year: 2008
  ident: 10.1124/pr.112.007278_bib36
  article-title: Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice
  publication-title: Atherosclerosis
  doi: 10.1016/j.atherosclerosis.2007.10.037
– volume: 281
  start-page: 19288
  year: 2006
  ident: 10.1124/pr.112.007278_bib269
  article-title: Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M602144200
– volume: 62
  start-page: 610
  year: 1997
  ident: 10.1124/pr.112.007278_bib359
  article-title: The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/S0009-9236(97)90080-1
– volume: 3
  start-page: 197
  year: 2011
  ident: 10.1124/pr.112.007278_bib106
  article-title: Angiotensin II-inhibiting drugs have no effect on intraneuronal Aβ or oligomeric Aβ levels in a triple transgenic mouse model of Alzheimer’s disease
  publication-title: Am J Transl Res
– volume: 266
  start-page: 114
  year: 1993
  ident: 10.1124/pr.112.007278_bib353
  publication-title: J Pharmacol Exp Ther
  doi: 10.1016/S0022-3565(25)38306-0
– volume: 39
  start-page: 1232
  year: 2012
  ident: 10.1124/pr.112.007278_bib300
  article-title: Brain penetration of telmisartan, a unique centrally acting angiotensin II type 1 receptor blocker, studied by PET in conscious rhesus macaques
  publication-title: Nucl Med Biol
  doi: 10.1016/j.nucmedbio.2012.06.012
– volume: 23
  start-page: 115
  year: 2008
  ident: 10.1124/pr.112.007278_bib201
  article-title: The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan
  publication-title: Drug Metab Pharmacokinet
  doi: 10.2133/dmpk.23.115
– volume: 53
  start-page: 445
  year: 1998
  ident: 10.1124/pr.112.007278_bib189
  article-title: Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s002280050405
– volume: 78
  start-page: 983
  year: 2010
  ident: 10.1124/pr.112.007278_bib315
  article-title: Functional selectivity in adrenergic and angiotensin signaling systems
  publication-title: Mol Pharmacol
  doi: 10.1124/mol.110.067066
– volume: 85
  start-page: 136
  year: 2009
  ident: 10.1124/pr.112.007278_bib33
  article-title: Binding sites of valsartan, candesartan and losartan with angiotensin II receptor 1 subtype by molecular modeling
  publication-title: Life Sci
  doi: 10.1016/j.lfs.2009.05.001
– volume: 40
  start-page: 50
  year: 2002
  ident: 10.1124/pr.112.007278_bib20
  article-title: Prejunctional and postjunctional inhibitory actions of eprosartan and candesartan in the isolated rabbit mesenteric artery
  publication-title: J Cardiovasc Pharmacol
  doi: 10.1097/00005344-200207000-00007
– volume: 130
  start-page: 3641
  year: 1992
  ident: 10.1124/pr.112.007278_bib38
  article-title: Angiotensin-II-binding sites on hepatocyte nuclei
  publication-title: Endocrinology
  doi: 10.1210/endo.130.6.1597161
– volume: 29
  start-page: 2422
  year: 2011
  ident: 10.1124/pr.112.007278_bib187
  article-title: Morning blood pressure surge, morning platelet aggregation, and silent cerebral infarction in older Japanese hypertensive patients
  publication-title: J Hypertens
  doi: 10.1097/HJH.0b013e32834cf1c0
– volume: 35
  start-page: 290
  year: 1993
  ident: 10.1124/pr.112.007278_bib309
  article-title: Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans
  publication-title: Br J Clin Pharmacol
  doi: 10.1111/j.1365-2125.1993.tb05696.x
– volume: 19
  start-page: S33
  year: 2001
  ident: 10.1124/pr.112.007278_bib425
  article-title: Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil
  publication-title: J Hypertens Suppl
  doi: 10.1097/00004872-200106001-00005
– volume: 385
  start-page: 13
  year: 2012
  ident: 10.1124/pr.112.007278_bib73
  article-title: Local renin-angiotensin systems in the genitourinary tract
  publication-title: Naunyn Schmiedebergs Arch Pharmacol
  doi: 10.1007/s00210-011-0706-y
– volume: 14
  start-page: 432
  year: 1999
  ident: 10.1124/pr.112.007278_bib354
  article-title: Pharmacokinetics of 14C-telmisartan (2): plasma concentration and distribution of 14C-telmisartan after repeated oral administration to rats
  publication-title: Xenobio Metabol Dispos
– volume: 359
  start-page: 1811
  year: 2008
  ident: 10.1124/pr.112.007278_bib102
  article-title: Uric acid and cardiovascular risk
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra0800885
– volume: 36
  start-page: 1275
  year: 2008
  ident: 10.1124/pr.112.007278_bib120
  article-title: Effect of plasma protein binding on in vitro-in vivo correlation of biliary excretion of drugs evaluated by sandwich-cultured rat hepatocytes
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.107.019026
– volume: 11
  start-page: S29
  issue: Suppl 2
  year: 1997
  ident: 10.1124/pr.112.007278_bib325
  article-title: Bioavailability of candesartan is unaffected by food in healthy volunteers administered candesartan cilexetil
  publication-title: J Hum Hypertens
– volume: 13
  start-page: S75
  issue: Suppl 1
  year: 1999
  ident: 10.1124/pr.112.007278_bib164
  article-title: Pharmacologic properties of candesartan cilexetil—possible mechanisms of long-acting antihypertensive action
  publication-title: J Hum Hypertens
  doi: 10.1038/sj.jhh.1000749
– volume: 410
  start-page: 508
  year: 2011
  ident: 10.1124/pr.112.007278_bib403
  article-title: Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-γ-dependent activity
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2011.06.012
– volume: 86
  start-page: 52
  year: 2010
  ident: 10.1124/pr.112.007278_bib184
  article-title: Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes
  publication-title: Life Sci
  doi: 10.1016/j.lfs.2009.11.006
– volume: 57
  start-page: 1405
  year: 2008
  ident: 10.1124/pr.112.007278_bib71
  article-title: Liver-specific peroxisome proliferator-activated receptor α target gene regulation by the angiotensin type 1 receptor blocker telmisartan
  publication-title: Diabetes
  doi: 10.2337/db07-0839
– volume: 14
  start-page: 577
  year: 2000
  ident: 10.1124/pr.112.007278_bib422
  article-title: Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptors
  publication-title: Fundam Clin Pharmacol
  doi: 10.1111/j.1472-8206.2000.tb00443.x
– volume: 41
  start-page: 893
  year: 2009
  ident: 10.1124/pr.112.007278_bib112
  article-title: Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients
  publication-title: Horm Metab Res
  doi: 10.1055/s-0029-1237359
– volume: 40
  start-page: 1312
  year: 2000
  ident: 10.1124/pr.112.007278_bib367
  article-title: Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers
  publication-title: J Clin Pharmacol
  doi: 10.1177/009127000004001202
– volume: 39
  start-page: 323
  year: 1996
  ident: 10.1124/pr.112.007278_bib460
  article-title: Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds
  publication-title: J Med Chem
  doi: 10.1021/jm950450f
– volume: 24
  start-page: 362
  year: 2011
  ident: 10.1124/pr.112.007278_bib317
  article-title: Blockade of AT1 receptors protects the blood-brain barrier and improves cognition in Dahl salt-sensitive hypertensive rats
  publication-title: Am J Hypertens
  doi: 10.1038/ajh.2010.241
– volume: 47
  start-page: 620
  year: 1997
  ident: 10.1124/pr.112.007278_bib148
  article-title: Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 3rd Communication: hemodynamic effects of valsartan in rats and dogs
  publication-title: Arzneimittelforschung
– volume: 129
  start-page: 1235
  year: 2000
  ident: 10.1124/pr.112.007278_bib362
  article-title: Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers
  publication-title: Br J Pharmacol
  doi: 10.1038/sj.bjp.0703150
– volume: 25
  start-page: 41
  year: 2005
  ident: 10.1124/pr.112.007278_bib183
  article-title: Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers
  publication-title: Int J Clin Pharmacol Res
– volume: 55
  start-page: 597
  year: 2003
  ident: 10.1124/pr.112.007278_bib296
  article-title: International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology
  publication-title: Pharmacol Rev
  doi: 10.1124/pr.55.4.4
– volume: 150
  start-page: 862
  year: 2009
  ident: 10.1124/pr.112.007278_bib388
  article-title: A selective peroxisome proliferator-activated receptor-γ modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones
  publication-title: Endocrinology
  doi: 10.1210/en.2008-0502
– volume: 37
  start-page: 981
  year: 2001
  ident: 10.1124/pr.112.007278_bib224
  article-title: Prevention of hypertension by irbesartan in Dahl S rats relates to central angiotensin II type 1 receptor blockade
  publication-title: Hypertension
  doi: 10.1161/01.HYP.37.3.981
– volume: 24
  start-page: 376
  year: 2009
  ident: 10.1124/pr.112.007278_bib395
  article-title: Comparative pharmacodynamics of olmesartan and azelnidipine in patients with hypertension: a population pharmacokinetic/pharmacodynamic analysis
  publication-title: Drug Metab Pharmacokinet
  doi: 10.2133/dmpk.24.376
– volume: 261
  start-page: 96
  year: 1992
  ident: 10.1124/pr.112.007278_bib430
  article-title: Renin-angiotensin system inhibition reduces glycine-induced glomerular hyperfiltration in conscious rats
  publication-title: J Pharmacol Exp Ther
  doi: 10.1016/S0022-3565(25)10995-6
– volume: 16
  start-page: 789
  year: 2010
  ident: 10.1124/pr.112.007278_bib228
  article-title: Characterization of the binding of angiotensin II receptor blockers to human serum albumin using docking and molecular dynamics simulation
  publication-title: J Mol Model
  doi: 10.1007/s00894-009-0612-0
– volume: 16
  start-page: 478
  year: 1999
  ident: 10.1124/pr.112.007278_bib363
  article-title: Grapefruit juice activates P-glycoprotein-mediated drug transport
  publication-title: Pharm Res
  doi: 10.1023/A:1011902625609
– volume: 33
  start-page: 850
  year: 1999
  ident: 10.1124/pr.112.007278_bib261
  article-title: Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists
  publication-title: Hypertension
  doi: 10.1161/01.HYP.33.3.850
– volume: 51
  start-page: 696
  year: 2008
  ident: 10.1124/pr.112.007278_bib338
  article-title: Effect of telmisartan on nitric oxide—asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor γ and peroxisome proliferator activated receptor γ signaling during endothelial aging
  publication-title: Hypertension
  doi: 10.1161/HYPERTENSIONAHA.107.104570
– volume: 464
  start-page: 151
  year: 2009
  ident: 10.1124/pr.112.007278_bib144
  article-title: Cerebroprotective action of telmisartan by inhibition of macrophages/microglia expressing HMGB1 via a peroxisome proliferator-activated receptor gamma-dependent mechanism
  publication-title: Neurosci Lett
  doi: 10.1016/j.neulet.2009.08.043
– volume: 41
  start-page: 515
  year: 2001
  ident: 10.1124/pr.112.007278_bib347
  article-title: Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects
  publication-title: J Clin Pharmacol
  doi: 10.1177/00912700122010393
– volume: 347
  start-page: 220
  year: 1993
  ident: 10.1124/pr.112.007278_bib479
  article-title: Characterization of the angiotensin II-receptor subtype in the longitudinal smooth muscle of the rat portal vein
  publication-title: Naunyn Schmiedebergs Arch Pharmacol
  doi: 10.1007/BF00169271
– volume: 65
  start-page: 2
  year: 2004
  ident: 10.1124/pr.112.007278_bib193
  article-title: Efficacy as a vector: the relative prevalence and paucity of inverse agonism
  publication-title: Mol Pharmacol
  doi: 10.1124/mol.65.1.2
– volume: 68
  start-page: 501
  year: 2000
  ident: 10.1124/pr.112.007278_bib134
  article-title: Effect of angiotensin II infusion with and without angiotensin II type 1 receptor blockade on nitric oxide metabolism and endothelin in human beings: a placebo-controlled study in healthy volunteers
  publication-title: Clin Pharmacol Ther
  doi: 10.1067/mcp.2000.111182
– volume: 54
  start-page: 782
  year: 2009
  ident: 10.1124/pr.112.007278_bib409
  article-title: Cognitive deficit in amyloid-β-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-γ activation
  publication-title: Hypertension
  doi: 10.1161/HYPERTENSIONAHA.109.136879
– volume: 23
  start-page: 285
  year: 1995
  ident: 10.1124/pr.112.007278_bib474
  article-title: Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174
  publication-title: Drug Metab Dispos
  doi: 10.1016/S0090-9556(25)06533-X
– volume: 106
  start-page: 233
  year: 1992
  ident: 10.1124/pr.112.007278_bib240
  article-title: Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible and syntopic action
  publication-title: Br J Pharmacol
  doi: 10.1111/j.1476-5381.1992.tb14322.x
– volume: 44
  start-page: 1329
  year: 2005
  ident: 10.1124/pr.112.007278_bib471
  article-title: Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients
  publication-title: Clin Pharmacokinet
  doi: 10.2165/00003088-200544120-00011
– volume: 281
  start-page: 161
  year: 1995
  ident: 10.1124/pr.112.007278_bib68
  article-title: Effects of irbesartan (SR47436/BMS-186295) on angiotensin II-induced pressor responses in the pithed rat: potential mechanisms of action
  publication-title: Eur J Pharmacol
  doi: 10.1016/0014-2999(95)00237-F
– volume: 33
  start-page: 1406
  year: 1999
  ident: 10.1124/pr.112.007278_bib279
  article-title: Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin
  publication-title: Hypertension
  doi: 10.1161/01.HYP.33.6.1406
– volume: 65
  start-page: 585
  year: 2009
  ident: 10.1124/pr.112.007278_bib141
  article-title: Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s00228-009-0624-9
– volume: 39
  start-page: 820
  year: 2011
  ident: 10.1124/pr.112.007278_bib86
  article-title: Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.110.037457
– volume: 36
  start-page: 555
  year: 1995
  ident: 10.1124/pr.112.007278_bib263
  article-title: Local action of the renin angiotensin system in the porcine ophthalmic circulation: effects of ACE-inhibitors and angiotensin receptor antagonists
  publication-title: Invest Ophthalmol Vis Sci
– volume: 319
  start-page: 137
  year: 1997
  ident: 10.1124/pr.112.007278_bib311
  article-title: Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor
  publication-title: Eur J Pharmacol
  doi: 10.1016/S0014-2999(96)00837-0
– volume: 59
  start-page: 308
  year: 2012
  ident: 10.1124/pr.112.007278_bib215
  article-title: Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade
  publication-title: Hypertension
  doi: 10.1161/HYPERTENSIONAHA.111.176263
– volume: 55
  start-page: 244
  year: 1997
  ident: 10.1124/pr.112.007278_bib306
  article-title: Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade
  publication-title: Pharmacology
  doi: 10.1159/000139534
– volume: 60
  start-page: 513
  year: 2008
  ident: 10.1124/pr.112.007278_bib333
  article-title: Pharmacogenomics of G protein-coupled receptor ligands in cardiovascular medicine
  publication-title: Pharmacol Rev
  doi: 10.1124/pr.108.000612
– volume: 30
  start-page: 87
  year: 2012
  ident: 10.1124/pr.112.007278_bib314
  article-title: Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-γ activation in human monocytes
  publication-title: J Hypertens
  doi: 10.1097/HJH.0b013e32834dde5f
– volume: 669
  start-page: 84
  year: 2011
  ident: 10.1124/pr.112.007278_bib214
  article-title: Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models
  publication-title: Eur J Pharmacol
  doi: 10.1016/j.ejphar.2011.07.014
– volume: 38
  start-page: 141
  year: 2001
  ident: 10.1124/pr.112.007278_bib19
  article-title: Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery
  publication-title: J Cardiovasc Pharmacol
  doi: 10.1097/00005344-200107000-00015
– volume: 12
  start-page: 1201
  year: 1999
  ident: 10.1124/pr.112.007278_bib247
  article-title: Assessment of angiotensin II receptor blockade in humans using a standardized angiotensin II receptor-binding assay
  publication-title: Am J Hypertens
  doi: 10.1016/S0895-7061(99)00133-8
– volume: 43
  start-page: 527
  year: 2000
  ident: 10.1124/pr.112.007278_bib443
  article-title: The PPARs: from orphan receptors to drug discovery
  publication-title: J Med Chem
  doi: 10.1021/jm990554g
– volume: 38
  start-page: 649
  year: 1998
  ident: 10.1124/pr.112.007278_bib191
  article-title: Eprosartan does not affect the pharmacodynamics of warfarin
  publication-title: J Clin Pharmacol
  doi: 10.1002/j.1552-4604.1998.tb04473.x
– volume: 251
  start-page: 143
  year: 1994
  ident: 10.1124/pr.112.007278_bib151
  article-title: Effect of SR 47436, a novel angiotensin II AT1 receptor antagonist, on human vascular smooth muscle cells in vitro
  publication-title: Eur J Pharmacol
  doi: 10.1016/0014-2999(94)90394-8
– volume: 43
  start-page: 271
  year: 1992
  ident: 10.1124/pr.112.007278_bib313
  article-title: Characterization and coupling of angiotensin-II receptor subtypes in cultured bovine adrenal fasciculata cells
  publication-title: J Steroid Biochem Mol Biol
  doi: 10.1016/0960-0760(92)90161-B
– volume: 29
  start-page: 163
  year: 2012
  ident: 10.1124/pr.112.007278_bib188
  article-title: Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin
  publication-title: Adv Ther
  doi: 10.1007/s12325-011-0098-x
– volume: 19
  start-page: S21
  year: 2001
  ident: 10.1124/pr.112.007278_bib217
  article-title: The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction
  publication-title: J Hypertens Suppl
  doi: 10.1097/00004872-200106001-00004
– volume: 103
  start-page: 176
  year: 2008
  ident: 10.1124/pr.112.007278_bib463
  article-title: Disposition of a CYP2C9 phenotyping agent, losartan, is not influenced by the common 3435C > T variation of the drug transporter gene ABCB1 (MDR1)
  publication-title: Basic Clin Pharmacol Toxicol
  doi: 10.1111/j.1742-7843.2008.00283.x
– volume: 11
  start-page: S45
  issue: Suppl 2
  year: 1997
  ident: 10.1124/pr.112.007278_bib25
  article-title: Inhibition of angiotensin II pressor response and ex vivo angiotensin II radioligand binding by candesartan cilexetil and losartan in healthy human volunteers
  publication-title: J Hum Hypertens
– volume: 29
  start-page: 640
  year: 2009
  ident: 10.1124/pr.112.007278_bib109
  article-title: Angiotensin II modulates BBB permeability via activation of the AT(1) receptor in brain endothelial cells
  publication-title: J Cereb Blood Flow Metab
  doi: 10.1038/jcbfm.2008.158
– volume: 61
  start-page: 627
  year: 2005
  ident: 10.1124/pr.112.007278_bib154
  article-title: CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s00228-005-0976-8
– volume: 1
  start-page: 33
  year: 1990
  ident: 10.1124/pr.112.007278_bib61
  article-title: Angiotensin II receptor subtypes and their selective nonpeptide ligands
  publication-title: Receptor
– volume: 22
  start-page: 267
  year: 2007
  ident: 10.1124/pr.112.007278_bib185
  article-title: Inhibitory effects of angiotensin receptor blockers on CYP2C9 activity in human liver microsomes
  publication-title: Drug Metab Pharmacokinet
  doi: 10.2133/dmpk.22.267
– volume: 27
  start-page: 59
  year: 1997
  ident: 10.1124/pr.112.007278_bib429
  article-title: Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose
  publication-title: Xenobiotica
  doi: 10.1080/004982597240767
– volume: 37
  start-page: 214
  year: 1997
  ident: 10.1124/pr.112.007278_bib72
  article-title: Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist
  publication-title: J Clin Pharmacol
  doi: 10.1002/j.1552-4604.1997.tb04783.x
– volume: 62
  start-page: 539
  year: 2006
  ident: 10.1124/pr.112.007278_bib437
  article-title: Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s00228-006-0121-3
– volume: 26
  start-page: 490
  year: 1995
  ident: 10.1124/pr.112.007278_bib305
  article-title: Persistent inhibition of the pressor and aldosterone responses to angiotensin-II by TCV-116 in normotensive subjects
  publication-title: J Cardiovasc Pharmacol
  doi: 10.1097/00005344-199509000-00021
– volume: 34
  start-page: 683
  year: 2009
  ident: 10.1124/pr.112.007278_bib268
  article-title: Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients
  publication-title: J Clin Pharm Ther
  doi: 10.1111/j.1365-2710.2009.01053.x
– volume: 260
  start-page: 175
  year: 1992
  ident: 10.1124/pr.112.007278_bib93
  article-title: Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566
  publication-title: J Pharmacol Exp Ther
  doi: 10.1016/S0022-3565(25)11212-3
– volume: 44
  start-page: 89
  year: 1992
  ident: 10.1124/pr.112.007278_bib237
  article-title: DuP 753, the selective angiotensin II receptor blocker, is a competitive antagonist to human platelet thromboxane A2/prostaglandin H2 (TP) receptors
  publication-title: Prostaglandins
  doi: 10.1016/0090-6980(92)90070-A
– volume: 18
  start-page: 42
  year: 1998
  ident: 10.1124/pr.112.007278_bib397
  article-title: Effect of hepatic disease on the pharmacokinetics and plasma protein binding of eprosartan
  publication-title: Pharmacotherapy
  doi: 10.1002/j.1875-9114.1998.tb03825.x
– volume: 35
  start-page: 589
  year: 2005
  ident: 10.1124/pr.112.007278_bib290
  article-title: Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes
  publication-title: Xenobiotica
  doi: 10.1080/00498250500158175
– volume: 271
  start-page: 429
  year: 1994
  ident: 10.1124/pr.112.007278_bib383
  article-title: Angiotensin type 1 receptors mediate smooth muscle proliferation and endothelin biosynthesis in rat vascular smooth muscle
  publication-title: J Pharmacol Exp Ther
  doi: 10.1016/S0022-3565(25)22812-9
– volume: 21
  start-page: 792
  year: 1993
  ident: 10.1124/pr.112.007278_bib160
  article-title: N-glucuronidation reactions. I. Tetrazole N-glucuronidation of selected angiotensin II receptor antagonists in hepatic microsomes from rats, dogs, monkeys, and humans
  publication-title: Drug Metab Dispos
  doi: 10.1016/S0090-9556(25)08163-2
– volume: 64
  start-page: 323
  year: 2009
  ident: 10.1124/pr.112.007278_bib179
  article-title: Pharmacokinetic and safety profile of olmesartan medoxomil in healthy Chinese subjects after single and multiple administrations
  publication-title: Pharmazie
– volume: 302
  start-page: 1089
  year: 2002
  ident: 10.1124/pr.112.007278_bib248
  article-title: In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.102.036772
– volume: 352
  start-page: 15
  year: 1998
  ident: 10.1124/pr.112.007278_bib322
  article-title: Evaluation of the ability of irbesartan to cross the blood-brain barrier following acute intragastric treatment
  publication-title: Eur J Pharmacol
  doi: 10.1016/S0014-2999(98)00329-X
– volume: 1
  start-page: 336
  year: 2000
  ident: 10.1124/pr.112.007278_bib23
  article-title: The pharmacological potency of various AT(1) antagonists assessed by Schild regression technique in man
  publication-title: J Renin Angiotensin Aldosterone Syst
  doi: 10.3317/jraas.2000.063
– volume: 104
  start-page: 771
  year: 1991
  ident: 10.1124/pr.112.007278_bib365
  article-title: Access of peripherally administered DuP 753 to rat brain angiotensin II receptors
  publication-title: Br J Pharmacol
  doi: 10.1111/j.1476-5381.1991.tb12503.x
– volume: 48
  start-page: 823
  year: 2008
  ident: 10.1124/pr.112.007278_bib331
  article-title: Evaluation of population pharmacokinetics and exposure-response relationship with coadministration of amlodipine besylate and olmesartan medoxomil
  publication-title: J Clin Pharmacol
  doi: 10.1177/0091270008317847
– volume: 20
  start-page: 281
  year: 1992
  ident: 10.1124/pr.112.007278_bib378
  article-title: The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices
  publication-title: Drug Metab Dispos
  doi: 10.1016/S0090-9556(25)08584-8
– volume: 26
  start-page: 1209
  year: 2008
  ident: 10.1124/pr.112.007278_bib382
  article-title: Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor-γ dependent pathway
  publication-title: J Hypertens
  doi: 10.1097/HJH.0b013e3282f9b58a
– volume: 272
  start-page: 619
  year: 1995
  ident: 10.1124/pr.112.007278_bib405
  article-title: Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure
  publication-title: J Pharmacol Exp Ther
  doi: 10.1016/S0022-3565(25)24448-2
– volume: 40
  start-page: 389
  year: 2000
  ident: 10.1124/pr.112.007278_bib316
  article-title: The pharmacokinetics and pharmacodynamics of losartan in continuous ambulatory peritoneal dialysis
  publication-title: J Clin Pharmacol
  doi: 10.1177/00912700022009099
– volume: 3
  start-page: 247
  year: 2002
  ident: 10.1124/pr.112.007278_bib356
  article-title: The pharmacokinetics and pharmacodynamics of angiotensin-receptor blockers in end-stage renal disease
  publication-title: J Renin Angiotensin Aldosterone Syst
  doi: 10.3317/jraas.2002.046
– volume: 348
  start-page: 101
  year: 1998
  ident: 10.1124/pr.112.007278_bib146
  article-title: Characterization and distribution of angiotensin II receptor subtypes in the mouse brain
  publication-title: Eur J Pharmacol
  doi: 10.1016/S0014-2999(98)00134-4
– volume: 62
  start-page: 1
  year: 2010
  ident: 10.1124/pr.112.007278_bib198
  article-title: Xenobiotic, bile acid, and cholesterol transporters: function and regulation
  publication-title: Pharmacol Rev
  doi: 10.1124/pr.109.002014
– volume: 23
  start-page: 631
  year: 2007
  ident: 10.1124/pr.112.007278_bib384
  article-title: Evaluation of a pharmacokinetic interaction between valsartan and simvastatin in healthy subjects
  publication-title: Curr Med Res Opin
  doi: 10.1185/030079906X167471
– volume: 1
  start-page: 288
  year: 2001
  ident: 10.1124/pr.112.007278_bib142
  article-title: CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro
  publication-title: Pharmacogenomics J
  doi: 10.1038/sj.tpj.6500063
– volume: 185
  start-page: 271
  year: 2010
  ident: 10.1124/pr.112.007278_bib135
  article-title: Modulation of PPAR-gamma by telmisartan protects the heart against myocardial infarction in experimental diabetes
  publication-title: Chem Biol Interact
  doi: 10.1016/j.cbi.2010.03.030
– volume: 38
  start-page: 433
  year: 1998
  ident: 10.1124/pr.112.007278_bib413
  article-title: Lack of effect of food on the oral bioavailability of irbesartan in healthy male volunteers
  publication-title: J Clin Pharmacol
  doi: 10.1002/j.1552-4604.1998.tb04449.x
– volume: 99
  start-page: 331
  year: 2000
  ident: 10.1124/pr.112.007278_bib100
  article-title: Comparative in vivo effects of irbesartan and losartan on angiotensin II receptor binding in the rat kidney following oral administration
  publication-title: Clin Sci (Lond)
  doi: 10.1042/cs0990331
– volume: 2
  start-page: 193
  year: 2009
  ident: 10.1124/pr.112.007278_bib122
  article-title: Telmisartan as a peroxisome proliferator-activated receptor-γ ligand is a new target in the treatment of human renal cell carcinoma
  publication-title: Mol Med Report
– volume: 55
  start-page: 279
  year: 1999
  ident: 10.1124/pr.112.007278_bib335
  article-title: Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19)
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s002280050629
– volume: 252
  start-page: 719
  year: 1990
  ident: 10.1124/pr.112.007278_bib445
  article-title: Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent
  publication-title: J Pharmacol Exp Ther
  doi: 10.1016/S0022-3565(25)19984-9
– volume: 58
  start-page: 641
  year: 1995
  ident: 10.1124/pr.112.007278_bib241
  article-title: Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/0009-9236(95)90020-9
– volume: 255
  start-page: 211
  year: 1990
  ident: 10.1124/pr.112.007278_bib448
  article-title: Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent
  publication-title: J Pharmacol Exp Ther
  doi: 10.1016/S0022-3565(25)12755-9
– volume: 150
  start-page: 1056
  year: 1993
  ident: 10.1124/pr.112.007278_bib393
  article-title: Angiotensin II receptors in the rat urinary bladder smooth muscle: type 1 subtype receptors mediate contractile responses
  publication-title: J Urol
  doi: 10.1016/S0022-5347(17)35685-9
– volume: 276
  start-page: 125
  year: 1996
  ident: 10.1124/pr.112.007278_bib95
  article-title: Interaction of nonpeptide angiotensin II receptor antagonists with the urate transporter in rat renal brush-border membranes
  publication-title: J Pharmacol Exp Ther
  doi: 10.1016/S0022-3565(25)12239-8
– volume: 369
  start-page: 69
  year: 2004
  ident: 10.1124/pr.112.007278_bib126
  article-title: Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution
  publication-title: Naunyn Schmiedebergs Arch Pharmacol
  doi: 10.1007/s00210-003-0813-5
– volume: 38
  start-page: 129
  year: 1998
  ident: 10.1124/pr.112.007278_bib255
  article-title: Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment
  publication-title: J Clin Pharmacol
  doi: 10.1002/j.1552-4604.1998.tb04401.x
– volume: 38
  start-page: 672
  year: 2001
  ident: 10.1124/pr.112.007278_bib375
  article-title: Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge
  publication-title: J Cardiovasc Pharmacol
  doi: 10.1097/00005344-200111000-00004
– volume: 52
  start-page: 415
  year: 2000
  ident: 10.1124/pr.112.007278_bib81
  article-title: International union of pharmacology. XXIII. The angiotensin II receptors
  publication-title: Pharmacol Rev
  doi: 10.1016/S0031-6997(24)01458-3
– volume: 30
  start-page: 33
  year: 1993
  ident: 10.1124/pr.112.007278_bib232
  article-title: Functional evidence that the angiotensin antagonist losartan crosses the blood-brain barrier in the rat
  publication-title: Brain Res Bull
  doi: 10.1016/0361-9230(93)90036-B
– volume: 36
  start-page: 1772
  year: 1993
  ident: 10.1124/pr.112.007278_bib210
  article-title: Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazoles
  publication-title: J Med Chem
  doi: 10.1021/jm00064a011
– volume: 22
  start-page: 2253
  year: 2004
  ident: 10.1124/pr.112.007278_bib213
  article-title: Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system
  publication-title: J Hypertens
  doi: 10.1097/00004872-200412000-00003
– volume: 36
  start-page: 1230
  year: 1993
  ident: 10.1124/pr.112.007278_bib258
  article-title: Molecular shape comparison of angiotensin II receptor antagonists
  publication-title: J Med Chem
  doi: 10.1021/jm00061a014
– volume: 35
  start-page: 2166
  year: 2007
  ident: 10.1124/pr.112.007278_bib453
  article-title: Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.107.017459
– volume: 83
  start-page: 1333
  year: 1991
  ident: 10.1124/pr.112.007278_bib67
  article-title: Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II
  publication-title: Circulation
  doi: 10.1161/01.CIR.83.4.1333
– volume: 298
  start-page: 62
  year: 2001
  ident: 10.1124/pr.112.007278_bib129
  article-title: AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats
  publication-title: J Pharmacol Exp Ther
  doi: 10.1016/S0022-3565(24)29352-6
– volume: 13
  start-page: 111
  year: 2003
  ident: 10.1124/pr.112.007278_bib381
  article-title: Binding properties of telmisartan (micardis) for human angiotensin II receptors
  publication-title: Clin Pharmacol Ther (Tokyo)
– volume: 46
  start-page: 2261
  year: 2003
  ident: 10.1124/pr.112.007278_bib342
  article-title: Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites
  publication-title: J Med Chem
  doi: 10.1021/jm0204237
– volume: 71
  start-page: 89
  year: 2002
  ident: 10.1124/pr.112.007278_bib465
  article-title: Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype
  publication-title: Clin Pharmacol Ther
  doi: 10.1067/mcp.2002.121216
– volume: 53
  start-page: 451
  year: 1998
  ident: 10.1124/pr.112.007278_bib343
  article-title: An interaction study with cimetidine and the new angiotensin II antagonist valsartan
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s002280050406
– volume: 52
  start-page: 1075
  year: 2000
  ident: 10.1124/pr.112.007278_bib115
  article-title: Comparative pharmacodynamics and pharmacokinetics of candesartan and losartan in man
  publication-title: J Pharm Pharmacol
  doi: 10.1211/0022357001774994
– volume: 134
  start-page: 225
  year: 2005
  ident: 10.1124/pr.112.007278_bib156
  article-title: Angiotensin type 1 receptor blockage improves ischemic injury following transient focal cerebral ischemia
  publication-title: Neuroscience
  doi: 10.1016/j.neuroscience.2005.03.054
– volume: 15
  start-page: 850
  year: 2008
  ident: 10.1124/pr.112.007278_bib455
  article-title: Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gammaactivation
  publication-title: Protein Pept Lett
  doi: 10.2174/092986608785203746
– volume: 28
  start-page: 1146
  year: 2000
  ident: 10.1124/pr.112.007278_bib299
  article-title: Both cMOAT/MRP2 and another unknown transporter(s) are responsible for the biliary excretion of glucuronide conjugate of the nonpeptide angiotensin II antagonist, telmisaltan
  publication-title: Drug Metab Dispos
  doi: 10.1016/S0090-9556(24)13658-6
– volume: 272
  start-page: 963
  year: 1995
  ident: 10.1124/pr.112.007278_bib192
  article-title: Pharmacologic characterization of CI-996, a new angiotensin receptor antagonist
  publication-title: J Pharmacol Exp Ther
  doi: 10.1016/S0022-3565(25)24563-3
– volume: 35
  start-page: 715
  year: 2012
  ident: 10.1124/pr.112.007278_bib8
  article-title: Structural basis for telmisartan-mediated partial activation of PPAR gamma
  publication-title: Hypertens Res
  doi: 10.1038/hr.2012.17
– volume: 45
  start-page: 567
  year: 1998
  ident: 10.1124/pr.112.007278_bib250
  article-title: Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man
  publication-title: Br J Clin Pharmacol
  doi: 10.1046/j.1365-2125.1998.00722.x
– volume: 13
  start-page: 61
  year: 2009
  ident: 10.1124/pr.112.007278_bib394
  article-title: Pharmacokinetics of olmesartan medoxomil in hemodialysis patients: little effect of dialysis upon its pharmacokinetics
  publication-title: Clin Exp Nephrol
  doi: 10.1007/s10157-008-0067-0
– volume: 325
  start-page: 349
  year: 2008
  ident: 10.1124/pr.112.007278_bib238
  article-title: Progress in brain penetration evaluation in drug discovery and development
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.107.130294
– volume: 8
  start-page: 1789
  year: 2011
  ident: 10.1124/pr.112.007278_bib390
  article-title: The involvement of organic anion transporting polypeptide in the hepatic uptake of telmisartan in rats: PET studies with [¹¹C]telmisartan
  publication-title: Mol Pharm
  doi: 10.1021/mp200160t
– volume: 12
  start-page: 746
  year: 2010
  ident: 10.1124/pr.112.007278_bib157
  article-title: Telmisartan effects on insulin resistance in obese or overweight adults without diabetes or hypertension
  publication-title: J Clin Hypertens (Greenwich)
  doi: 10.1111/j.1751-7176.2010.00335.x
– volume: 26
  start-page: A12
  issue: Suppl A
  year: 2004
  ident: 10.1124/pr.112.007278_bib303
  article-title: Antagonizing the angiotensin II subtype I Receptor: a focus on olmesartan medoxomil
  publication-title: Clin Ther
  doi: 10.1016/S0149-2918(04)90141-5
– volume: 24
  start-page: 1809
  year: 2006
  ident: 10.1124/pr.112.007278_bib176
  article-title: Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-γ activation
  publication-title: J Hypertens
  doi: 10.1097/01.hjh.0000242405.68461.84
– volume: 23
  start-page: 720
  year: 2003
  ident: 10.1124/pr.112.007278_bib223
  article-title: Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals
  publication-title: Pharmacotherapy
  doi: 10.1592/phco.23.6.720.32187
– volume: 291
  start-page: 417
  year: 1995
  ident: 10.1124/pr.112.007278_bib170
  article-title: A long-term receptor stimulation is requisite for angiotensin II-dependent DNA synthesis in vascular smooth muscle cells from spontaneously hypertensive rats
  publication-title: Eur J Pharmacol
  doi: 10.1016/0922-4106(95)90084-5
– volume: 7
  start-page: 140
  year: 2007
  ident: 10.1124/pr.112.007278_bib98
  article-title: Metabolic actions of angiotensin receptor antagonists: PPAR-γ agonist actions or a class effect?
  publication-title: Curr Opin Pharmacol
  doi: 10.1016/j.coph.2006.11.008
SSID ssj0014585
Score 2.5232956
SecondaryResourceType review_article
Snippet Angiotensin II type 1 receptor antagonists (ARBs) have become an important drug class in the treatment of hypertension and heart failure and the protection...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 809
SubjectTerms Angiotensin II Type 1 Receptor Blockers - chemistry
Angiotensin II Type 1 Receptor Blockers - pharmacokinetics
Angiotensin II Type 1 Receptor Blockers - therapeutic use
Animals
Binding Sites
Diabetic Nephropathies - metabolism
Diabetic Nephropathies - prevention & control
Drug Interactions
Heart Failure - drug therapy
Heart Failure - metabolism
Humans
Hypertension - drug therapy
Hypertension - metabolism
Molecular Structure
Receptor, Angiotensin, Type 1 - metabolism
Tissue Distribution
Title A Systematic Comparison of the Properties of Clinically Used Angiotensin II Type 1 Receptor Antagonists
URI https://dx.doi.org/10.1124/pr.112.007278
https://www.ncbi.nlm.nih.gov/pubmed/23487168
https://www.proquest.com/docview/1317409431
Volume 65
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF5BuXBBvAkvLRLKJTHY67WJjxFqSVAoHFwpN2tfLpWqOEqcQ_rrO7O7flRKpMLFsVZ-JPk-78ysZ74h5HMINk2bLAqADlnAlTCB5LEOWKpTJkIteYT1zr_O09kF_7lMll3amK0uqeUXdXOwruR_UIUxwBWrZP8B2faiMAD7gC9sAWHY3gvjaV-IWfU7CvoKqGqNadNOV7apgbzej3Zbgwqtl1eVzV9fjeZztxYbjWACNOvaZlbi-yrU1d32Hdg_ndS1hdermba42cxSXwRUY0VhZ-aaHiA2x2TfkhK1D3zVzQzsZpfBuLjauVWD7V_j7atfnsBWEW1Wi59RWRSg4-EMzoExPw27lhGebqw3p06sfsKBuZ5xbFC8wT2rgO56Ad3V1D7_XZxdLBZFfrrMH5JHDIIJ7HPxY9kmAkU8sY1b2y_VKLEy_vXOxY95LsciE-uh5E_JEx9a0KnjyTPywKyek6EHbD-meVdqtx3TIe1BuX9BLqe0IxPtyESrkgKZaEcmHOnIRJFMtEcmOp9TJBONaEMm2iPTS5KfnebfZ4HvwhEoCPbrgBuwpUpJYViYykybSRrrMhSp5kxzzjOjwAdVOuWhUSU841xkqTAQ1ydKfjPxK3KyqlbmDaGiNKmMpNKxklyEiUxEVkomtEp0OUnlgIybP7hQXqEeG6VcFzZSZbxYb_CzcHgMyLA9fO2kWY4dGDZoFd6vdP5iAVQ6dsqnBtUC5lt8iSZWptptiwh-LK6JxNGAvHZwt3dnMcf1h8nbe5z9jjzuHpf35KTe7MwH8G9r-dHS8xaZfatP
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+systematic+comparison+of+the+properties+of+clinically+used+angiotensin+II+type+1+receptor+antagonists&rft.jtitle=Pharmacological+reviews&rft.au=Michel%2C+Martin+C&rft.au=Foster%2C+Carolyn&rft.au=Brunner%2C+Hans+R&rft.au=Liu%2C+Lisheng&rft.date=2013-04-01&rft.issn=1521-0081&rft.eissn=1521-0081&rft.volume=65&rft.issue=2&rft.spage=809&rft_id=info:doi/10.1124%2Fpr.112.007278&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0031-6997&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0031-6997&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0031-6997&client=summon